

~~10/764,529~~

10/608,333

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1201txs

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAplus - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

| | |
|------------|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:20:11 ON 27 SEP 2005

FILE 'REGISTRY' ENTERED AT 15:20:18 ON 27 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

10/764,529

provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2005 HIGHEST RN 863963-04-6
DICTIONARY FILE UPDATES: 26 SEP 2005 HIGHEST RN 863963-04-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\Program Files\Stnexp\Queries\106083331.str



chain nodes :

10/764,529

18 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
2-16 3-11 13-18 18-19 18-20 18-21
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17
exact/norm bonds :
2-3 3-4 3-11 4-5 13-18 18-19 18-20 18-21
exact bonds :
1-2 1-5 2-16
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 6 : 12 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> s 11
SAMPLE SEARCH INITIATED 15:20:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 104 TO ITERATE

100.0% PROCESSED 104 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1469 TO 2691
PROJECTED ANSWERS: 406 TO 1154

L2 39 SEA SSS SAM L1

=> s 11 ful
FULL SEARCH INITIATED 15:20:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2117 TO ITERATE

100.0% PROCESSED 2117 ITERATIONS 621 ANSWERS
SEARCH TIME: 00.00.01

L3 621 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 15:20:46 ON 27 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Sep 2005 VOL 143 ISS 14
FILE LAST UPDATED: 26 Sep 2005 (20050926/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 62 L3

=> d 14 ibib hirstr abs 1-62
'HIRSTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATTS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

10/764,529

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name; its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

=> d his

(FILE 'HOME' ENTERED AT 15:20:11 ON 27 SEP 2005)

FILE 'REGISTRY' ENTERED AT 15:20:18 ON 27 SEP 2005

L1 STRUCTURE UPLOADED
L2 39 S L1
L3 621 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:20:46 ON 27 SEP 2005

L4 62 S L3

=> d l4 ibib hitstr abs 1-62

L4 ANSWER 1 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:369275 CAPLUS
DOCUMENT NUMBER: 142:430265
TITLE: Preparation of substituted pyrazoles and isoxazoles as
large conductance Ca-activated K channel openers
INVENTOR(S): Imanishi, Yasuhiro; Awai, Nobumasa; Hirai, Miki;
Hosaka, Toshihiro; Kono, Rikako
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 224 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2005037271 | A2 | 20050428 | WO 2004-JP15662 | 20041015 |
| WO 2005037271 | A3 | 20050901 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ; OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

| | | |
|------------------------|-----------------|------------|
| PRIORITY APPLN. INFO.: | JP 2003-357325 | A 20031017 |
| | JP 2004-17662 | A 20040126 |
| | JP 2004-85143 | A 20040323 |
| | JP 2004-194172 | A 20040630 |
| | US 2004-584451P | P 20040701 |

OTHER SOURCE(S): MARPAT 142:430265


IT 850829-04-8P 850832-40-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazoles and isoxazoles as large conductance Ca-activated K channel openers)


RN 850829-04-8 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 850832-40-5 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-, sodium salt (9CI) (CA INDEX NAME)




● Na

GI



AB Title compds. I [A = benzene, heterocycle; B = benzene, heterocycle, etc.; Q = pyrazolyl, isoxazolyl; R₁, R₃ = carboxamido, hydrazido, etc.; m, n = 0-2; R₂, R₄ = oxo, CN, NO₂, etc.] are prepared. For instance, 4,4,4-trifluoro-1-(4-methylphenyl)butane-1,3-dione is reacted with 3-methylphenylhydrazine•HCl (EtOH, reflux, 20 h) to give 1-(3-methylphenyl)-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole (II). Data for over 400 compds. is given. The relaxation effect on K-induced contraction of isolated rabbit urinary bladder and the inhibitory effect on the rhythmic bladder contractions induced by substance P in anesthetized rats is provided for selected example compds. I are useful for the treatment of pollakiuria, urinary incontinence, etc.

L4 ANSWER 2 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:256013 CAPLUS
 DOCUMENT NUMBER: 143:19231
 TITLE: 3D-QSAR and preliminary evaluation of anti-inflammatory activity of series of N-pyrrolylcarboxylic acids
 AUTHOR(S): Lessigiarska, Iglika; Nankov, Atanas; Bocheva, Adriana; Pajeva, Ilza; Bilev, Atanas
 CORPORATE SOURCE: Centre of Biomedical Engineering, Bulgarian Academy of Sciences, Bulg.
 SOURCE: Farmaco (2005), 60(3), 209-218
 CODEN: FRMCE8; ISSN: 0014-827X
 PUBLISHER: Editions Scientifiques et Medicales Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 170570-43-1
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (3D-QSAR and preliminary evaluation of anti-inflammatory activity of N-pyrrolylcarboxylic acids)
 RN 170570-43-1 CAPLUS
 CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)



AB The present study focuses on development of new potential inhibitors of cyclooxygenase-2 (COX-2): series of N-pyrrolylcarboxylic acids. 3D-QSAR (Quant. Structure-Activity Relationship) CoMFA (Comparative Mol. Field Anal.) and CoMSIA (Comparative Mol. Similarity Index Anal.) models for predicting inhibitory activities against COX-1 and COX-2 as well as for evaluating in vivo anti-inflammatory activity were obtained and used for preliminary screening of new anti-inflammatory N-pyrrolylcarboxylic acids. Nine compds. were selected for in vivo testing and evaluated for their potency to decrease carrageenin-induced edema in rats. The compds. were applied i.p. at doses 20 mg/kg and 40 mg/kg and p.o. at doses 10 mg/kg and 40 mg/kg. Six compds. showed more than 70% protection of the edema. Indomethacin (2 mg/kg i.p.), used as a reference drug, possessed 54% anti-inflammatory activity under similar exptl. conditions.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:99157 CAPLUS

DOCUMENT NUMBER: 142:170033

TITLE: Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents

INVENTOR(S): Maziasz, Timothy

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 172 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------------------------|------------------------|
| US 2005026902 | A1 | 20050203 | US 2004-769485
US 2003-443910P | 20040130
P 20030131 |

PRIORITY APPLN. INFO.: MARPAT 142:170033



OTHER SOURCE(S): IT 165251-89-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of HIV infection and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents)


10/764,529

RN 165251-89-8 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The present invention provides compns. and methods for the treatment of human immunodeficiency virus (HIV) infection as well as HIV associated diseases and related disorders. More particularly, the invention provides a combination therapy for the treatment of HIV infection as well as HIV associated diseases and related disorders comprising the administration to a subject of an anti-human immunodeficiency virus agent in combination with a cyclooxygenase-2 selective inhibitor or an isomer or a pharmaceutically acceptable salt, ester, or prodrug thereof.

L4 ANSWER 4 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:4716 CAPLUS

DOCUMENT NUMBER: 142:329295

TITLE: Effects of Intravenous Administration of FR122047 (a Selective Cyclooxygenase 1 Inhibitor) and FR188582 (a Selective Cyclooxygenase 2 Inhibitor) on Prostaglandin-E2-Induced Aqueous Flare Elevation in Pigmented Rabbits

AUTHOR(S): Abe, Tomohiro; Hayasaka, Yoriko; Zhang, Xue-Yun; Hayasaka, Seiji

CORPORATE SOURCE: Department of Ophthalmology, Toyama Medical and

SOURCE: Pharmaceutical University, Toyama, Japan
 Ophthalmic Research (2004), 36(6), 321-326
 CODEN: OPRSAQ; ISSN: 0030-3747

PUBLISHER: S. Karger AG
 DOCUMENT TYPE: Journal
 LANGUAGE: English


IT 189699-82-9, FR 188582

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(i.v. FR188582 administration before transcorneal PGE2 application and
 with FR122047 infusion inhibit aqueous flare elevation dose-dependently,
 induce slight change in COX-1, COX-2 mRNA level in iris-ciliary body of
 pigmented rabbit)

RN 189699-82-9 CAPLUS

CN 1H-Pyrazole, 3-chloro-5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA
 INDEX NAME)



AB Purpose: Two isoforms of cyclooxygenase (COX-1 and COX-2) exist. To determine in vivo effects of the i.v. administration of FR122047 (a selective COX-1 inhibitor), FR188582 (a selective COX-2 inhibitor), diclofenac sodium or dexamethasone phosphate disodium on prostaglandin-E2 (PGE2)-induced aqueous flare elevation and mRNA levels for COX-1 and COX-2 in pigmented rabbits. Methods: To produce aqueous flare elevation in rabbits, PGE2, 25 µg/mL, was applied to the cornea with the use of a glass cylinder. FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium was i.v. injected before PGE2 application. Aqueous flare was measured with a laser flare-cell meter. The mRNA levels for COX-1 and COX-2 in the iris-ciliary body were determined by real-time polymerase chain reaction. Results: FR122047, FR188582 and diclofenac sodium (15 µmol/kg each) injected i.v. 30 min before PGE2 application inhibited 29 ± 5, 40 ± 12 and 50 ± 9% of aqueous flare elevation, resp. Simultaneous injection of FR122047 (15 µmol/kg) and FR188582 (15 µmol/kg) 30 min before PGE2 application inhibited 61 ± 8% of flare elevation. Dexamethasone phosphate disodium (15 µmol/kg) injected i.v. 300 min before PGE2 application inhibited 68 ± 8% of aqueous flare elevation. Less than 3-fold changes in mRNA levels for COX-1 and COX-2 in the iris-ciliary body were noted after PGE2, FR122047, FR188582, diclofenac sodium or dexamethasone phosphate disodium treatment. Conclusion: It is possible that enzyme activities of both COX-1 and COX-2 may be involved in the mechanism of PGE2-induced aqueous flare elevation in pigmented rabbits.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:967778 CAPLUS

DOCUMENT NUMBER: 142:113957

TITLE: 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2)

10/764,529

AUTHOR(S) : inhibitors
Ranatunge, Ramani R.; Earl, Richard A.; Garvey, David S.; Janero, David R.; Letts, L. Gordon; Martino, Allison M.; Murty, Madhavi G.; Richardson, Stewart K.; Schwalb, David J.; Young, Delano V.; Zemtseva, Irina S.

CORPORATE SOURCE : NitroMed Inc., Lexington, MA, 02421, USA
SOURCE : Bioorganic & Medicinal Chemistry Letters (2004), 14(24), 6049-6052
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER : Elsevier B.V.

DOCUMENT TYPE : Journal

LANGUAGE : English


OTHER SOURCE(S) : CASREACT 142:113957

IT 823191-22-6P 823191-23-7P 823191-24-8P
823191-25-9P 823191-26-0P 823191-27-1P
823191-28-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of diaryl(methoxytetrahydrofuryl)pyrazoles as selective human cyclooxygenase-2 inhibitors)

RN 823191-22-6 CAPPLUS

CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(tetrahydro-2-methoxy-2-furanyl)- (9CI) (CA INDEX NAME)




RN 823191-23-7 CAPPLUS
CN 1H-Pyrazole, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2-methoxy-2-furanyl)- (9CI) (CA INDEX NAME)




RN 823191-24-8 CAPLUS

CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2-methoxy-2-furanyl)-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 823191-25-9 CAPLUS


CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2-methoxy-2-furanyl)- (9CI) (CA INDEX NAME)



RN 823191-26-0 CAPLUS


10/764,529

CN 1H-Pyrazole, 1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2-methoxy-2-furanyl)- (9CI) (CA INDEX NAME)




RN 823191-27-1 CAPLUS

CN 1H-Pyrazole, 1-(4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2-methoxy-2-furanyl)- (9CI) (CA INDEX NAME)




RN 823191-28-2 CAPLUS

CN Benzonitrile, 4-[5-[4-(methylsulfonyl)phenyl]-3-(tetrahydro-2-methoxy-2-furanyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



GI



I

AB A series of 3-(2-methoxytetrahydrofuran-2-yl)pyrazoles I ($R = H, Me, F3C, F, Cl, Br, CN$) was synthesized. I were evaluated for their ability to inhibit cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) activity in human whole blood. I ($R = Me$) showed potent and selective COX-2 inhibition (IC_{50} for COX-1: $>100 \mu M$ and COX-2: $1.2 \mu M$).

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370908 CAPLUS

DOCUMENT NUMBER: 140:391278

TITLE: Preparation of pyrazole-4-alkanoic acid derivatives as cyclooxygenase and 5-lipoxygenase inhibitors

INVENTOR(S): Kawano, Katsuhiro; Taniguchi, Makoto; Igarashi, Atsushi; Yamada, Mie; Naito, Kenji; Toyota, Yoshihiro

PATENT ASSIGNEE(S): Wakamoto Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

| | | | | |
|--|----|----------|-----------------|----------|
| WO 2004037793 | A1 | 20040506 | WO 2003-JP13596 | 20031024 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU; MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

PRIORITY APPLN. INFO.: JP 2002-309922 A 20021024

OTHER SOURCE(S): MARPAT 140:391278

IT 685856-90-0P 685856-94-4P 685857-13-0P


685858-94-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole-4-alkanoic acid derivs. as cyclooxygenase and 5-lipoxygenase inhibitors)

RN 685856-90-0 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[(1E)-2-(4-chlorophenyl)ethenyl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 685856-94-4 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[(1E)-2-(4-chlorophenyl)ethenyl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 685857-13-0 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[(1Z)-2-(4-chlorophenyl)ethenyl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 685858-94-0 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-[(1Z)-2-(4-chlorophenyl)ethenyl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 685857-71-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazole-4-alkanoic acid derivs. as cyclooxygenase and 5-lipoxygenase inhibitors)

RN 685857-71-0 CAPLUS

CN 1H-Pyrazole-4-acetic acid, 3-formyl-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




GI




AB The title compds. I [Ar1, Ar2 = (un)substituted Ph, etc.; R1 = H, alkyl, etc.; m = 1 - 3; X = CH2, etc.; Y = (un)substituted phenyl] are prepared I inhibit the production of both of prostaglandin and leukotriene and are useful in the treatment of inflammation and pain. The PGE2 and LTB4 inhibiting activities of compds. of this invention were demonstrated.

10/764,529

L4 ANSWER 7 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:252948 CAPLUS
DOCUMENT NUMBER: 140:423618
TITLE: Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles
AUTHOR(S): Ranatunge, Ramani R.; Augustyniak, Michael; Bandarage, Upul K.; Earl, Richard A.; Ellis, James L.; Garvey, David S.; Janero, David R.; Letts, L. Gordon; Martino, Allison M.; Murty, Madhavi G.; Richardson, Stewart K.; Schroeder, Joseph D.; Shumway, Matthew J.; Tam, S. William; Trocha, A. Mark; Young, Delano V.
CORPORATE SOURCE: NitroMed Inc., Bedford, MA, 01730, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(9), 2180-2193
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 640727-87-3P 640727-88-4P 640728-01-4P
640728-02-5P 641639-12-5P 641639-17-0P
641639-22-7P 641639-27-2P 641639-58-9P
641639-63-6P 641640-13-3P 693288-12-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and selective cyclooxygenase-2 inhibitory activity of nitric oxide donor-containing pyrazoles)
RN 640727-87-3 CAPLUS
CN 1-Butanone, 4-hydroxy-1-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl] - (9CI) (CA INDEX NAME)




RN 640727-88-4 CAPLUS
CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-4-(nitrooxy) - (9CI) (CA INDEX NAME)




RN 640728-01-4 CAPLUS

CN Benzonitrile, 4-[3-(4-hydroxy-1-oxobutyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 640728-02-5 CAPLUS

CN Benzonitrile, 4-[5-[4-(methylsulfonyl)phenyl]-3-[4-(nitrooxy)-1-oxobutyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 641639-12-5 CAPLUS

CN 3-Buten-1-ol, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-, (3Z)- (9CI) (CA INDEX NAME)


10/764,529

Double bond geometry as shown.




RN 641639-17-0 CAPLUS

CN 1-Butanone, 4-hydroxy-1-[1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 641639-22-7 CAPLUS


CN 1-Butanone, 1-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 641639-27-2 CAPLUS


CN 1-Butanone, 1-[1-(4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-hydroxy- (9CI) (CA INDEX NAME)

10/764,529




RN 641639-58-9 CAPLUS

CN 1-Butanone, 4-hydroxy-1-[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 641639-63-6 CAPLUS

CN 1-Butanone, 4-hydroxy-1-[1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 641640-13-3 CAPLUS

CN 1-Butanone, 1-[1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-

10/764,529


3-yl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 693288-12-9 CAPLUS

CN 3-Buten-1-ol, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 640727-83-9P 640727-97-5P 641639-07-8P
641639-08-9P 641639-13-6P 641639-18-1P
641639-23-8P 641639-54-5P 641639-59-0P
641640-09-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and selective cyclooxygenase-2 inhibitory activity of nitric oxide donor-containing pyrazoles)


RN 640727-83-9 CAPLUS

CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-4-(nitrooxy)-, oxime (9CI) (CA INDEX NAME)



RN 640727-97-5 CAPLUS


CN Benzonitrile, 4-[3-[1-(hydroxyimino)-4-(nitrooxy)butyl]-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 641639-07-8 CAPLUS

CN 3-Buten-1-ol, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-, nitrate (ester), (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 641639-08-9 CAPLUS

CN 3-Buten-1-ol, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-, nitrate (ester), (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 641639-13-6 CAPLUS
CN 1-Butanone, 1-[1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)




RN 641639-18-1 CAPLUS
CN 1-Butanone, 1-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)




RN 641639-23-8 CAPLUS
CN 1-Butanone, 1-[1-(4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)

10/764,529




RN 641639-54-5 CAPLUS

CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)



RN 641639-59-0 CAPLUS


CN 1-Butanone, 1-[1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)




RN 641640-09-7 CAPLUS

CN 1-Butanone, 1-[1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-

3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)



GI



I

AB The synthesis of a series of novel pyrazoles containing a nitrate (ONO_2) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. The data demonstrate that pyrazole ring substituents play an important role in COX-2 selective inhibition, such that a cycloalkylpyrazole (I, X = CH₂) was found to be a potent and selective COX-2 inhibitor. Other modifications at the 3 position of the central pyrazole ring [I, X = (CH₂)₃, C(:NOH)(CH₂)₃, (Z)-CH:CHCH₂CH₂] enhanced COX-2 inhibitory potency. Among the pyrazoles synthesized, the oxime [I, X = C(:NOH)(CH₂)₃] was identified as the most potent COX-2 selective inhibitor. Accordingly, this compound was profiled pharmacol. in the rat after oral administration and shown to possess potent antiinflammatory activity in the carrageenan-induced air-pouch model and less gastric toxicity than a standard COX-2 inhibitor when administered with background aspirin treatment. The enhanced gastric tolerance of an NO-donor COX-2 selective inhibitor has the potential to augment the clin. profile of this drug class.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:182531 CAPLUS

DOCUMENT NUMBER: 140:229475

TITLE: Combinations of ω -3 fatty acids and

cyclooxygenase-2 inhibitors for the treatment or prevention of cardiovascular disease, inflammation-related conditions, and cancer

INVENTOR(S) : Obukowicz, Mark G.

PATENT ASSIGNEE(S) : USA

SOURCE: U.S. Pat. Appl. Publ., 49 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|------------|
| US 2004044028 | A1 | 20040304 | US 2002-113269 | 20020401 |
| | | | US 2001-280183P | P 20010330 |

PRIORITY APPLN. INFO.: MARPAT 140:229475



OTHER SOURCE(S): IT 165251-89-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations of ω -3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease, inflammation-related conditions, and cancer)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





AB The invention discloses combinations of ω -3 polyunsatd. fatty acids (PUFAs) and cyclooxygenase-2 selective inhibitors for treatment or prevention of cardiovascular disease, inflammation-related disorders or cancer. The preferred ω -3 PUFAs of the invention have 18-22 carbon atoms, and more preferably 20-22 carbon atoms.

L4 ANSWER 9 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN



ACCESSION NUMBER: 2004:142952 CAPLUS
 DOCUMENT NUMBER: 140:175165
 TITLE: Amyloid immunization and COX-2 inhibitors for the treatment of Alzheimer's disease
 INVENTOR(S): Robertson, David W.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 165 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004014367 | A2 | 20040219 | WO 2003-US24263 | 20030804 |
| WO 2004014367 | A3 | 20040325 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004138296 | A1 | 20040715 | US 2003-627357 | 20030725 |
| CA 2494108 | AA | 20040219 | CA 2003-2494108 | 20030804 |
| EP 1539142 | A2 | 20050615 | EP 2003-784887 | 20030804 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003013413 | A | 20050712 | BR 2003-13413 | 20030804 |
| PRIORITY APPLN. INFO.: | | | US 2002-402655P | P 20020812 |
| | | | US 2002-402674P | P 20020812 |
| | | | US 2002-402675P | P 20020812 |
| | | | US 2002-402676P | P 20020812 |
| | | | US 2002-402760P | P 20020812 |
| | | | US 2002-402773P | P 20020812 |
| | | | US 2002-402778P | P 20020812 |
| | | | WO 2003-US24263 | W 20030804 |


10/764,529

OTHER SOURCE(S) : MARPAT 140:175165
IT 165251-89-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(amyloid immunization and COX-2 inhibitors for treatment of Alzheimer's
disease)
RN 165251-89-8 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The invention provides compns. and methods for the treatment or prevention of Alzheimer's disease. More particularly, the invention provides a combination therapy for the treatment or prevention of Alzheimer's disease, wherein the therapy comprises administering to a subject an amyloid- β vaccine in combination with a cyclooxygenase-2 selective inhibitor.

L4 ANSWER 10 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:41336 CAPLUS
DOCUMENT NUMBER: 140:105282
TITLE: Cyclooxygenase-2 inhibitors and thrombolytic agents
for the treatment or prevention of a vaso-occlusive
event
INVENTOR(S): Isakson, Peter C.

10/764,529

PATENT ASSIGNEE(S) : Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 202 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-----------------|-----------------|----------|
| WO 2004004833 | A1 | 20040115 | WO 2003-US20558 | 20030630 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2491479 | AA | 20040115 | CA 2003-2491479 | 20030630 |
| US 2004063697 | A1 | 20040401 | US 2003-610085 | 20030630 |
| BR 2003012402 | A | 20050426 | BR 2003-12402 | 20030630 |
| EP 1536863 | A1 | 20050608 | EP 2003-763058 | 20030630 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 2002-393136P | P | 20020702 |
| | | US 2002-393172P | P | 20020702 |
| | | US 2002-393199P | P | 20020702 |
| | | US 2002-393258P | P | 20020702 |
| | | US 2002-393269P | P | 20020702 |
| | | US 2002-393296P | P | 20020702 |
| | | US 2002-393297P | P | 20020702 |
| | | WO 2003-US20558 | W | 20030630 |



IT 165251-89-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitors and thrombolytic agents for treatment of vaso-occlusive event)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The present invention provides compns. and methods for the treatment or prevention of a vaso-occlusive event. More particularly, the invention provides a combination therapy for the treatment or prevention of a vaso-occlusive event comprising the administration to a subject of a thrombolytic agent in combination with a cyclooxygenase-2 selective inhibitor. Thrombosis was induced in mice, and the above combination therapy was administered to the mice to treat a vaso-occlusive event.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:20441 CAPLUS

DOCUMENT NUMBER: 140:77147

TITLE: Preparation of optionally nitrosated and/or nitrosylated oxime and/or hydrazone cyclooxygenase-2 selective inhibitors, compositions and methods of use

INVENTOR(S): Garvey, David S.; Ranatunge, Ramani R.; Richardson, Stewart K.

PATENT ASSIGNEE(S): Nitromed, Inc., USA

SOURCE: PCT Int. Appl., 166 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2004002420 | A2 | 20040108 | WO 2003-US20421 | 20030630 |
| WO 2004002420 | A3 | 20040701 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2492066 | AA | 20040108 | CA 2003-2492066 | 20030630 |
| EP 1539679 | A2 | 20050615 | EP 2003-742299 | 20030630 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRIORITY APPLN. INFO.: US 2002-392044P P 20020628
WO 2003-US20421 W 20030630 | | | | |

OTHER SOURCE(S): MARPAT 140:77147

IT 640727-83-9P, 1-[3-[1-(Hydroxyimino)-4-(nitrooxy)butyl]-1-phenylpyrazol-5-yl]-4-(methylsulfonyl)benzene 640727-97-5P,


4-[3-[1-(Hydroxyimino)-4-(nitrooxy)butyl]-5-[4-(methylsulfonyl)phenyl]pyrazol-1-yl]benzenecarbonitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of optionally nitrosated and/or nitrosylated oxime and/or hydrazone cyclooxygenase-2 selective inhibitors, compns. and methods of use)


RN 640727-83-9 CAPLUS

CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-4-(nitrooxy)-, oxime (9CI) (CA INDEX NAME)



RN 640727-97-5 CAPLUS

CN Benzonitrile, 4-[3-[1-(hydroxyimino)-4-(nitrooxy)butyl]-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




IT 640727-87-3P, 4-Hydroxy-1-[5-[4-(methylsulfonyl)phenyl]phenyl]-1-phenylpyrazol-3-ylbutan-1-one 640727-88-4P,
 1-[5-[4-(Methylsulfonyl)phenyl]phenyl]-1-phenylpyrazol-3-yl]-4-(nitrooxy)butan-1-one 640728-01-4P, 4-[3-(4-Hydroxybutanoyl)-5-[4-(methylsulfonyl)phenyl]pyrazolyl]benzenecarbonitrile 640728-02-5P
 , 4-[5-[4-(Methylsulfonyl)phenyl]-3-[4-(nitrooxy)butanoyl]pyrazolyl]benzenecarbonitrile
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of optionally nitrosated and/or nitrosylated oxime and/or hydrazone cyclooxygenase-2 selective inhibitors, compns. and methods of use)


RN 640727-87-3 CAPLUS

CN 1-Butanone, 4-hydroxy-1-[5-[4-(methylsulfonyl)phenyl]phenyl]-1-phenyl-1H-pyrazol-3-yl] - (9CI) (CA INDEX NAME)




RN 640727-88-4 CAPLUS

CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]phenyl]-1-phenyl-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)




RN 640728-01-4 CAPLUS

CN Benzonitrile, 4-[3-(4-hydroxy-1-oxobutyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl] - (9CI) (CA INDEX NAME)





RN 640728-02-5 CAPLUS

CN Benzonitrile, 4-[5-[4-(methylsulfonyl)phenyl]-3-[4-(nitrooxy)-1-oxobutyl]-1H-pyrazol-1-yl] - (9CI) (CA INDEX NAME)



GI



AB The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group optionally nitrosated and/or nitrosylated (one class shown as I; variables defined below; e.g. II; 15 other classes of compds. are also described in the 1st claim) and novel compns. and kits comprising at least one I and optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors. Six examples of I were tested for inhibition of COX-1 and COX-2; e.g. 1-[1-cyclohexyl-3-[1-(hydroxyimino)-4-(nitrooxy)butyl]pyrazol-4-yl]-4-(methylsulfonyl)benzene inhibited COX-1 10 % at 100 μ M and COX-2 100 % at 10 μ M. Although the methods of preparation are not claimed, 6 example preps. are included. For example, II was prepared in 7 steps (79, 68, 84, 79, 51, 84 and 48 % yields, resp.) starting from di-Me oxalate, NaOMe and 4'-(methylthio)acetophenone in toluene and involving intermediates Me (2Z)-2-hydroxy-4-(4-methylthiophenyl)-4-oxobut-2-enoate, Me 5-(4-methylthiophenyl)-1-phenylpyrazole-3-carboxylate, N-methoxy-N-methyl-5-(4-methylthiophenyl)-1-phenylpyrazole-3-carboxamide, 1-[5-(4-methylthiophenyl)-1-phenylpyrazol-3-yl]-4-(1,1,2,2-tetramethyl-1-silapropoxy)butan-1-one, 4-hydroxy-1-[5-(4-methylsulfonyl)phenyl]-1-phenylpyrazol-3-yl]butan-1-one, and 1-[5-[4-(methylsulfonyl)phenyl]-1-phenylpyrazol-3-yl]-4-(nitrooxy)butan-1-one. For I: when side b is a double bond, and sides a and c are single bonds, -X1-Y1-Z1- is: -CR4(R5)CR5(R5')CR4(R5)-, -C(O)CR4(R4')CR5(R5')-, -CR4(R4')CR5(R5')C(O)-, -[CR5(R5')]kOC(O)-, etc.; when sides a and c are double bonds and side b is a single bond, -X1-Y1-Z1- is: :CR4OCR5:,

:CR4NR3CR5:, :NSCR4:, :CR4SN:, etc. R1 is S(O)2Me, S(O)2NR8(D1), S(O)2N(D1)C(O)CF3, S(O)(NH)NH(D1), S(O)(NH)N(D1)C(O)CF3, P(O)MeNH(D1), P(O)Me2, C(S)NH(D1), S(O)(NH)Me, P(O)MeOD1, or P(O)MeNH(D1); R1' is H, halo, Me, or CH2OH. R2 is lower alkyl, cycloalkyl, mono, di- or trisubstituted Ph or naphthyl, mono, di- or trisubstituted heteroaryl (wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1-3 addnl. N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1-4 addnl. N atoms), benzoheteroaryl, NR10R11, SR11, OR11, R11, alkenyl, alkynyl, unsubstituted, mono, di, tri- or tetrasubstituted cycloalkenyl, mono, di, tri- or tetrasubstituted heterocycloalkyl group of 5-7 members, or a benzoheterocycle, wherein said heterocycloalkyl or benzoheterocycle contains 1 or 2 heteroatoms selected from O, S, or N and, optionally, contains a carbonyl group or a sulfonyl group, styryl, mono or disubstituted styryl, phenylacetylene, mono- or disubstituted phenylacetylene, fluoroalkenyl, mono- or disubstituted bicyclic heteroaryl of 8-10 members, containing 2-5 heteroatoms (wherein at least one heteroatom resides on each ring of said bicyclic heteroaryl, said heteroatoms are each independently O, S and N), K, aryl, arylalkyl, cycloalkylalkyl, -C(O)R11, hydrogen, arylalkenyl, arylalkoxy, alkoxy, aryloxy, cycloalkoxy, arylthio, alkylthio, arylalkylthio, or cycloalkylthio. R3 is hydrogen, haloalkyl (preferably CF3), CN, lower alkyl, [C(Re)(Rf)]p-U-V, K, (un)substituted lower alkyl-Q, lower alkyl-O-lower alkyl-Q, etc., Q, alkylcarbonyl, arylcarbonyl, alkylarylcarbonyl, arylalkylcarbonyl, carboxylic ester, carboxamido, cycloalkyl, mono, di- or trisubstituted Ph or naphthyl, alkenyl, alkynyl, arylalkyl, lower alkyl-OD1, alkoxyalkyl, aminoalkyl, lower alkyl-CO2R10, lower alkyl-C(O)NR10(R10'), heterocyclic alkyl, or heterocyclic ring-C(O)-; with the proviso that one oxime or hydrazone group must be present; addnl. details are given in the claims.

L4 ANSWER 12 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:20431 CAPLUS
 DOCUMENT NUMBER: 140:77146
 TITLE: Preparation of trisubstituted pyrazole cyclooxygenase-2 selective inhibitors
 INVENTOR(S): Bandarage, Upul K.; Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Garvey, David S.; Khanapure, Subhash P.; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.; Stevenson, Cheri A.; Wey, Shiow-jyi
 PATENT ASSIGNEE(S): Nitromed, Inc., USA
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2004002409 | A2 | 20040108 | WO 2003-US19850 | 20030625 |
| WO 2004002409 | A3 | 20040819 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, | | | | |


KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2489428 AA 20040108 CA 2003-2489428 20030625
 US 2004053985 A1 20040318 US 2003-603098 20030625
 EP 1534683 A2 20050601 EP 2003-762000 20030625
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: US 2002-391769P P 20020627
 US 2003-454307P P 20030314
 WO 2003-US19850 W 20030625

OTHER SOURCE(S): MARPAT 140:77146

IT 641638-86-0P, 3-(Nitrooxy)propyl 5-[4-(methylsulfonyl)phenyl]-1-phenylpyrazole-3-carboxylate

RL: BYP (Byproduct); PREP (Preparation)
 (preparation of trisubstituted pyrazole cyclooxygenase-2 selective inhibitors)

RN 641638-86-0 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-,
 3-(nitrooxy)propyl ester (9CI) (CA INDEX NAME)


IT 640728-01-4P, 4-[3-(4-Hydroxybutanoyl)-5-[4-(methylsulfonyl)phenyl]pyrazolyl]benzenecarbonitrile 641638-80-4P
 , 4-[3-[(3-Hydroxypropoxy)methyl]-1-phenylpyrazol-5-yl]-1-(methylsulfonyl)benzene 641638-85-9P, 1-[3-[Difluoro(3-hydroxypropoxy)methyl]-1-phenylpyrazol-5-yl]-4-(methylsulfonyl)benzene 641638-91-7P, 1-[1-(4-Chlorophenyl)-3-[(3-hydroxypropoxy)methyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene 641638-96-2P, 1-[3-[(3-Hydroxypropoxy)methyl]-1-(4-methylphenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene 641639-01-2P
 , 1-[3-[(3-Hydroxypropoxy)methyl]-1-[4-(trifluoromethyl)phenyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene 641639-06-7P, 1-[3-[(3-Hydroxypropoxy)methyl]-1-(4-methoxyphenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene 641639-12-5P, 1-[3-[(1Z)-4-(Hydroxybut-1-enyl)-1-phenylpyrazol-5-yl]-4-(methylsulfonyl)benzene 641639-17-0P, 4-Hydroxy-1-[1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]butanone 641639-22-7P, 1-[1-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-hydroxybutanone 641639-27-2P, 1-[1-(4-Bromophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-hydroxybutanone 641639-43-2P, 1-[1-(4-Fluorophenyl)-3-[(3-hydroxypropoxy)methyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene 641639-46-5P, 1-[3-[(3-Hydroxybutoxy)methyl]-1-phenylpyrazol-5-yl]-4-(methylsulfonyl)benzene 641639-58-9P, 4-Hydroxy-1-[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]butanone 641639-63-6P, 4-Hydroxy-1-[1-(4-methoxyphenyl)-5-[4-

10/764,529

(methylsulfonyl)phenyl]pyrazol-3-yl]butanone 641640-13-3P,
1-[1-(4-Chlorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-hydroxybutanone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of trisubstituted pyrazole cyclooxygenase-2 selective inhibitors)


RN 640728-01-4 CAPLUS

CN Benzonitrile, 4-[3-(4-hydroxy-1-oxobutyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 641638-80-4 CAPLUS

CN 1-Propanol, 3-[[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 641638-85-9 CAPLUS


CN 1-Propanol, 3-[difluoro[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)



10/764,529


RN 641638-91-7 CAPLUS

CN 1-Propanol, 3-[[1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)




RN 641638-96-2 CAPLUS

CN 1-Propanol, 3-[[1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 641639-01-2 CAPLUS

CN 1-Propanol, 3-[[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)




RN 641639-06-7 CAPLUS

CN 1-Propanol, 3-[[1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-

10/764,529


pyrazol-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 641639-12-5 CAPLUS


CN 3-Buten-1-ol, 4-[(5-[(4-methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl)- (3Z)]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 641639-17-0 CAPLUS


CN 1-Butanone, 4-hydroxy-1-[(1-[(4-methylphenyl)ethyl]-5-(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 641639-22-7 CAPLUS


CN 1-Butanone, 1-[(1-[(4-fluorophenyl)methyl]-5-(4-methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-hydroxy- (9CI) (CA INDEX NAME)

10/764,529




RN 641639-27-2 CAPLUS

CN 1-Butanone, 1-[1-(4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 641639-43-2 CAPLUS

CN 1-Propanol, 3-[[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]methoxy- (9CI) (CA INDEX NAME)




RN 641639-46-5 CAPLUS

CN 2-Butanol, 4-[[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]methoxy- (9CI) (CA INDEX NAME)




RN 641639-58-9 CAPLUS

CN 1-Butanone, 4-hydroxy-1-[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 641639-63-6 CAPLUS

CN 1-Butanone, 4-hydroxy-1-[1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 641640-13-3 CAPLUS

CN 1-Butanone, 1-[1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-hydroxy- (9CI) (CA INDEX NAME)




IT 640728-02-5P, 4-[5-[4-(Methylsulfonyl)phenyl]-3-[4-(nitrooxy)butanoyl]pyrazolyl] benzenecarbonitrile 641638-76-8P
 641638-81-5P, 1-[3-[Difluoro[3-(nitrooxy)propoxy]methyl]-1-phenylpyrazol-5-yl]-4-(methylsulfonyl)benzene 641638-87-1P,
 1-[1-(4-Chlorophenyl)-3-[(3-nitrooxy)propoxy]methyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene 641638-92-8P, 1-[1-(4-Methylphenyl)-3-[(3-nitrooxy)propoxy]methyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene
 641638-97-3P, 4-(Methylsulfonyl)-1-[3-[(3-nitrooxy)propoxy]methyl]-1-[4-(trifluoromethyl)phenyl]pyrazol-5-yl]benzene 641639-02-3P, 1-[1-(4-Methoxy-3-nitrophenyl)-3-[(3-nitrooxy)propoxy]methyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene
 641639-07-8P, 1-[3-[(1Z)-4-(Nitrooxy)but-1-enyl]-1-phenylpyrazol-5-yl]-4-(methylsulfonyl)benzene 641639-08-9P, 1-[3-[(1E)-4-(Nitrooxy)but-1-enyl]-1-phenylpyrazol-5-yl]-4-(methylsulfonyl)benzene
 641639-13-6P, 1-[1-(4-Methylphenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-(nitrooxy)butanone
 641639-18-1P, 1-[1-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-(nitrooxy)butanone
 641639-23-8P, 1-[1-(4-Bromophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-(nitrooxy)butanone
 641639-39-6P, 1-[1-(4-Fluorophenyl)-3-[(3-nitrooxy)propoxy]methyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene
 641639-44-3P, 4-(Methylsulfonyl)-1-[3-[(3-nitrooxy)butoxy]methyl]-1-phenylpyrazol-5-yl]benzene 641639-54-5P, 1-[5-[4-(Methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]-4-(nitrooxy)butanone 641639-59-0P, 1-[1-(4-Methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-(nitrooxy)butanone
 641639-99-8P, 4-[1-(4-Methoxyphenyl)-3-[(3-nitrooxy)propoxy]methyl]pyrazol-5-yl]-1-(methylsulfonyl)benzene
 641640-00-8P, 4-[1-(4-Methyl-3-nitrophenyl)-3-[(3-nitrooxy)propoxy]methyl]pyrazol-5-yl]-1-(methylsulfonyl)benzene
 641640-09-7P, 1-[1-(4-Chlorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]-4-(nitrooxy)butanone
 641640-20-2P, 3-(Nitrooxy)propyl 4-[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]butanoate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of trisubstituted pyrazole cyclooxygenase-2 selective inhibitors)

RN 640728-02-5 CAPLUS
 CN Benzonitrile, 4-[5-[4-(methylsulfonyl)phenyl]-3-[4-(nitrooxy)-1-oxobutyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 641638-76-8 CAPLUS

CN 1-Propanol, 3-[(5-[4-(methylsulfonyl)phenyl]phenyl]-1-phenyl-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 641638-81-5 CAPLUS

CN 1-Propanol, 3-[(difluoro[5-[4-(methylsulfonyl)phenyl]phenyl]-1-phenyl-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 641638-87-1 CAPLUS


CN 1-Propanol, 3-[(1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 641638-92-8 CAPLUS
CN 1-Propanol, 3-[[1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)



RN 641638-97-3 CAPLUS
CN 1-Propanol, 3-[[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 641639-02-3 CAPLUS
CN 1-Propanol, 3-[[1-(4-methoxy-3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)



RN 641639-07-8 CAPLUS

CN 3-Buten-1-ol, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-, nitrate (ester), (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 641639-08-9 CAPLUS

CN 3-Buten-1-ol, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-, nitrate (ester), (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 641639-13-6 CAPLUS

CN 1-Butanone, 1-[1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)


10/764,529



RN 641639-18-1 CAPLUS
CN 1-Butanone, 1-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)




RN 641639-23-8 CAPLUS
CN 1-Butanone, 1-[1-(4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)



RN 641639-39-6 CAPLUS


10/764,529

CN 1-Propanol, 3-[[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 641639-44-3 CAPLUS

CN 2-Butanol, 4-[[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 641639-54-5 CAPLUS

CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)




RN 641639-59-0 CAPLUS


CN 1-Butanone, 1-[1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-4-(nitrooxy)- (9CI) (CA INDEX NAME)




RN 641639-99-8 CAPLUS
CN 1-Propanol, 3-[(1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)



RN 641640-00-8 CAPLUS
CN 1-Propanol, 3-[(1-(4-methyl-3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl)methoxy]-, nitrate (ester) (9CI) (CA INDEX NAME)




RN 641640-09-7 CAPLUS
CN 1-Butanone, 1-[(1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl)-4-(nitrooxy)-, (9CI) (CA INDEX NAME)



RN 641640-20-2 CAPLUS

CN 1H-Pyrazole-3-butanoic acid, 5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-, 3-(nitrooxy)propyl ester (9CI) (CA INDEX NAME)




IT 134730-09-9P 641638-77-9P, Methyl 5-[4-(methylsulfonyl)phenyl]-1-phenylpyrazole-3-carboxylate
 641638-78-0P, 4-[3-(Hydroxymethyl)-1-phenylpyrazol-5-yl]-1-(methylsulfonyl)benzene 641638-79-1P, 4-[3-(Bromomethyl)-1-phenylpyrazol-5-yl]-1-(methylsulfonyl)benzene 641638-82-6P,
 3-(Phenylmethoxy)propyl 5-[4-(methylsulfonyl)phenyl]-1-phenylpyrazole-3-carboxylate 641638-83-7P, 1-(Methylsulfonyl)-4-[1-phenyl-3-[3-(phenylmethoxy)propoxy]thioxomethyl]pyrazol-5-yl]benzene
 641638-84-8P, 4-[3-[Difluoro[3-(phenylmethoxy)propoxy]methoxy]methyl]-1-phenylpyrazol-5-yl]-1-(methylsulfonyl)benzene 641638-88-2P,
 Methyl 1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazole-3-carboxylate 641638-89-3P, 1-[1-(4-Chlorophenyl)-3-(hydroxymethyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene
 641638-90-6P, 1-[3-(Bromomethyl)-1-(4-chlorophenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene 641638-93-9P, Methyl 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]pyrazole-3-carboxylate
 641638-94-0P, 1-[3-(Hydroxymethyl)-1-(4-methylphenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene 641638-95-1P, 1-[3-(Bromomethyl)-1-(4-methylphenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene 641638-98-4P,
 Methyl 5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]pyrazole-3-carboxylate 641638-99-5P, 1-[3-(Hydroxymethyl)-1-[4-(trifluoromethyl)phenyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene
 641639-00-1P, 1-[3-(Bromomethyl)-1-[4-

(trifluoromethyl)phenyl]pyrazol-5-yl]-4-(methylsulfonyl)benzene
641639-03-4P, Methyl 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]pyrazole-3-carboxylate **641639-04-5P**,
 1-[3-(Hydroxymethyl)-1-(4-methoxyphenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene **641639-05-6P**, 1-[3-(Bromomethyl)-1-(4-methoxyphenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene **641639-40-9P**, Methyl 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazole-3-carboxylate **641639-41-0P**, 1-[1-(4-Fluorophenyl)-3-(hydroxymethyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene **641639-42-1P**, 1-[3-(Bromomethyl)-1-(4-fluorophenyl)pyrazol-5-yl]-4-(methylsulfonyl)benzene **641639-45-4P**, 4-(Methylsulfonyl)-1-[1-phenyl-3-[(3-phenoxybutoxy)methyl]pyrazol-5-yl]benzene
641640-24-6P, 4-[5-[4-(Methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]butanoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of trisubstituted pyrazole cyclooxygenase-2 selective inhibitors)


RN 134730-09-9 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 641638-77-9 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 641638-78-0 CAPLUS


CN 1H-Pyrazole-3-methanol, 5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 641638-79-1 CAPLUS
CN 1H-Pyrazole, 3- (bromomethyl) -5- [4- (methylsulfonyl) phenyl] -1-phenyl- (9CI)
(CA INDEX NAME)




RN 641638-82-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-, 3-(phenylmethoxy)propyl ester (9CI) (CA INDEX NAME)




RN 641638-83-7 CAPLUS
CN 1H-Pyrazole-3-carbothioic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-, O-[3-(phenylmethoxy)propyl] ester (9CI) (CA INDEX NAME)




RN 641638-84-8 CAPLUS
CN 1H-Pyrazole, 3-[difluoro[3-(phenylmethoxy)propoxy]methyl]-5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 641638-88-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 641638-89-3 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 641638-90-6 CAPLUS
CN 1H-Pyrazole, 3-(bromomethyl)-1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 641638-93-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 641638-94-0 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 641638-95-1 CAPLUS
CN 1H-Pyrazole, 3-(bromomethyl)-1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 641638-98-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 641638-99-5 CAPLUS
CN 1H-Pyrazole-3-methanol, 5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 641639-00-1 CAPLUS

CN 1H-Pyrazole, 3-(bromomethyl)-5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 641639-03-4 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 641639-04-5 CAPLUS

CN 1H-Pyrazole-3-methanol, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)


10/764,529




RN 641639-05-6 CAPLUS
CN 1H-Pyrazole, 3-(bromomethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 641639-40-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 641639-41-0 CAPLUS
CN 1H-Pyrazole-3-methanol, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 641639-42-1 CAPLUS
CN 1H-Pyrazole, 3-(bromomethyl)-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)





RN 641639-45-4 CAPLUS
CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-3-[(3-phenoxybutoxy)methyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 641640-24-6 CAPLUS
CN 1H-Pyrazole-3-butanoic acid, 5-[4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. I [R1 = SO₂CH₃, SO₂NH₂; R1' = H, halo, Me, CH₂OH; R2 = alkyl, cycloalkyl, aryl, heterocyclic ring; R3 = (un)substituted alkyl, acyl, etc.] are prepared. For instance, Me (Z)-2-hydroxy-4-(4-methylthiophenyl)-4-oxobut-2-enoate (preparation given) is reacted with cyclooctylhydrazine trifluoroacetate (preparation given) (MeOH, 70°) to give Me 1-cyclooctyl-5-(4-methylthiophenyl)pyrazole-3-carboxylate. This is reduced (THF, LAH), oxidized to the sulfone (MeOH/H₂O, oxone) and reacted with NHO₃/Ac₂O (CHCl₃) to give II. Compds. of the invention exhibit cyclooxygenase 2 (COX-2) selectivity; II exhibits 75% inhibition of COX-2 at 10 μM and 35% inhibition of COX 1 at 100 μM. The

invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated and optionally at least one nitric oxide donor and/or optionally at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. Therapies are also disclosed that provide methods for: treating inflammation, pain and fever, for improving the gastrointestinal properties of COX-2 selective inhibitors, for facilitating wound healing, etc.

L4 ANSWER 13 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:20345 CAPLUS

DOCUMENT NUMBER: 140:77144

TITLE: Preparation of optionally nitrosated and/or nitrosylated oxime and/or hydrazone cyclooxygenase-2 selective inhibitors, compositions and methods of use

INVENTOR(S): Ranatunge, Ramani R.; Garvey, David S.; Richardson, Stewart K.

PATENT ASSIGNEE(S): Nitromed, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 74 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|-------|----------|-----------------|------------|
| ----- | ----- | ----- | ----- | ----- |
| US 2004006133 | A1 | 20040108 | US 2003-608333 | 20030630 |
| | | | US 2002-392044P | P 20020628 |


PRIORITY APPLN. INFO.: MARPAT 140:77144

OTHER SOURCE(S): IT 640727-83-9P 640727-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of optionally nitrosated and/or nitrosylated oxime and/or hydrazone cyclooxygenase-2 selective inhibitors, compns. and methods of use)


RN 640727-83-9 CAPLUS

CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-4-(nitrooxy)-, oxime (9CI) (CA INDEX NAME)



RN 640727-97-5 CAPLUS

CN Benzonitrile, 4-[3-[1-(hydroxyimino)-4-(nitrooxy)butyl]-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




IT 640727-87-3P 640727-88-4P 640728-01-4P

640728-02-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of optionally nitrosated and/or nitrosylated oxime and/or hydrazone cyclooxygenase-2 selective inhibitors, compns. and methods of use)


RN 640727-87-3 CAPLUS

CN 1-Butanone, 4-hydroxy-1-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl] - (9CI) (CA INDEX NAME)



RN 640727-88-4 CAPLUS


CN 1-Butanone, 1-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazol-3-yl]-4-(nitrooxy) - (9CI) (CA INDEX NAME)



RN 640728-01-4 CAPLUS


10/764,529

CN Benzonitrile, 4-[3-(4-hydroxy-1-oxobutyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)





RN 640728-02-5 CAPLUS

CN Benzonitrile, 4-[5-[4-(methylsulfonyl)phenyl]-3-[4-(nitrooxy)-1-oxobutyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



GI



AB The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group optionally nitrosated and/or nitrosylated (one class shown as I; variables defined below; e.g. II; 15 other classes of compds. are also described in the 1st claim) and novel compns. and kits comprising at least one I and optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors. Six examples of I were tested for inhibition of COX-1 and COX-2; e.g. 1-[1-cyclohexyl-3-[1-(hydroxyimino)-4-(nitrooxy)butyl]pyrazol-4-yl]-4-(methylsulfonyl)benzene inhibited COX-1 10 % at 100 μ M and COX-2 100 % at 10 μ M. Although the methods of preparation are not claimed, 6 example preps. are included. For example, II was prepared in 7 steps (79, 68, 84, 79, 51, 84 and 48 % yields, resp.) starting from di-Me oxalate, NaOMe and 4'-(methylthio)acetophenone in toluene and involving intermediates Me (2Z)-2-hydroxy-4-(4-methylthiophenyl)-4-oxobut-2-enoate, Me 5-(4-methylthiophenyl)-1-phenylpyrazole-3-carboxylate, N-methoxy-N-methyl-5-(4-methylthiophenyl)-1-phenylpyrazole-3-carboxamide, 1-[5-(4-methylthiophenyl)-1-phenylpyrazol-3-yl]-4-(1,1,2,2-tetramethyl-1-silapropoxy)butan-1-one, 4-hydroxy-1-[5-(4-methylsulfonyl)phenyl]-1-phenylpyrazol-3-yl]butan-1-one, and 1-[5-[4-(methylsulfonyl)phenyl]-1-phenylpyrazol-3-yl]-4-(nitrooxy)butan-1-one. For I: when side b is a double bond, and sides a and c are single bonds, -X1-Y1-Z1- is: -CR4(R5)CR5(R5')CR4(R5)-, -C(O)CR4(R4')CR5(R5')-, -CR4(R4')CR5(R5')C(O)-, -[CR5(R5')]kOC(O)-, etc.; when sides a and c are double bonds and side b is a single bond, -X1-Y1-Z1- is: :CR4OCR5:,

:CR4NR3CR5:, :NSCR4:, :CR4SN:, etc. R1 is S(O)2Me, S(O)2NR8(D1), S(O)2N(D1)C(O)CF₃, S(O)(NH)NH(D1), S(O)(NH)N(D1)C(O)CF₃, P(O)MeNH(D1), P(O)Me₂, C(S)NH(D1), S(O)(NH)Me, P(O)MeOD1, or P(O)MeNH(D1); R1' is H, halo, Me, or CH₂OH. R2 is lower alkyl, cycloalkyl, mono, di- or trisubstituted Ph or naphthyl, mono, di- or trisubstituted heteroaryl (wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one heteroatom which is S, O, or N, and, optionally, 1-3 addnl. N atoms; or the heteroaryl is a monocyclic ring of 6 atoms, said ring having one heteroatom which is N, and, optionally, 1-4 addnl. N atoms), benzoheteroaryl, NR10R11, SR11, OR11, R11, alkenyl, alkynyl, unsubstituted, mono, di, tri- or tetrasubstituted cycloalkenyl, mono, di, tri- or tetrasubstituted heterocycloalkyl group of 5-7 members, or a benzoheterocycle, wherein said heterocycloalkyl or benzoheterocycle contains 1 or 2 heteroatoms selected from O, S, or N and, optionally, contains a carbonyl group or a sulfonyl group, styryl, mono or disubstituted styryl, phenylacetylene, mono- or disubstituted phenylacetylene, fluoroalkenyl, mono- or disubstituted bicyclic heteroaryl of 8-10 members, containing 2-5 heteroatoms (wherein at least one heteroatom resides on each ring of said bicyclic heteroaryl, said heteroatoms are each independently O, S and N), K, aryl, arylalkyl, cycloalkylalkyl, -C(O)R11, hydrogen, arylalkenyl, arylalkoxy, alkoxy, aryloxy, cycloalkoxy, arylthio, alkylthio, arylalkylthio, or cycloalkylthio. R3 is hydrogen, haloalkyl (preferably CF₃), CN, lower alkyl, [C(Re)(Rf)]p-U-V, K, (un)substituted lower alkyl-Q, lower alkyl-O-lower alkyl-Q, etc., Q, alkylcarbonyl, arylcarbonyl, alkylarylcarbonyl, arylalkylcarbonyl, carboxylic ester, carboxamido, cycloalkyl, mono, di- or trisubstituted Ph or naphthyl, alkenyl, alkynyl, arylalkyl, lower alkyl-OD1, alkoxyalkyl, aminoalkyl, lower alkyl-CO₂R10, lower alkyl-C(O)NR10(R10'), heterocyclic alkyl, or heterocyclic ring-C(O)-; with the proviso that one oxime or hydrazone group must be present; addnl. details are given in the claims.

L4 ANSWER 14 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:1007863 CAPLUS

DOCUMENT NUMBER: 140:35975

TITLE: Compositions of tricyclic cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain

INVENTOR(S): Seibert, Karen

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 82 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--------|-----------|-----------------|------------|
| ----- | ----- | ----- | ----- | ----- |
| US 2003236293 | A1 | 20031225 | US 2002-246848 | 20020918 |
| PRIORITY APPLN. INFO.: | | | US 2001-322932P | P 20010918 |
| OTHER SOURCE(S): | MARPAT | 140:35975 | | |

IT 165251-89-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. of tricyclic cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain)



RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-


10/764,529

(trifluoromethyl) - (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB A composition is provided comprising a tricyclic cyclooxygenase-2 selective inhibitor and acetaminophen. The composition is effective for the treatment and prevention of inflammation, an inflammation-mediated disorder, and pain. A method of treatment is also claimed wherein the therapeutic effect is through prostaglandin synthesis inhibition.

L4 ANSWER 15 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:1001998 CAPLUS

DOCUMENT NUMBER: 140:314411

TITLE: Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors

AUTHOR(S): Singh, Sunil K.; Reddy, P. Ganapati; Rao, K. Srinivasa; Lohray, Braj B.; Misra, P.; Rajjak, Shaikh A.; Rao, Yeleswarapu K.; Venkateswarlu, A.

CORPORATE SOURCE: Discovery Chemistry, Discovery Research-Dr. Reddy's Laboratories Ltd, Miyapur, Hyderabad, 500 049, India

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(2), 499-504

PUBLISHER: CODEN: BMCL8; ISSN: 0960-894X

DOCUMENT TYPE: Elsevier Science B.V.

Journal

LANGUAGE: English


IT 304647-89-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(polar substitutions in benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors)

RN 304647-89-0 CAPLUS

CN Benzenesulfonamide, 2-(hydroxymethyl)-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)



AB Several chemical modifications in the N1-benzenesulfonamide ring of celecoxib are presented. The series with a hydroxymethyl group adjacent to the sulfonamide was found to be the most potent modification that yielded many compds. selectively active against COX-2 enzyme in vitro.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:971878 CAPLUS

DOCUMENT NUMBER: 140:13075

TITLE: Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX 2) inhibitor(s)

INVENTOR(S): Isakson, Peter C.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2003101441 | A1 | 20031211 | WO 2003-US14548 | 20030528 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |

10/764,529

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ; BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004063752 A1 20040401 US 2003-444072 20030523
CA 2487923 AA 20031211 CA 2003-2487923 20030528
BR 2003011518 A 20050222 BR 2003-11518 20030528
EP 1509217 A1 20050302 EP 2003-756170 20030528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: US 2002-384139P P 20020531
US 2003-444072 A 20030523
WO 2003-US14548 W 20030528

OTHER SOURCE(S): MARPAT 140:13075



IT 165251-89-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(monotherapy for treatment of amyotrophic lateral sclerosis with
selective cyclooxygenase-2 inhibitor(s) over cyclooxygenase-1)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB A method of treating, preventing, or inhibiting amyotrophic lateral



sclerosis (ALS), in a subject in need of such treatment, inhibition or prevention. The method comprises administering to a subject one or more cyclooxygenase-2 selective inhibitor(s), or isomer(s), or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, wherein the amount of the cyclooxygenase-2 selective inhibitor(s), isomer(s), ester(s), salt(s) or prodrug(s) thereof constitutes an ALS treatment, inhibition or prevention effective amount of the COX 2 inhibitor(s).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:971836 CAPLUS
 DOCUMENT NUMBER: 140:23256
 TITLE: Combination therapy for treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX 2) inhibitor(s) and a second drug
 INVENTOR(S): Isakson, Peter C.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 358 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003101380 | A2 | 20031211 | WO 2003-US14547 | 20030528 |
| WO 2003101380 | A3 | 20041111 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004063751 | A1 | 20040401 | US 2003-444071 | 20030523 |
| CA 2487885 | AA | 20031211 | CA 2003-2487885 | 20030528 |
| BR 2003011524 | A | 20050510 | BR 2003-11524 | 20030528 |
| EP 1539169 | A2 | 20050615 | EP 2003-731134 | 20030528 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRIORITY APPLN. INFO.: | | | US 2002-384104P | P 20020531 |
| | | | US 2003-444071 | A 20030523 |
| | | | WO 2003-US14547 | W 20030528 |

OTHER SOURCE(S): MARPAT 140:23256
 IT 165251-89-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy for amyotrophic lateral sclerosis treatment of with COX-2 inhibitor and second drug)
 RN 165251-89-8 CAPLUS
 CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



- AB A method of treating, preventing, or inhibiting ALS, in a subject in need of such treatment, inhibition or prevention. The method comprises administering to a subject one or more cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes an ALS treatment, inhibition or prevention effective amount

L4 ANSWER 18 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855795 CAPLUS

ACCESSION NUMBER: 139-345939
DOCUMENT NUMBER: 139:345939

TITLE: Monotherapy for the treatment of Parkinson's disease with cyclooxygenase 2 (COX2) inhibitor(s)

INVENTOR(S) : Stephenson, Diane T.; Isakson, Peter C.; Maziasz, Timothy J.

PATENT ASSIGNEE(S) : Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2003088959 | A2 | 20031030 | WO 2003-US11517 | 20030414 |
| WO 2003088959 | A3 | 20031231 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2482510 | AA | 20031030 | CA 2003-2482510 | 20030414 |
| US 2004006100 | A1 | 20040108 | US 2003-412970 | 20030414 |
| BR 2003009337 | A | 20050215 | BR 2003-9337 | 20030414 |
| EP 1505962 | A2 | 20050216 | EP 2003-746984 | 20030414 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRIORITY APPLN. INFO.: | | | US 2002-373317P | P 20020418 |
| | | | WO 2003-US11517 | W 20030414 |

OTHER SOURCE(S) : MARPAT 139:345939



IT 165251-89-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(cyclooxygenase 2 (COX2) inhibitor for treatment of Parkinson's
disease)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





AB The invention provides a method for treating, preventing, or inhibiting Parkinson's disease (PD), in a subject in need of such treatment, inhibition or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s), ester(s), salt(s) or prodrug(s) thereof, wherein the amount of the cyclooxygenase-2 selective inhibitor(s), ester(s), salt(s) or prodrug(s) thereof constitutes a PD treatment-, inhibition- or prevention-effective amount of the COX2 inhibitor(s).

L4 ANSWER 19 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855794 CAPLUS
 DOCUMENT NUMBER: 139:345938
 TITLE: Combination therapy including cyclooxygenase 2 (COX2) inhibitor(s) for the treatment of Parkinson's disease
 INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz, Timothy J.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 266 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--------|------------|-----------------|------------|
| WO 2003088958 | A2 | 20031030 | WO 2003-US11269 | 20030414 |
| WO 2003088958 | A3 | 20040819 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, ÅM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2481934 | AA | 20031030 | CA 2003-2481934 | 20030414 |
| US 2004034083 | A1 | 20040219 | US 2003-413348 | 20030414 |
| EP 1494664 | A2 | 20050112 | EP 2003-719717 | 20030414 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003009259 | A | 20050209 | BR 2003-9259 | 20030414 |
| JP 2005528403 | T2 | 20050922 | JP 2003-585710 | 20030414 |
| PRIORITY APPLN. INFO.: | | | US 2002-373311P | P 20020418 |
| | | | WO 2003-US11269 | W 20030414 |
| OTHER SOURCE(S): | MARPAT | 139:345938 | | |
| IT 165251-89-8 | | | | |



10/764,529

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(combination therapy including cyclooxygenase 2 inhibitor for treatment
of Parkinson's disease)


RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The invention discloses a method for treating, preventing, or inhibiting Parkinson's disease (PD) in a subject in need of such treatment, inhibition, or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes a PD treatment-, inhibition- or prevention-effective amount

L4 ANSWER 20 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:570814 CAPLUS

DOCUMENT NUMBER: 139:138734

TITLE: Use of COX-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections

INVENTOR(S) : Chong, Kong Teck
 PATENT ASSIGNEE(S) : Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 121 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003059347 | A1 | 20030724 | WO 2003-US16 | 20030110 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2472459 | AA | 20030724 | CA 2003-2472459 | 20030110 |
| US 2003211163 | A1 | 20031113 | US 2003-339906 | 20030110 |
| EP 1463500 | A1 | 20041006 | EP 2003-700670 | 20030110 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003006820 | A | 20041207 | BR 2003-6820 | 20030110 |
| JP 2005519061 | T2 | 20050630 | JP 2003-559509 | 20030110 |
| PRIORITY APPLN. INFO.: | | | US 2002-347550P | P 20020110 |
| | | | WO 2003-US16 | W 20030110 |



OTHER SOURCE(S): MARPAT 139:138734

IT 165251-89-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical COX-2 inhibitors in combination with antiviral agents for
 treatment of papilloma virus infections)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB A method of treating papilloma virus infections comprising administering topically a cyclooxygenase-2 (COX-2) inhibitor or its pharmaceutically acceptable salt in combination with an antiviral agent. An antiviral agent is selected from a podophyllin, a nucleoside analog, an immunomodulator, an antisense oligonucleotide, or a vaccine. For example, celecoxib and valdecoxit topical compns. were prepared in ethanol using 5% parecoxib as a permeation enhancer. The presence of parecoxib enhanced the flux of celecoxib and valdecoxit across the cadaver skin membrane by factor of 11.5 and 8.4, resp.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:492716 CAPLUS

DOCUMENT NUMBER: 139:63316

TITLE: Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia

INVENTOR(S): Masferrer, Jaime L.; Cherrington, Julie M.; Leahy, Kathleen M.; Zweifel, Ben S.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of Appl.

No. PCT/US99/30693.

CODEN: USXXCO



DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 21
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-----------------|-----------------|----------|
| US 2003119895 | A1 | 20030626 | US 2002-150546 | 20020516 |
| WO 2000038730 | A2 | 20000706 | WO 1999-US30693 | 19991222 |
| WO 2000038730 | A3 | 20001102 | | |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1522313 | A1 | 20050413 | EP 2004-26577 | 19991222 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY | | | | |
| CA 2484324 | AA | 20031127 | CA 2003-2484324 | 20030515 |
| WO 2003097044 | A1 | 20031127 | WO 2003-US15582 | 20030515 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| BR 2003010027 | A | 20050215 | BR 2003-10027 | 20030515 |
| EP 1509224 | A1 | 20050302 | EP 2003-734058 | 20030515 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 1998-113786P | P 19981223 | |
| | | WO 1999-US30693 | A2 19991222 | |
| | | US 1999-385214 | A 19990827 | |
| | | EP 1999-968939 | A3 19991222 | |
| | | US 2002-150546 | A 20020516 | |
| | | WO 2003-US15582 | W 20030515 | |


OTHER SOURCE(S): MARPAT 139:63316
 IT 165251-89-8 165251-89-8D, prodrug derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (heteroaryl indolinone-cyclooxygenase 2 inhibitor combination for treatment of neoplasia)
 RN 165251-89-8 CAPLUS
 CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A





PAGE 2-A




RN 165251-89-8 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The invention provides methods and compns. useful for treatment or prevention of neoplasia by administering a combination comprising a 3-heteroaryl-2-indolinone compound (preparation included) and a COX-2 selective inhibitor. Further provided are compns., pharmaceutical compns., and kits for treatment and prevention of neoplasia.

L4 ANSWER 22 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:154262 CAPLUS

DOCUMENT NUMBER: 138:198610

TITLE: Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate

INVENTOR(S): Pulaski, Steven P.; Kundel, Susan

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2003015799 | A1 | 20030227 | WO 2002-US25673 | 20020813 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003114416 A1 20030619 US 2002-215539 20020809

CA 2457452 AA 20030227 CA 2002-2457452 20020813

EP 1416941 A1 20040512 EP 2002-773188 20020813

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002011977 A 20040921 BR 2002-11977 20020813

JP 2005501850 T2 20050120 JP 2003-520758 20020813

PRIORITY APPLN. INFO.: US 2001-312211P P 20010814
US 2002-215539 A 20020809
WO 2002-US25673 W 20020813

OTHER SOURCE(S): MARPAT 138:198610



IT 165252-03-9 165252-03-9D, prodrug derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 inhibitor and chondroitin sulfate for treatment and prevention of pain and inflammation)

RN 165252-03-9 CAPLUS

CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





10/764,529

PAGE 2-A



RN 165252-03-9 CAPLUS
CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB A method of treating, preventing, or inhibiting pain, inflammation, or inflammation-associated disorder in a subject in need of such treatment or prevention includes treating the subject with chondroitin sulfate and a cyclooxygenase-2 selective inhibitor, or a prodrug thereof, wherein the amount of chondroitin sulfate and the amount of a cyclooxygenase-2 selective inhibitor or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain- or inflammation-suppressing treatment or prevention effective amount. Glucosamine can optionally be present. Compns.

that contain the combination of chondroitin sulfate and cyclooxygenase-2 selective inhibitor and, optionally, the glucosamine, are disclosed, as are pharmaceutical compns.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 23 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:154260 CAPLUS
 DOCUMENT NUMBER: 138:198609
 TITLE: Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
 INVENTOR(S): Pulaski, Steven P.; Kundel, Susan
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003015797 | A1 | 20030227 | WO 2002-US25674 | 20020813 |
| WO 2003015797 | C1 | 20041229 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2003114418 | A1 | 20030619 | US 2002-215816 | 20020809 |
| CA 2457453 | AA | 20030227 | CA 2002-2457453 | 20020813 |
| EP 1416940 | A1 | 20040512 | EP 2002-768522 | 20020813 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002011936 | A | 20041026 | BR 2002-11936 | 20020813 |
| JP 2005507871 | T2 | 20050324 | JP 2003-520756 | 20020813 |
| PRIORITY APPLN. INFO.: | | | US 2001-312272P | P 20010814 |
| | | | US 2002-215216 | A 20020809 |
| | | | US 2002-215816 | A 20020809 |
| | | | WO 2002-US25674 | W 20020813 |

OTHER SOURCE(S): MARPAT 138:198609

IT 165252-03-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment and prevention of pain and inflammation with formulations containing cyclooxygenase-2 selective inhibitors and glucosamine)
 RN 165252-03-9 CAPLUS
 CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with glucosamine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of glucosamine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount of the composition Compns. and pharmaceutical compns. that contain glucosamine and a cyclooxygenase-2 selective inhibitor are also disclosed.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:43025 CAPLUS

DOCUMENT NUMBER: 138:83362

TITLE: Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia

INVENTOR(S): Masferrer, Jaime L.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U. S. Ser. No. 470,951.

CODEN: USXXCO

DOCUMENT TYPE: Patent

10/764,529

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 21

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| US 2003013739 | A1 | 20030116 | US 2002-135793 | 20020430 |
| EP 1522313 | A1 | 20050413 | EP 2004-26577 | 19991222 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, RO, CY | | | | |
| CA 2483785 | AA | 20031113 | CA 2003-2483785 | 20030425 |
| WO 2003092691 | A1 | 20031113 | WO 2003-US13080 | 20030425 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| BR 2003004648 | A | 20040803 | BR 2003-4648 | 20030425 |
| EP 1499315 | A1 | 20050126 | EP 2003-728569 | 20030425 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| ZA 2003009905 | A | 20050314 | ZA 2003-9905 | 20031222 |
| PRIORITY APPLN. INFO.: | | | US 1998-113786P | P 19981223 |
| | | | US 1999-470951 | A2 19991222 |
| | | | US 1999-385214 | A 19990827 |
| | | | EP 1999-968939 | A3 19991222 |
| | | | US 2002-135793 | A 20020430 |
| | | | WO 2003-US13080 | W 20030425 |

OTHER SOURCE(S): MARPAT 138:83362



IT 165251-89-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(cyclooxygenase-2 inhibitor; combination of cyclooxygenase-2 selective
inhibitors and thalidomide for treatment of neoplasia)


RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The present invention provides compns. and methods for the treatment, prevention or inhibition of neoplasia by administering an effective amount of a cyclooxygenase-2 selective inhibitor in combination with an effective amount of thalidomide.

L4 ANSWER 25 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:942791 CAPLUS
 DOCUMENT NUMBER: 138:14058
 TITLE: Preparation of pyrazolylbenzenesulfonamides as cyclooxygenase inhibitors for treatment of inflammation.
 INVENTOR(S): Talley, John J.; Penning, Thomas D.; Collins, Paul W.; Rogier, Donald J., Jr.; Malecha, James W.; Miyashiro, Julie M.; Bertenshaw, Stephen R.; Khanna, Ish K.; Graneto, Matthew J.; Rogers, Roland S.; Carter, Jeffery S.; Docter, Stephen H.; Yu, Stella S.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: U.S., 55 pp., Cont.-in-part of U.S. 6,413,960.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|--|-----------------|-------------|
| US 6492411 | B1 | 20021210 | US 2002-125325 | 20020417 |
| US 5466823 | A | 19951114 | US 1993-160594 | 19931130 |
| US 5521207 | A | 19960528 | US 1994-223629 | 19940406 |
| WO 9515316 | A1 | 19950608 | WO 1994-US12720 | 19941114 |
| | W: | AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US | | |
| | RW: | KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | |
| US 5760068 | A | 19980602 | US 1996-648113 | 19960906 |
| US 6156781 | A | 20001205 | US 1999-449076 | 19991124 |
| US 6413960 | B1 | 20020702 | US 2000-609011 | 20000530 |
| US 6586603 | B1 | 20030701 | US 2002-274679 | 20021021 |
| US 6716991 | B1 | 20040406 | US 2003-378781 | 20030304 |
| US 2004192930 | A1 | 20040930 | US 2003-700019 | 20031103 |
| US 2005131050 | A1 | 20050616 | US 2005-48037 | 20050131 |
| PRIORITY APPLN. INFO.: | | | US 1993-160594 | A2 19931130 |
| | | | US 1994-223629 | A1 19940406 |
| | | | WO 1994-US12720 | A1 19941114 |
| | | | US 1996-648113 | A1 19960906 |
| | | | US 1997-957345 | B1 19971024 |
| | | | US 1999-449076 | A1 19991124 |
| | | | US 2000-609011 | A2 20000530 |
| | | | US 2002-125325 | A1 20020417 |
| | | | US 2002-274679 | A1 20021021 |
| | | | US 2003-378781 | A1 20030304 |
| | | | US 2003-700019 | A3 20031103 |


OTHER SOURCE(S): MARPAT 138:14058

IT 170570-43-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolylbenzenesulfonamides as cyclooxygenase inhibitors for treatment of inflammation)

RN 170570-43-1 CAPLUS

CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl] - (9CI) (CA INDEX NAME)



GI



AB A method for the treatment of headache comprises administration of an asthma treating-effective amount of title compds. [I; R₂ = H, alkyl, haloalkyl, alkoxy carbonyl, cyano, cyanoalkyl, CO₂H, aminocarbonyl, alkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, aminocarbonylalkyl, alkoxy carbonylcyanalkenyl hydroxyalkyl; R₃ = H, alkyl, cyano, hydroxyalkyl, cycloalkyl, alkylsulfonyl, halo; R₄ = aralkenyl, aryl, cycloalkyl, cycloalkenyl heterocyclic; R₄ is optionally substituted with ≥1 of alkylthio, alkylsulfonyl, cyano, nitro, haloalkyl, alkyl, OH, alkenyl, hydroxyalkyl, CO₂H, cycloalkyl, alkylamino, dialkylamino, alkoxy carbonyl, aminocarbonyl, alkoxy, haloalkoxy, sulfamyl, heterocyclic, amino; provided R₂ and R₃ are not both H; further provided that R₂ ≠ CO₂H or Me when R₃ = H and when R₄ = Ph; further provided that R₄ ≠ triazolyl when R₂ = Me; further provided that R₄ ≠ aralkenyl when R₂ = carboxyl, aminocarbonyl, ethoxycarbonyl; further provided that R₄ ≠ Ph when R₂ = Me and R₃ = CO₂H; and further provided that R₄ ≠ unsubstituted thieryl when R₂ = CF₃], is claimed. Thus, 4,4,4-trifluoro-1-[4-(chlorophenyl)butane-1,3-dione (preparation given) 4-sulfonamidophenylhydrazine hydrochloride were refluxed 20 h in EtOH to give 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide. The latter at 10 mg/kg gave 44% inhibition in the rat paw edema test.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:927290 CAPLUS

DOCUMENT NUMBER: 138:11413

TITLE: Use of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease

INVENTOR(S): Keller, Patricia G.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 160 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2002096516 | A1 | 20021205 | WO 2002-US17552 | 20020529 |
| WO 2002096516 | C1 | 20030220 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, | | | | |

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2447657 AA 20021205 CA 2002-2447657 20020529
 EP 1406696 A1 20040414 EP 2002-739651 20020529
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2002009776 A 20040713 BR 2002-9776 20020529
 JP 2004536073 T2 20041202 JP 2002-593022 20020529
 ZA 2003008822 A 20050214 ZA 2003-8822 20031112
 PRIORITY APPLN. INFO.: US 2001-294077P P 20010529
 WO 2002-US17552 W 20020529

OTHER SOURCE(S): MARPAT 138:11413



IT 165251-89-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(cyclooxygenase-2 selective inhibitors and radiation for inhibition or
prevention of cardiovascular disease)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10/764,529


AB The invention discusses the use of cyclooxygenase-2 selective inhibitor with a dose of radiation for the prevention or inhibition of cardiovascular disease.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:856309 CAPLUS
DOCUMENT NUMBER: 139:17018
TITLE: Enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis
AUTHOR(S): Perez-Maseda, C.; Calvet, C.; Cuberes, R.; Frigola, J.
CORPORATE SOURCE: Medicinal Chemistry Department, Laboratorios Dr. Esteve S.A., Barcelona, E-08041, Spain
SOURCE: Bioforum International (2002), 6(5), 275-277
CODEN: BINTFQ; ISSN: 1434-2693
PUBLISHER: GIT Verlag GmbH & Co. KG
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 134729-22-9P, E 6302 475590-76-2P, E 6612
RL: ANT (Analyte); PUR (Purification or recovery); ANST (Analytical study); PREP (Preparation)
(enantiosep. of novel COX-2 anti-inflammatory drugs by capillary electrophoresis)
RN 134729-22-9 CAPLUS
CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 475590-76-2 CAPLUS
CN 1H-Pyrazole, 1-(2,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



AB A capillary electrophoresis (CE) method was developed for the enantiosepn. of three novel COX-2 inhibitor drugs (E-6259, E-6036 and E-6087) with anti-inflammatory and analgesic activities using sulfobutylether- β -cyclodextrin (SBE- β -CD) as a chiral selector. The use of 50 mM sodium tetraborate at pH 9.2, 7.1 mM SBE- β -CD and 30 % MeOH (volume/volume), as a background electrolyte (BGE), allowed the complete enantiosepn. of the three neutral racemates and their corresponding metabolites in a single run. Migration times were shortened by adding 1.75 mM dimethyl- β -cyclodextrin (DM- β -CD) to the previous BGE (dual CD system). The reversal of the migration order of E-6259 enantiomers in the dual CD system was also studied.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:811992 CAPLUS
 DOCUMENT NUMBER: 137:310913
 TITLE: Preparation of fluoro-substituted benzenesulfonyl pyrazoles and isoxazoles for the treatment of cyclooxygenase-2 mediated disorders such as inflammation
 INVENTOR(S): Brown, David L.; Graneto, Matthew J.; Ludwig, Cindy L.; Molyneaux, John M.; Talley, John J.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: Eur. Pat. Appl., 171 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| EP 1251126 | A2 | 20021023 | EP 2002-8273 | 20020419 |
| EP 1251126 | A3 | 20021030 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2003032657 | A1 | 20030213 | US 2002-124209 | 20020416 |
| US 6673818 | B2 | 20040106 | | |
| US 2003149078 | A1 | 20030807 | US 2002-319916 | 20021213 |
| US 6699884 | B2 | 20040302 | | |
| US 2004138261 | A1 | 20040715 | US 2003-734829 | 20031212 |
| PRIORITY APPLN. INFO.: | | | US 2001-285264P | P 20010420 |

US 2002-124209
US 2002-319916A1 20020416
A1 20021213

OTHER SOURCE(S) : MARPAT 137:310913

IT 473299-26-2P, 5-[3,5-Difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole 473299-31-9P,
 1-(3-Chloro-4-methylphenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazole 473299-32-0P,
 5-[3,5-Difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1-[3-(trifluoromethyl)phenyl]-1H-pyrazole 473299-33-1P,
 5-[3,5-Difluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473299-35-3P,
 1-(3-Chloro-4-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473299-36-4P,
 1-(4-Chlorophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473299-37-5P,
 5-[2,5-Difluoro-4-(methylsulfonyl)phenyl]-1-[4-methoxyphenyl]-3-(trifluoromethyl)-1H-pyrazole 473299-39-7P,
 5-[3,5-Difluoro-4-(methylsulfonyl)phenyl]-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole 473299-40-0P,
 5-[3,5-Difluoro-4-(methylsulfonyl)phenyl]-1-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole 473299-42-2P,
 5-[2,5-Difluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-45-7P, 1-Phenyl-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-46-8P,
 1-(3-Chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-47-9P,
 1-(4-Chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-48-0P, 1-(3-Bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-49-1P, 1-(4-Bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-50-4P, 1-(3-Fluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-51-5P, 1-(3-Methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-52-6P, 1-(3-Cyanophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-53-7P, 1-(4-Cyanophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-54-8P, 1-(4-Trifluoromethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-55-9P, 1-(3-Trifluoromethoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-56-0P, 1-(3,4-Dichlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473300-57-1P, 1-(3,4-Dibromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-58-2P*
 , 1-(3,4-Difluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole *473300-59-3P, 1-(3,5-Dichlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-60-6P, 1-(3,5-Dibromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-61-7P, 1-(3,5-Difluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-62-8P, 1-(3,4-Dimethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-63-9P, 1-(3,5-Dimethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-64-0P, 1-(3-Methyl-4-chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-65-1P, 1-(3-Methyl-4-

fluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-66-2P, 1-(4-Methyl-3-fluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-67-3P, 1-(3-Methyl-4-bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-68-4P, 1-(4-Methyl-3-bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-69-5P, 1-(3-Methyl-4-trifluoromethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-70-8P, 1-(4-Methyl-3-trifluoromethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-71-9P, 1-(3-Methyl-4-trifluoromethoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-72-0P, 1-(4-Methyl-3-trifluoromethoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-73-1P, 1-(3-Cyano-4-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-74-2P, 1-(4-Cyano-3-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-75-3P, 1-(3-Chloro-4-methoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-76-4P, 1-(4-Chloro-3-methoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473300-85-5P, 1-Phenyl-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-86-6P, 1-(3-Chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-87-7P, 1-(4-Chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-88-8P, 1-(3-Bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-89-9P, 1-(4-Bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-90-2P, 1-(3-Fluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-91-3P, 1-(4-Fluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-92-4P, 1-(3-Methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-93-5P, 1-(4-Methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-94-6P, 1-(3-Cyanophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-95-7P, 1-(4-Cyanophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-96-8P, 1-(3-Trifluoromethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-97-9P, 1-(4-Trifluoromethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-98-0P, 1-(3-Trifluoromethoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473300-99-1P, 1-(4-Trifluoromethoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473301-00-7P, 1-(3,4-Dichlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473301-01-8P, 1-(3,4-Dibromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473301-02-9P, 1-(3,4-Difluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473301-03-0P, 1-(3,5-Dichlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole

473301-04-1P, 1-(3,5-Dibromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-05-2P, 1-(3,5-Difluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-06-3P, 1-(3,4-Dimethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-07-4P, 1-(3,5-Dimethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-08-5P, 1-(3-Methyl-4-chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-09-6P, 1-(3-Methyl-4-fluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-11-0P, 1-(4-Methyl-3-fluorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-12-1P, 1-(3-Methyl-4-bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-13-2P, 1-(4-Methyl-3-bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-14-3P, 1-(3-Methyl-4-trifluoromethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-15-4P, 1-(4-Methyl-3-trifluoromethylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-16-5P, 1-(3-Methyl-4-trifluoromethoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-17-6P, 1-(4-Methyl-3-trifluoromethoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-18-7P, 1-(3-Cyano-4-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-19-8P, 1-(4-Cyano-3-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-20-1P, 1-(3-Chloro-4-methoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473301-21-2P, 1-(4-Chloro-3-methoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-13-8P, 1-Phenyl-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole 473303-14-9P, 1-(3-Chlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-15-0P, 1-(3-Bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-16-1P, 1-(4-Bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-17-2P, 1-(3-Fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-18-3P, 1-(4-Fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-19-4P, 1-(3-Methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-20-7P, 1-(4-Methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-21-8P, 1-(3-Cyanophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-22-9P, 1-(4-Cyanophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-23-0P, 1-(3-Trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-24-1P, 1-(4-Trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-25-2P, 1-(3-Trifluoromethoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-26-3P, 1-(3,4-Dichlorophenyl)-5-[3,6-difluoro-4-

(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-27-4P, 1-(3,4-Dibromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-28-5P, 1-(3,4-Difluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-29-6P, 1-(3,5-Dichlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-30-9P, 1-(3,5-Dibromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-31-0P, 1-(3,5-Difluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-33-2P, 1-(3,4-Dimethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-34-3P, 1-(3,5-Dimethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-35-4P, 1-(4-Methyl-3-chlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-36-5P, 1-(4-Methyl-3-chlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-37-6P, 1-(3-Methyl-4-fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-38-7P, 1-(4-Methyl-3-fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-39-8P, 1-(3-Methyl-4-bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-40-1P, 1-(4-Methyl-3-bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-41-2P, 1-(3-Methyl-4-trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-42-3P, 1-(4-Methyl-3-trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-43-4P, 1-(3-Methyl-4-trifluoromethoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-44-5P, 1-(4-Methyl-3-trifluoromethoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-45-6P, 1-(3-Cyano-4-methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-46-7P, 1-(4-Cyano-3-methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-47-8P, 1-(3-Chloro-4-methoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-48-9P, 1-(4-Chloro-3-methoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole
 473303-57-0P, 1-Phenyl-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole 473303-58-1P, 1-(3-Chlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-59-2P, 1-(4-Chlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-60-5P, 1-(3-Bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-61-6P, 1-(4-Bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-62-7P, 1-(3-Fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-63-8P, 1-(4-Fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-64-9P, 1-(3-Methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-65-0P, 1-(4-Methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole


473303-66-1P, 1-(3-Cyanophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-67-2P, 1-(4-Cyanophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-68-3P, 1-(3-Trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-69-4P, 1-(4-Trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-70-7P, 1-(3-Trifluoromethoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-71-8P, 1-(4-Trifluoromethoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-72-9P, 1-(3,4-Dichlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-73-0P, 1-(3,4-Dibromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-74-1P, 1-(3,4-Difluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-75-2P, 1-(3,5-Dichlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-76-3P, 1-(3,5-Dibromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-77-4P, 1-(3,5-Difluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-78-5P, 1-(3,4-Dimethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-79-6P, 1-(3,5-Dimethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-80-9P, 1-(3-Methyl-4-chlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-81-0P, 1-(4-Methyl-3-chlorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-82-1P, 1-(3-Methyl-4-fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-83-2P, 1-(4-Methyl-3-fluorophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-84-3P, 1-(3-Methyl-4-bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-85-4P, 1-(4-Methyl-3-bromophenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-86-5P, 1-(3-Methyl-4-trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-87-6P,
 , 1-(4-Methyl-3-trifluoromethylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-88-7P, 1-(3-Methyl-4-trifluoromethoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-89-8P, 1-(4-Methyl-3-trifluoromethoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-90-1P, 1-(3-Cyano-4-methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-91-2P, 1-(4-Cyano-3-methylphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-92-3P, 1-(3-Chloro-4-methoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 473303-93-4P, 1-(4-Chloro-3-methoxyphenyl)-5-[3,6-difluoro-4-(methylsulfonyl)phenyl]-3-(difluoromethyl)-1H-pyrazole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/764,529

(drug candidate; preparation of fluoro-substituted benzenesulfonyl pyrazoles and isoxazoles for treatment of cyclooxygenase-2 mediated disorders such as inflammation)


RN 473299-26-2 CAPLUS

CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473299-31-9 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 473299-32-0 CAPLUS


CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 473299-33-1 CAPLUS


10/764,529

CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473299-35-3 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473299-36-4 CAPLUS

CN 1H-Pyrazole, 1-(4-chlorophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473299-37-5 CAPLUS


CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-methoxyphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473299-39-7 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-methoxyphenyl)-
3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473299-40-0 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-methylphenyl)-
3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473299-42-2 CAPLUS
CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-45-7 CAPLUS

CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-46-8 CAPLUS

CN 1H-Pyrazole, 1-(3-chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-47-9 CAPLUS


CN 1H-Pyrazole, 1-(4-chlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-48-0 CAPLUS
CN 1H-Pyrazole, 1-(3-bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-49-1 CAPLUS
CN 1H-Pyrazole, 1-(4-bromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-50-4 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-fluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-51-5 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-52-6 CAPLUS
CN Benzonitrile, 3-[5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473300-53-7 CAPLUS
CN Benzonitrile, 4-[5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473300-54-8 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473300-55-9 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)






RN 473300-57-1 CAPLUS

CN 1H-Pyrazole, 1-(3,4-dibromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-58-2 CAPLUS

CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,4-difluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-59-3 CAPLUS

CN 1H-Pyrazole, 1-(3,5-dichlorophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-60-6 CAPLUS

CN 1H-Pyrazole, 1-(3,5-dibromophenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-61-7 CAPLUS

CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-difluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-62-8 CAPLUS

CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,4-dimethylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-63-9 CAPLUS

CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-dimethylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-64-0 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-65-1 CAPLUS


CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluoro-3-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-66-2 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-fluoro-4-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-67-3 CAPLUS
CN 1H-Pyrazole, 1-(4-bromo-3-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-68-4 CAPLUS
CN 1H-Pyrazole, 1-(3-bromo-4-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-69-5 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-methyl-4-(trifluoromethyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-70-8 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-methyl-3-(trifluoromethyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-71-9 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-72-0 CAPLUS
CN 1H-Pyrazole, 5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-methyl-3-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473300-73-1 CAPLUS
CN Benzonitrile, 5-[5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473300-74-2 CAPLUS
CN Benzonitrile, 4-[5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473300-75-3 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-76-4 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methoxyphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473300-85-5 CAPLUS


CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 473300-86-6 CAPLUS
CN 1H-Pyrazole, 1-(3-chlorophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 473300-87-7 CAPLUS
CN 1H-Pyrazole, 1-(4-chlorophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473300-88-8 CAPLUS
CN 1H-Pyrazole, 1-(3-bromophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473300-89-9 CAPLUS

CN 1H-Pyrazole, 1-(4-bromophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473300-90-2 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473300-91-3 CAPLUS


CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473300-92-4 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-
1-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 473300-93-5 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-
1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 473300-94-6 CAPLUS
CN Benzonitrile, 3-[3-(difluoromethyl)-5-[3,5-difluoro-4-
(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473300-95-7 CAPLUS

CN Benzonitrile, 4-[3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473300-96-8 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473300-97-9 CAPLUS


CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473300-98-0 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473300-99-1 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-00-7 CAPLUS
CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-01-8 CAPLUS
CN 1H-Pyrazole, 1-(3,4-dibromophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 473301-02-9 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 473301-03-0 CAPLUS
CN 1H-Pyrazole, 1-(3,5-dichlorophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-04-1 CAPLUS

CN 1H-Pyrazole, 1-(3,5-dibromophenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-05-2 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 473301-06-3 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 473301-07-4 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 473301-08-5 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methylphenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-09-6 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluoro-3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 473301-11-0 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-fluoro-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 473301-12-1 CAPLUS

CN 1H-Pyrazole, 1-(4-bromo-3-methylphenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-13-2 CAPLUS


CN 1H-Pyrazole, 1-(3-bromo-4-methylphenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-14-3 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[3-methyl-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-15-4 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-16-5 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[3-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-17-6 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[4-methyl-3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 473301-18-7 CAPLUS
CN Benzonitrile, 5-[3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473301-19-8 CAPLUS
CN Benzonitrile, 4-[3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473301-20-1 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473301-21-2 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methoxyphenyl)-3-(difluoromethyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-13-8 CAPLUS


CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-14-9 CAPLUS
CN 1H-Pyrazole, 1-(3-chlorophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473303-15-0 CAPLUS
CN 1H-Pyrazole, 1-(3-bromophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-16-1 CAPLUS
CN 1H-Pyrazole, 1-(4-bromophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-17-2 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-fluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-18-3 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-19-4 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-20-7 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-21-8 CAPLUS

CN Benzonitrile, 3-[5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473303-22-9 CAPLUS

CN Benzonitrile, 4-[5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473303-23-0 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-24-1 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-25-2 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-26-3 CAPLUS

CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-27-4 CAPLUS

CN 1H-Pyrazole, 1-(3,4-dibromophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-28-5 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,4-difluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-29-6 CAPLUS

CN 1H-Pyrazole, 1-(3,5-dichlorophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-30-9 CAPLUS

CN 1H-Pyrazole, 1-(3,5-dibromophenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-31-0 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-difluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-33-2 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,4-dimethylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-34-3 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-dimethylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-35-4 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methylphenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-36-5 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-37-6 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluoro-3-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-38-7 CAPLUS

CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-fluoro-4-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-39-8 CAPLUS

CN 1H-Pyrazole, 1- (4-bromo-3-methylphenyl) -5-[2,5-difluoro-4-(methylsulfonyl)phenyl] -3-(trifluoromethyl) - (9CI) (CA INDEX NAME)




RN 473303-40-1 CAPLUS

CN 1H-Pyrazole, 1- (3-bromo-4-methylphenyl) -5-[2,5-difluoro-4-(methylsulfonyl)phenyl] -3-(trifluoromethyl) - (9CI) (CA INDEX NAME)




RN 473303-41-2 CAPLUS


CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-methyl-4-(trifluoromethyl)phenyl]-3-(trifluoromethyl) - (9CI) (CA INDEX NAME)




RN 473303-42-3 CAPLUS
CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-methyl-3-(trifluoromethyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473303-43-4 CAPLUS
CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[3-methyl-4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-44-5 CAPLUS
CN 1H-Pyrazole, 5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-methyl-3-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-45-6 CAPLUS

CN Benzonitrile, 5-[5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473303-46-7 CAPLUS

CN Benzonitrile, 4-[5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473303-47-8 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-48-9 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methoxyphenyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473303-57-0 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 473303-58-1 CAPLUS


CN 1H-Pyrazole, 1-(3-chlorophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-59-2 CAPLUS
CN 1H-Pyrazole, 1-(4-chlorophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-60-5 CAPLUS
CN 1H-Pyrazole, 1-(3-bromophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-61-6 CAPLUS
CN 1H-Pyrazole, 1-(4-bromophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-62-7 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473303-63-8 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473303-64-9 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 473303-65-0 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 473303-66-1 CAPLUS
CN Benzonitrile, 3-[3-(difluoromethyl)-5-[2,5-difluoro-4-
(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473303-67-2 CAPLUS
CN Benzonitrile, 4-[3-(difluoromethyl)-5-[2,5-difluoro-4-
(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 473303-68-3 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-69-4 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-70-7 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-71-8 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-72-9 CAPLUS
CN 1H-Pyrazole, 1-(3,4-dichlorophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-73-0 CAPLUS
CN 1H-Pyrazole, 1-(3,4-dibromophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-74-1 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 473303-75-2 CAPLUS
CN 1H-Pyrazole, 1-(3,5-dichlorophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-76-3 CAPLUS
CN 1H-Pyrazole, 1-(3,5-dibromophenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-77-4 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 473303-78-5 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 473303-79-6 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 473303-80-9 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methylphenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-81-0 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-82-1 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(4-fluoro-3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 473303-83-2 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-(3-fluoro-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 473303-84-3 CAPLUS

CN 1H-Pyrazole, 1-(4-bromo-3-methylphenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-85-4 CAPLUS


CN 1H-Pyrazole, 1-(3-bromo-4-methylphenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-86-5 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[3-methyl-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-87-6 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-88-7 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-
1-[3-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-89-8 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1-[4-methyl-3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 473303-90-1 CAPLUS
CN Benzonitrile, 5-[3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473303-91-2 CAPLUS
CN Benzonitrile, 4-[3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 473303-92-3 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 473303-93-4 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methoxyphenyl)-3-(difluoromethyl)-5-[2,5-difluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



GI



AB Fluoro-substituted benzenesulfonyl compds. (shown as I (e.g. 1-(3-chloro-4-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole), or a pharmaceutically-acceptable salt, tautomer or prodrug thereof) for treating cyclooxygenase-2 mediated disorders such as inflammation are described. In I, A is a 5- or 6-member ring substituent selected from partially saturated or unsatd. heterocyclic and carbocyclic rings; X is fluoro; n ≥ 2; R1 is cyclohexyl, pyridinyl, or Ph, optionally substituted with 1-3 radicals selected from C1-2-alkyl, C1-2-haloalkyl, cyano, carboxy, C1-2-alkoxycarbonyl, hydroxy, C1-2-hydroxyalkyl, C1-2-haloalkoxy, amino, C1-2-alkylamino, phenylamino, nitro, C1-2-alkoxy-C1-2-alkyl, C1-2-alkylsulfinyl, halo, C1-2-alkoxy and C1-3-alkylthio; R2 is alkyl or amino. R3 represents ≥1 radicals selected from hydrido, halo, C1-2-alkyl, C2-3-alkenyl, C2-3-alkynyl, oxo, cyano, carboxy, cyano-C1-3-alkyl, heterocyclyloxy, C1-3-alkoxy, C1-3-alkylthio, alkylcarbonyl, cycloalkyl, Ph, C1-3-haloalkyl, heterocyclyl, cycloalkenyl, phenyl-C1-3-alkyl, heterocyclyl-C1-3-alkyl, C1-3-alkylthio-C1-3-alkyl, C1-3-hydroxyalkyl, C1-3-alkoxycarbonyl, phenylcarbonyl, phenyl-C1-3-alkylcarbonyl, phenyl-C2-3-alkenyl, C1-3-alkoxy-C1-3-alkyl, phenylthio-C1-3-alkyl, phenoxyalkyl, alkoxyphenylalkoxyalkyl, alkoxy carbonylalkyl, aminocarbonyl, aminocarbonyl-C1-3-alkyl, C1-3-alkylaminocarbonyl, N-phenylaminocarbonyl, N-(C1-3-alkyl)-N-phenylaminocarbonyl, C1-3-alkylaminocarbonyl-C1-3-alkyl, carboxy-C1-3-alkyl, C1-3-alkylamino, N-arylamino, N-aralkylamino, N-(C1-3-alkyl)-N-aralkylamino, N-(C1-3-alkyl)-N-arylamino, amino-C1-3-alkyl, C1-3-alkylaminoalkyl, N-phenylamino-C1-3-alkyl, N-phenyl-C1-3-alkylaminoalkyl, N-(C1-3-alkyl)-N-(phenyl-C1-3-alkyl)amino-C1-3-alkyl, N-(C1-3-alkyl)-N-phenylamino-C1-3-alkyl, phenoxy, phenylalkoxy, phenylthio, phenyl-C1-3-alkylthio, C1-3-alkylsulfinyl, C1-3-alkylsulfonyl, aminosulfonyl, C1-3-alkylaminosulfonyl, N-phenylaminosulfonyl, phenylsulfonyl, and N-(C1-3-alkyl)-N-phenylaminosulfonyl. The selective inhibition of COX-2 compared to COX-1 is reported for 10 examples of I; e.g. 1-(3-chloro-4-methylphenyl)-5-[3,5-difluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazole shows IC50 values of 0.09 and >100 μM, resp. Although the methods of preparation are not claimed, 15 example preps. are included and hundreds of pyrazoles and isoxazoles are listed in the claims.

L4 ANSWER 29 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:777650 CAPLUS
 DOCUMENT NUMBER: 137:299910
 TITLE: Therapeutic combinations containing COX-2 inhibitors for cardiovascular and inflammatory diseases treatment
 INVENTOR(S): Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.; Krul, Elaine S.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 316 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2002078626 | A2 | 20021010 | WO 2002-US9346 | 20020328 |
| WO 2002078626 | A3 | 20040429 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2442328 | AA | 20021010 | CA 2002-2442328 | 20020328 |
| US 2003199482 | A1 | 20031023 | US 2002-107809 | 20020328 |
| EP 1435956 | A2 | 20040714 | EP 2002-725362 | 20020328 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| CN 1527709 | A | 20040908 | CN 2002-810210 | 20020328 |
| JP 2005507854 | T2 | 20050324 | JP 2002-576894 | 20020328 |
| US 2004186154 | A1 | 20040923 | US 2004-473045 | 20040506 |
| PRIORITY APPLN. INFO.: | | | US 2001-279239P | P 20010328 |
| | | | WO 2002-US9346 | W 20020328 |



IT 165251-89-8


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic combinations containing COX-2 inhibitors for cardiovascular
 and inflammatory diseases treatment)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





AB The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an ASBT inhibitor combined with COX-2 inhibitor. A further therapeutic combination comprises an ASBT inhibitor, a COX-2 inhibitor and an HMG Co-A reductase inhibitor. Another therapeutic combination comprises a chromene COX-2 inhibitor and an HMG Co-A reductase inhibitor. Thus, a tablet composition contained benzothiepine 5, celecoxib 20, lactose 54, microcryst. cellulose 15, HPMC 3, Croscarmellose sodium 2, and Mg stearate 1 mg/tablet.

L4 ANSWER 30 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:505977 CAPLUS

DOCUMENT NUMBER: 137:375361

TITLE: Enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems

AUTHOR(S): Calvet, Carmen; Cuberes, Rosa; Perez-Maseda, Carlos; Frigola, Jordi

CORPORATE SOURCE: Medicinal Chemistry Department, Laboratorios Dr. Esteve S. A., Barcelona, E-08041, Spain

SOURCE: Electrophoresis (2002), 23(11), 1702-1708
CODEN: ELCTDN; ISSN: 0173-0835

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 134729-22-9 475590-76-2

RL: ANT (Analyte); ANST (Analytical study)
(enantiosep. of novel COX-2 anti-inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems)


RN 134729-22-9 CAPLUS

CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 475590-76-2 CAPLUS

CN 1H-Pyrazole, 1-(2,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



AB A capillary electrophoresis method was developed for the enantiosepn. of three novel cyclooxygenase-2 (COX-2) inhibitor drugs (E-6259, E-6036 and E-6087) with anti-inflammatory and analgesic activities using sulfobutyl ether- β -cyclodextrin (SBE- β -CD) as a chiral selector. The use of 50 mM sodium tetraborate at pH 9.2 with 30% volume/volume methanol, containing

7.1 mM SBE- β -CD, as a background electrolyte (BGE) allowed the complete enantiosepn. of the three neutral racemic mixts: (resolution = 2.4, 3.0 and 8.7, resp.) and their corresponding metabolites (oxidation products) in a single run. Migration times were shortened with some loss of enantioresln. by adding 1.75 mM dimethyl- β -cyclodextrin (DM- β -CD) to the previous BGE (dual CD system). The reversal of the migration order of E-6259 enantiomers in the dual CD system was also studied. Furthermore, the addition of DM- β -CD to the BGE introduced a new chemoselectivity in the system that allowed E-6259 to be separated from the structurally similar compound E-6036.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:71857 CAPLUS

DOCUMENT NUMBER: 136:139826

TITLE: Selective cyclooxygenase-2 inhibitors and

vasomodulator compounds for generalized pain and
headache pain



INVENTOR(S) : Hassan, Fred; Forbes, James C.
PATENT ASSIGNEE(S) : Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|--|--|
| WO 2002005799 | A2 | 20020124 | WO 2001-US22103 | 20010713 |
| WO 2002005799 | A3 | 20021121 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2415697 | AA | 20020124 | CA 2001-2415697 | 20010713 |
| AU 2001082886 | A5 | 20020130 | AU 2001-82886 | 20010713 |
| US 2002077328 | A1 | 20020620 | US 2001-905292 | 20010713 |
| EP 1299122 | A2 | 20030409 | EP 2001-961637 | 20010713 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004503588 | T2 | 20040205 | JP 2002-511732
US 2000-218101P
US 2001-284248P
US 2001-296196P
WO 2001-US22103 | 20010713
P 20000713
P 20010417
P 20010606
W 20010713 |
| PRIORITY APPLN. INFO.: | | | | |

OTHER SOURCE(S) : MARPAT 136:139826

IT 165251-89-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitors and vasomodulators for generalized pain
and headache pain treatment)
RN 165251-89-8 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB A therapeutic combination useful in the treatment, amelioration, prevention, or delay of pain comprising a high energy form of a selective cyclooxygenase-2 inhibitor, a vasomodulator, and a pharmaceutically acceptable excipient, carrier, or diluent, the cyclooxygenase-2 inhibitor and vasomodulator each being present in an amount effective to contribute to the treatment, prevention, or delay of pain. Thus, capsules contained celecoxib 200, Labrasol 280, diethylene glycol monoethyl ether 280, and propylene glycol laurate 140/capsule.

L4 ANSWER 32 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:798213 CAPLUS

DOCUMENT NUMBER: 135:344477

TITLE: Preparation of 2-fluorobenzenesulfonyl-heterocycles with COX-1 and COX-2 inhibiting activity for pharmaceutical use in the treatment of inflammation

INVENTOR(S): Brown, David L.; Graneto, Matthew J.; Ludwig, Cindy L.; Talley, John J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 242 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2001081332 | A2 | 20011101 | WO 2001-US12983 | 20010420 |
| WO 2001081332 | A3 | 20020404 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002183362 | A1 | 20021205 | US 2001-839424 | 20010420 |
| EP 1296971 | A2 | 20030402 | EP 2001-927279 | 20010420 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 6600052 | B1 | 20030729 | US 2001-838986 | 20010420 |
| JP 2003531201 | T2 | 20031021 | JP 2001-578423 | 20010420 |
| US 2004092552 | A1 | 20040513 | US 2003-258493 | 20030711 |
| PRIORITY APPLN. INFO.: | | | | |
| US 2000-199533P P 20000425 | | | | |
| US 2000-253380P P 20001127 | | | | |
| WO 2001-US12983 W 20010420 | | | | |


OTHER SOURCE(S) : MARPAT 135:344477

IT 370874-38-7P 370874-40-1P 370874-41-2P
 370874-42-3P 370874-43-4P 370874-44-5P
 370874-45-6P 370874-47-8P 370874-48-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-fluorobenzenesulfonyl-heterocycles with COX-1 and COX-2 inhibiting activity for pharmaceutical use in the treatment of inflammation)

RN 370874-38-7 CAPLUS

CN 1H-Pyrazole, 5-[3-fluoro-4-(methylsulfonyl)phenyl]-1-(4-fluorophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 370874-40-1 CAPLUS
 CN 1H-Pyrazole, 5-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 370874-41-2 CAPLUS

CN 1H-Pyrazole, 5-[3-fluoro-4-(methylsulfonyl)phenyl]-1-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 370874-42-3 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 370874-43-4 CAPLUS


CN Benzonitrile, 4-[5-[3-fluoro-4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 370874-44-5 CAPLUS
CN 1H-Pyrazole, 5-[3-fluoro-4-(methylsulfonyl)phenyl]-1-(3-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 370874-45-6 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-1-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 370874-47-8 CAPLUS
CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-3-(difluoromethyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 370874-48-9 CAPLUS
 CN 1H-Pyrazole, 3-(difluoromethyl)-5-[3-fluoro-4-(methylsulfonyl)phenyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




GI



AB 2-Fluorobenzenesulfonyl-heterocycles, such as I [A = 5 or 6 membered heterocycle or carbocycle, such as pyrazole, thiophene, isoxazole, furan; R1 = cyclohexyl, pyridinyl, Ph; R2 = Me, NH₂; R3 = H, oxo, CN, halogen, alkyl, alkenyl, carboxyl, haloalkyl, heterocyclyl, cycloalkenyl, aminocarbonyl, etc.] with COX-1 and COX-2 inhibiting activity, were prepared for therapeutic use as anti-inflammatory agents. Thus, pyrazole II was prepared via a multistep synthetic sequence in which the last step was a cyclocondensation reaction of 4-H₂NSO₂-3-F-C₆H₃NHNH₂ and 3-Cl-4-Me-C₆H₃COCH₂COCHF₂ achieved by refluxing for 1 h. concentrated HCl in EtOH to give II with 53% yield. The prepared heterocycles were tested for COX-1 and -2 inhibiting activity.

L4 ANSWER 33 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:699248 CAPLUS
 DOCUMENT NUMBER: 136:2171
 TITLE: QSAR and k-Nearest Neighbor Classification Analysis of Selective Cyclooxygenase-2 Inhibitors Using Topologically-Based Numerical Descriptors
 AUTHOR(S): Kauffman, Gregory W.; Jurs, Peter C.
 CORPORATE SOURCE: Department of Chemistry, The Pennsylvania State University, University Park, PA, 16802, USA
 SOURCE: Journal of Chemical Information and Computer Sciences (2001), 41(6), 1553-1560
 CODEN: JCISD8; ISSN: 0095-2338
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 170570-43-1
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase-2 inhibitor; QSAR and k-nearest neighbor classification anal. of selective cyclooxygenase-2 inhibitors using topol.-based numerical descriptors)
 RN 170570-43-1 CAPLUS
 CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)



AB Exptl. IC₅₀ data for 314 selective cyclooxygenase-2 (COX-2) inhibitors are used to develop quantitation and classification models as a potential screening mechanism for larger libraries of target compds. Exptl. log(IC₅₀) values ranged from 0.23 to ≥ 5.00. Numerical descriptors encoding solely topol. information are calculated for all structures and are used as inputs for linear regression, computational neural network, and classification anal. routines. Evolutionary optimization algorithms are then used to search the descriptor space for information-rich subsets which minimize the rms error of a diverse training set of compds. An eight-descriptor model was identified as a robust predictor of exptl. log(IC₅₀) values, producing a root-mean-square error of 0.625 log units for an external prediction set of inhibitors which took no part in model development. A k-nearest neighbor classification study of the data set discriminating between active and inactive members produced a nine-descriptor model able to accurately classify 83.3% of the prediction set compds. correctly.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS

10/764,529


RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 62 CAPLUS COPYRIGHT 2005 ACS on STM
ACCESSION NUMBER: 2001:167997 CAPLUS
DOCUMENT NUMBER: 134:207814
TITLE: Preparation of sulfonylphenylpyrazoles as COX-2 inhibitors
INVENTOR(S): Kolasa, Teodozyj; Patel, Meena V.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2001016138 | A1 | 20010308 | WO 2000-US23214 | 20000824 |
| W: CA, JP, MX
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE | | | | |
| CA 2379421 | AA | 20010308 | CA 2000-2379421 | 20000824 |
| EP 1206474 | A1 | 20020522 | EP 2000-955867 | 20000824 |
| EP 1206474 | B1 | 20040526 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY | | | | |
| AT 267830 | E | 20040615 | AT 2000-955867 | 20000824 |
| PT 1206474 | T | 20041029 | PT 2000-955867 | 20000824 |
| ES 2222919 | T3 | 20050216 | ES 2000-955867 | 20000824 |
| US 6472416 | B1 | 20021029 | US 2000-648202 | 20000825 |
| PRIORITY APPLN. INFO.: | | | US 1999-151247P | P 19990827 |
| | | | US 1999-384954 | A 19990827 |
| | | | WO 2000-US23214 | W 20000824 |


OTHER SOURCE(S): MARPAT 134:207814

IT 329076-51-9P 329076-52-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylphenylpyrazoles as COX-2 inhibitors)
RN 329076-51-9 CAPLUS
CN 3H-Pyrazol-3-one, 1-(3,4-difluorophenyl)-4-(4-fluorophenyl)-1,2-dihydro-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 329076-52-0 CAPLUS

CN 1H-Pyrazole, 1-(3,4-difluorophenyl)-4-(4-fluorophenyl)-3-methoxy-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-III; one of R1 and R2 = IV, V (wherein R7 = alkyl, NH₂, (di)alkylamino; X₄ = SO₂, SO(NR₈); R₈ = H, alkyl, cycloalkyl; R₉ = H, halo) and the other of R1 and R2 = hydroxyalkyl, halo, alkyl, etc.; R₃ = alkyl, alkenyl, aryl, etc.; R₄ = H, alkyl, alkenyl, etc.; X₁ = O, NR₄, S; X₂ = O(CH₂)_n, S(CH₂)_n, NR₄(CH₂)_n (n = 0-1), etc.; X₃ = absent, CH₂, CR₁₅R₁₆ (R₁₅, R₁₆ = H, alkyl); R₅, R₆ = H, alkyl, aryl, etc.; R₅ and R₆ taken together with the atoms to which they are attached = (un)substituted 5-7 membered ring, optionally aromatic, and optionally containing 1-2 heteroatoms

selected from O, N, and S], useful in the treatment of cyclooxygenase-2 mediated diseases, were prepared E.g., a multi-step synthesis of the pyrazolooxazine VI which showed IC₅₀ of 720 nM against COX-2, was given.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS


RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 35 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:150965 CAPLUS
 DOCUMENT NUMBER: 135:286
 TITLE: The anti-inflammatory effect of FR188582, a highly selective inhibitor of cyclooxygenase-2, with an ulcerogenic sparing effect in rats
 AUTHOR(S): Ochi, Takehiro; Yamane-Sugiyama, Aiko; Ohkubo, Yoshitaka; Sakane, Kazuo; Tanaka, Hirokazu
 CORPORATE SOURCE: Department of Immunology and Inflammation, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
 SOURCE: Japanese Journal of Pharmacology (2001), 85(2), 175-182
 CODEN: JJPAAZ; ISSN: 0021-5198
 PUBLISHER: Japanese Pharmacological Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT 189699-82-9
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-inflammatory and ulcerogenic effect of FR188582, a cyclooxygenase-2 inhibitor, in rats)

RN 189699-82-9 CAPLUS

CN 1H-Pyrazole, 3-chloro-5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)



AB The anti-inflammatory and ulcerogenic effects of FR188582, 3-chloro-5-[4-(methylsulfonyl)phenyl]-1-phenyl-1H-pyrazole, were investigated. In a recombinant human cyclooxygenase (COX) enzyme activity, FR188582 inhibited COX-2 with an IC₅₀ value of 0.017 μM, and the inhibition of prostaglandin (PG) E2 formation by FR188582 was over 6000 times more selective for COX-2 than COX-1. Oral administration of FR188582 dose-dependently inhibited adjuvant arthritis. This effect was threefold more potent than that of indomethacin. FR188582 and indomethacin dose-dependently suppressed the formation of immunoreactive PGE₂, but not immunoreactive leukotriene B₄, in arthritic paw. Unlike indomethacin, FR188582 did not induce visible gastric lesions in rats at doses up to 32 mg/kg, p.o. Furthermore, FR188582 did not inhibit the level of immunoreactive PGE₂ and immunoreactive 6-keto PGF_{1α} in rat gastric mucosa. These results suggest that FR188582, a highly selective COX-2 inhibitor, has a potent anti-inflammatory effect mediated by inhibition of PGE₂ in inflamed tissues. The safety profile of FR188582 appears to be improved over the safety profile of indomethacin.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:790480 CAPLUS
 DOCUMENT NUMBER: 133:335232
 TITLE: Preparation of pyrazoles as antiinflammatory agents
 INVENTOR(S): Lohray, Vidya Bhushan; Sunil, Kumar Singh; Akella, Venkateswarlu; Lohray, Braj Bhushan; Pamulapati, Ganapathi Reddy; Ramanujam, Rajagopalan; Parimal, Misra
 PATENT ASSIGNEE(S): Reddy's Research Foundation, India
 SOURCE: PCT Int. Appl., 134 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2000066562 | A1 | 20001109 | WO 2000-IB556 | 20000502 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |


PRIORITY APPLN. INFO.: IN 1999-MA508 A 19990503

OTHER SOURCE(S): MARPAT 133:335232

IT 304647-89-0P 304648-08-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazoles as antiinflammatory agents)


RN 304647-89-0 CAPLUS

CN Benzenesulfonamide, 2-(hydroxymethyl)-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)




RN 304648-08-6 CAPLUS
 CN Benzenesulfonamide, 2-(hydroxymethyl)-4-[5-[3-methyl-4-

(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = NH₂, alkyl, alkylamino, etc.; R2 = CN, NO₂, N₃, etc.; R3 = H, halo, OH, etc.; R4-R6 = H, halo, OH, etc.; m = 0-2], useful for the treatment and/or prophylaxis of diseases of cyclooxygenase, more particularly COX-2, were prepared. E.g., a multi-step synthesis of the pyrazole II which showed IC₅₀ of 0.56 ± 0.03 (100 μM) against COX-2 vs. IC₅₀ of 264 ± 0.5 (100 μM) against COX-1, was given.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 37 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:512989 CAPLUS

DOCUMENT NUMBER: 134:25105

TITLE: Three-dimensional quantitative structural activity relationship (3D-QSAR) studies of some 1,5-diarylpyrazoles: Analogue based design of selective cyclooxygenase-2 inhibitors

AUTHOR(S): Desiraju, Gautam R.; Gopalakrishnan, Bulusu; Jetti, Ram K. R.; Raveendra, Dayam; Sarma, Jagarlapudi A. R.

CORPORATE SOURCE: P., Subramanya, Hosahalli S.
 School of Chemistry, University of Hyderabad,
 Hyderabad, 500 046, India
 SOURCE: Molecules [online computer file] (2000), 5(7), 945-955
 CODEN: MOLEFW; ISSN: 1420-3049
 URL: <http://www.mdpi.org/molecules/papers/50700945.pdf>
 PUBLISHER: Molecular Diversity Preservation International
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
IT 312304-51-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (3D-QSAR studies of some 1,5-diarylpyrazoles: design of selective cyclooxygenase-2 inhibitors)
RN 312304-51-1 CAPLUS
CN Benzenesulfonamide, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl] - (9CI) (CA INDEX NAME)



AB Selective cyclooxygenase inhibitors have attracted much attention in recent times in the design of new non-steroidal anti-inflammatory drugs (NSAID). 3D-QSAR studies have been performed on a series of 1,5-diarylpyrazoles that act as selective cyclooxygenase-2 (COX-2) inhibitors, using three different methods: comparative mol. field anal. (CoMFA) with partial least squares (PLS) fit; mol. field anal. (MFA) and; receptor surface anal. (RSA) with genetic function algorithms (GFA). The analyses were carried out on 30 analogs of which 25 were used in the training set and the rest considered for the test set. These studies produced reasonably good predictive models with high cross-validated and conventional r^2 values in all the three cases.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:456913 CAPLUS
 DOCUMENT NUMBER: 133:84241
 TITLE: Combination therapy of radiation and a cyclooxygenase 2 (COX-2) inhibitor for the treatment of neoplasia
 INVENTOR(S): McKearn, John P.; Masferrer, Jaime L.; Milas, Luka
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 21

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 20000038716 | A1 | 20000706 | WO 1999-US30669 | 19991222 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6649645 | B1 | 20031118 | US 1999-385214 | 19990827 |
| CA 2356547 | AA | 20000706 | CA 1999-2356547 | 19991222 |
| EP 1140181 | A1 | 20011010 | EP 1999-968939 | 19991222 |
| EP 1140181 | B1 | 20041110 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| BR 9916544 | A | 20020108 | BR 1999-16544 | 19991222 |
| JP 2002535249 | T2 | 20021022 | JP 2000-590667 | 19991222 |
| AU 769665 | B2 | 20040129 | AU 2000-27134 | 19991222 |
| AU 2000027134 | A5 | 20000731 | | |
| AT 281845 | E | 20041115 | AT 1999-968939 | 19991222 |
| PT 1140181 | T | 20050228 | PT 1999-968939 | 19991222 |
| EP 1522313 | A1 | 20050413 | EP 2004-26577 | 19991222 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY | | | | |
| ES 2232205 | T3 | 20050516 | ES 1999-968939 | 19991222 |
| NO 2001003064 | A | 20010823 | NO 2001-3064 | 20010620 |
| US 2004053934 | A1 | 20040318 | US 2003-460866 | 20030613 |
| US 2004053935 | A1 | 20040318 | US 2003-461983 | 20030613 |
| PRIORITY APPLN. INFO.: | | | US 1998-113786P | P 19981223 |
| | | | US 1999-385214 | A 19990827 |
| | | | EP 1999-968939 | A3 19991222 |
| | | | WO 1999-US30669 | W 19991222 |

IT 165251-89-8 165251-89-8D, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(COX-2 inhibitor-radiotherapy combination for neoplasia treatment)

RN 165251-89-8 CAPLUS


CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)

10/764,529




PAGE 1-A



PAGE 2-A



RN 165251-89-8 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a COX-2 inhibitor.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

1.4 ANSWER 39 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:227637 CAPLUS

ACCESSION NUMBER: 100-00000
DOCUMENT NUMBER: 132:251149

TITLE: Preparation of phenylpyrazoles as cyclooxygenase-2 inhibitors

INVENTOR(S) : Konishi, Nobukiyo; Nakamura, Katsuya; Yamamoto, Hirofumi; Manabe, Takashi

PATENT ASSIGNEE(S) : Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE :

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2000018741 | A2 | 20000406 | WO 1999-JP5289 | 19990927 |
| WO 2000018741 | A3 | 20000608 | | |

W: BR, CA, CN, JP, KR, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

PRIORITY APPLN. INFO.:

AU 1998-6231

A 19980930

AU 1999-2243

A 19990816

OTHER SOURCE(S): MARPAT 132:251149


IT 262850-06-6P 262850-08-8P 262850-10-2P
262850-11-3P 262850-14-6P 262850-25-9P
262850-27-1P 262850-97-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenylpyrazoles as cyclooxygenase-2 inhibitors)


RN 262850-06-6 CAPLUS

CN Methanol, [[4-[3-chloro-1-(3-chloro-4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262850-08-8 CAPLUS

CN 1-Propanol, 3-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-10-2 CAPLUS

CN Ethanol, 2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-


10/764,529

pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-11-3 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-5-[4-[(2-methylthio)ethyl]sulfonyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 262850-14-6 CAPLUS

CN Acetic acid, [[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 262850-25-9 CAPLUS

CN Methanol, [[4-[1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-27-1 CAPLUS

CN Methanol, [[4-[3-chloro-1-(4-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262850-97-5 CAPLUS


CN Methanol, [[4-[3-chloro-1-(3-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



IT 262850-07-7P 262850-09-9P 262850-12-4P
 262850-13-5P 262850-15-7P 262850-16-8P
 262850-17-9P 262850-18-0P 262850-19-1P
 262850-20-4P 262850-21-5P 262850-22-6P
 262850-23-7P 262850-30-6P 262850-31-7P
 262850-32-8P 262850-33-9P 262850-34-0P
 262850-36-2P 262850-37-3P 262850-38-4P
 262850-40-8P 262850-41-9P 262850-42-0P
 262850-43-1P 262850-44-2P 262850-46-4P
 262850-47-5P 262850-49-7P 262850-51-1P
 262850-53-3P 262850-56-6P 262850-57-7P
 262850-58-8P 262850-59-9P 262850-60-2P
 262850-63-5P 262850-64-6P 262850-65-7P
 262850-66-8P 262850-67-9P 262850-68-0P
 262850-69-1P 262850-70-4P 262850-73-7P
 262850-74-8P 262850-76-0P 262850-77-1P
 262850-78-2P 262850-79-3P 262850-80-6P
 262850-81-7P 262850-82-8P 262850-83-9P
 262850-85-1P 262850-86-2P 262850-87-3P
 262850-88-4P 262850-89-5P 262850-91-9P
 262850-92-0P 262850-93-1P 262850-94-2P
 262850-95-3P 262850-98-6P 262851-00-3P
 262851-01-4P 262851-03-6P 262851-04-7P
 262851-06-9P 262851-07-0P 262851-09-2P
 262851-10-5P 262851-11-6P 262851-14-9P
 262851-15-0P 262851-21-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylpyrazoles as cyclooxygenase-2 inhibitors)

RN 262850-07-7 CAPLUS
 CN Methanol, [[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-09-9 CAPLUS

CN Ethanol, 2-[[4-[3-chloro-1-(3-chloro-4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-12-4 CAPLUS

CN 1-Pentanol, 5-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-13-5 CAPLUS

CN 1-Butanol, 4-[(4-[(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-15-7 CAPLUS

CN Ethanamine, 2-[(4-[(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 262850-16-8 CAPLUS

CN Ethanamine, 2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-17-9 CAPLUS

CN Ethanol, 2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262850-18-0 CAPLUS


CN Ethanol, 2-[4-[4-(3-chloro-4-methoxyphenyl)-1H-pyrazol-5-yl]phenylsulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262850-19-1 CAPLUS


CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-5-[4-[[2-(methylsulfonyl)ethyl]sulfonyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/764,529




RN 262850-20-4 CAPLUS

CN Methanol, [[4-[1-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenylsulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-21-5 CAPLUS

CN Ethanol, 2-[[4-[1-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenylsulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-22-6 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-[4-[(acetoxy)methylsulfonyl]phenyl]-1-(4-chloro-3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 262850-23-7 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-chloro-3-methoxyphenyl)-5-[4-[(2-hydroxyethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 262850-30-6 CAPLUS

CN 1H-Pyrazole, 3-chloro-5-[4-[(2-methoxyethyl)sulfonyl]phenyl]-1-[(1-methylethenyl)phenyl]- (9CI) (CA INDEX NAME)




RN 262850-31-7 CAPLUS

CN Ethanol, 2-[(4-[3-chloro-1-[4-(1-methylethenyl)phenyl]-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-32-8 CAPLUS

CN Ethanol, 2-[(4-[1-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-33-9 CAPLUS

CN 1-Propanol, 3-[(4-[1-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




10/764,529


RN 262850-34-0 CAPLUS
CN Ethanol, 2-[[4-[1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-36-2 CAPLUS
CN Ethanol, 2-[[4-[1-(3-chloro-4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-37-3 CAPLUS
CN Ethanol, 2-[[4-[1-(3-chloro-4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-38-4 CAPLUS

CN Ethanol, 2-[(4-[1-(4-fluoro-3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-40-8 CAPLUS


CN 1H-Pyrazole, 1-(4-fluoro-3-methylphenyl)-5-[(2-methoxyethyl)sulfonyl]phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 262850-41-9 CAPLUS
CN 1H-Pyrazole, 5-[4-[(2-methoxyethyl)sulfonyl]phenyl]-1-(3-methylphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 262850-42-0 CAPLUS
CN Ethanol, 2-[[4-[(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-43-1 CAPLUS
CN 1H-Pyrazole, 1-(3-fluoro-4-methylphenyl)-5-[(2-


10/764,529

methoxyethyl) sulfonyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 262850-44-2 CAPLUS

CN Ethanol, 2-[[4-[1-(3-fluoro-4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-46-4 CAPLUS

CN Ethanol, 2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-fluorophenyl]sulfonyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 262850-47-5 CAPLUS
CN 1H-Pyrazole, 1-(4-chloro-3-methylphenyl)-5-[4-[(2-methoxyethyl)sulfonyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 262850-49-7 CAPLUS
CN 1H-Pyrazole, 5-[4-[(2-methoxyethyl)sulfonyl]phenyl]-1-[4-(1-methylethenyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 262850-51-1 CAPLUS
CN Ethanol, 2-[[4-[1-(3-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-53-3 CAPLUS
CN 1H-Pyrazole, 1-(3-chlorophenyl)-5-[4-[(2-methoxyethyl)sulfonyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 262850-56-6 CAPLUS
CN 1H-Pyrazole, 5-[4-[(2-methoxyethyl)sulfonyl]phenyl]-1-[4-(1-methylethyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 262850-57-7 CAPLUS
CN Benzonitrile, 5-[5-[4-[(acetyloxy)methylsulfonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 262850-58-8 CAPLUS

CN Benzonitrile, 5-[5-[(4-[(2-hydroxyethyl)sulfonyl]phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-2-methoxyphenyl]acetonitrile (9CI) (CA INDEX NAME)




RN 262850-59-9 CAPLUS

CN 1H-Pyrazole, 1-[(3-chloro-4-methoxyphenyl)-5-[(3-methoxypropyl)sulfonyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 262850-60-2 CAPLUS

CN Acetamide, 2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 262850-63-5 CAPLUS

CN Acetamide, 2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 262850-64-6 CAPLUS

CN 2-Propanone, 1-[(4-[(1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]sulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 262850-65-7 CAPLUS

CN 1-Propanol, 3-[(4-[(1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]sulfonyl)phenyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-66-8 CAPLUS
CN 1-Propanamine, 3-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 262850-67-9 CAPLUS
CN Ethanamine, 2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 262850-68-0 CAPLUS

CN Methanol, [[4-[1-(3-chloro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-69-1 CAPLUS

CN 1-Propanol, 3-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-70-4 CAPLUS

CN Ethanol, 2-[[2-[[4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 262850-73-7 CAPLUS

CN Ethanol, 2-[[4-[1-(4-bromo-3-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-74-8 CAPLUS

CN 1-Propanol, 3-[(4-[1-(4-bromo-3-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-76-0 CAPLUS


CN Methanol, [[4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262850-77-1 CAPLUS


10/764,529

CN Ethanol, 2-[4-[3-(difluoromethyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-78-2 CAPLUS

CN Methanol, [[4-[1-(3-bromophenyl)-3-chloro-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-79-3 CAPLUS

CN 1-Propanol, 3-[[4-[1-(3-bromophenyl)-3-chloro-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-80-6 CAPLUS

CN Methanol, [[4-[3-chloro-1-(3-fluoro-4-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-81-7 CAPLUS

CN 1-Propanol, 3-[(4-[3-chloro-1-(4-fluoro-4-methylphenyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-82-8 CAPLUS

CN Methanol, [(4-[3-chloro-1-(4-fluoro-3-methylphenyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262850-83-9 CAPLUS

CN Ethanol, 2-[[4-[3-chloro-1-(4-fluoro-3-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-85-1 CAPLUS

CN 1-Propanol, 3-[[4-[3-chloro-1-(4-fluoro-3-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-86-2 CAPLUS

CN 1-Propanol, 3-[(4-[3-chloro-1-(3-chloro-4-methoxyphenyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 262850-87-3 CAPLUS

CN Ethanol, 2-[(4-[1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 262850-88-4 CAPLUS
CN 1-Propanol, 3-[[4-[3-chloro-1-[4-(1-methylethenyl)phenyl]-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-89-5 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(3-chloro-4-methoxyphenyl)-5-[4-[(2-methoxyethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 262850-91-9 CAPLUS
CN Ethanol, 2-[[4-[3-chloro-1-(4-chloro-3-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-92-0 CAPLUS


CN 1-Propanol, 3-[(4-[3-chloro-1-(4-chloro-3-methylphenyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-93-1 CAPLUS


CN 1-Propanol, 3-[(4-[3-chloro-1-(3-chloro-4-methylphenyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 262850-94-2 CAPLUS

CN Ethanol, 2-[[4-[3-chloro-1-(3-chloro-4-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-95-3 CAPLUS


CN 1-Propanol, 3-[[4-[3-chloro-1-(4-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 262850-98-6 CAPLUS


10/764,529

CN Ethanol, 2-[[4-[3-chloro-1-(3-methylphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262851-00-3 CAPLUS

CN Methanol, [[4-(3-chloro-1-phenyl-1H-pyrazol-5-yl)phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262851-01-4 CAPLUS

CN 1-Propanol, 3-[[4-(3-chloro-1-phenyl-1H-pyrazol-5-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262851-03-6 CAPLUS


CN Methanol, [[4-[3-chloro-1-(4-chloro-3-methoxyphenyl)-1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262851-04-7 CAPLUS
CN 1-Propanol, 3-[(4-[3-chloro-1-(4-chloro-3-methoxyphenyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 262851-06-9 CAPLUS.
CN Methanol, [(4-[3-chloro-1-(3-chlorophenyl)-1H-pyrazol-5-yl]phenyl)sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262851-07-0 CAPLUS
CN 1-Propanol, 3-[(4-[3-chloro-1-(3-chlorophenyl)-1H-pyrazol-5-


10/764,529

yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262851-09-2 CAPLUS

CN Methanol, [[4- [3-chloro-1- (4-chlorophenyl) -1H-pyrazol-5-yl]phenyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 262851-10-5 CAPLUS

CN Ethanol, 2- [[4- [3-chloro-1- (4-chlorophenyl) -1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262851-11-6 CAPLUS


CN 1-Propanol, 3- [[4- [3-chloro-1- (4-chlorophenyl) -1H-pyrazol-5-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 262851-14-9 CAPLUS
CN Methanol, [[4-[3-chloro-1-(4-fluorophenyl)-1H-pyrazol-5-yl]phenylsulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 262851-15-0 CAPLUS
CN 1-Propanol, 3-[[4-[3-chloro-1-(4-fluorophenyl)-1H-pyrazol-5-yl]phenylsulfonyl]- (9CI) (CA INDEX NAME)





RN 262851-21-8 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(3-chloro-4-methoxyphenyl)-5-[4-[(2-methoxyethyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

GI



AB The title compds. (I) [wherein R¹ = haloalkyl, halo, or cyano; R² = (un)substituted aryl; R³ = H, OH, acyloxy, (un)substituted alkoxy; R⁴ = H or halo; A = alkylene (un)substituted with :O or OH; n = 0-2, provided that when R³ = H, R² = aryl substituted with alkenyl or A is alkylene substituted with oxo], and its salt, were prepared. For example, Na 4-[1-(3-chloro-4-methoxyphenyl)-3-(trifluoromethyl)pyrazol-5-yl]benzenesulfinate (preparation given) reacted with 3-bromopropanol in DMF to give II. In tests against human cyclooxygenase (COX) in transfected Chinese hamster ovary cells, II inhibited COX-II ($IC_{50} = \leq 1 \mu M$) selectively over COX-I ($IC_{50} = > 100 \mu M$). I are useful for the

treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, various immunity diseases, analgesic, thrombosis, cancer, or neurodegenerative diseases (no data).

L4 ANSWER 40 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:753114 CAPLUS
 DOCUMENT NUMBER: 132:6353
 TITLE: Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
 INVENTOR(S): Boyce, Susan; Hill, Raymond George; Rupniak, Nadia Melanie
 PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK
 SOURCE: PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 9959635 | A1 | 19991125 | WO 1999-GB1632 | 19990519 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2327585 | AA | 19991125 | CA 1999-2327585 | 19990519 |
| AU 9939486 | A1 | 19991206 | AU 1999-39486 | 19990519 |
| AU 758983 | B2 | 20030403 | | |
| EP 1079863 | A1 | 20010307 | EP 1999-922393 | 19990519 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002515461 | T2 | 20020528 | JP 2000-549299 | 19990519 |
| US 2004097573 | A1 | 20040520 | US 2003-614389 | 20030707 |
| PRIORITY APPLN. INFO.: | | | GB 1998-10920 | A 19980521 |
| | | | WO 1999-GB1632 | W 19990519 |
| | | | US 2000-700776 | B1 20001120 |

OTHER SOURCE(S): MARPAT 132:6353



IT 165251-89-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (COX-2 inhibitor and a NK-1 receptor antagonist for treating
 inflammation)


RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The present invention provides the use of a COX-2 inhibitor and a NK-1 receptor antagonist for the manufacture of a medicament for the treatment or prevention of inflammatory disorders, methods of treatment using the COX-2 inhibitor and NK-1 receptor antagonist and pharmaceutical compns. and products containing them. One example NK-1 antagonist is 2R-[1R-[3,5-bis(trifluoromethyl)phenyl]ethoxy]3S-(4-fluorophenyl)-4-[3-(5-oxo-1H,4H-1,2,4-triazolo)methyl]morpholine. Tablet formulations were given.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:222918 CAPLUS
 DOCUMENT NUMBER: 130:252354
 TITLE: Preparation of 1,5-diphenylpyrazoles as COX-2 inhibitors
 INVENTOR(S): Nakamura, Katsuya; Okumura, Kazuo; Ogino, Takashi; Kato, Takeshi; Yamamoto, Hirofumi; Terasaka, Tadashi; Noda, Yuka
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 9915505 | A1 | 19990401 | WO 1998-JP4150 | 19980914 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2303359 | AA | 19990401 | CA 1998-2303359 | 19980914 |
| AU 9890038 | A1 | 19990412 | AU 1998-90038 | 19980914 |
| AU 750356 | B2 | 20020718 | | |
| EP 1017678 | A1 | 20000712 | EP 1998-941873 | 19980914 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| JP 2002510333 | T2 | 20020402 | JP 1999-518803 | 19980914 |
| BR 9812389 | A | 20050524 | BR 1998-12389 | 19980914 |
| TW 429253 | B | 20010411 | TW 1998-87115706 | 19980921 |
| ZA 9808681 | A | 19990331 | ZA 1998-8681 | 19980922 |
| US 6316485 | B1 | 20011113 | US 2000-508507 | 20000323 |
| PRIORITY APPLN. INFO.: | | | AU 1997-9414 | A 19970924 |
| | | | WO 1998-JP4150 | W 19980914 |

OTHER SOURCE(S) : MARPAT 130:252354


IT 221686-11-9P 221686-12-0P 221686-13-1P
 221686-14-2P 221686-15-3P 221686-16-4P
 221686-17-5P 221686-18-6P 221686-19-7P
 221686-20-0P 221686-21-1P 221686-22-2P
 221686-23-3P 221686-24-4P 221686-25-5P
 221686-26-6P 221686-27-7P 221686-28-8P
 221686-29-9P 221686-30-2P 221686-31-3P
 221686-32-4P 221686-33-5P 221686-34-6P
 221686-35-7P 221686-36-8P 221686-37-9P
 221686-38-0P 221686-39-1P 221686-40-4P
 221686-41-5P 221686-42-6P 221686-43-7P
 221686-44-8P 221686-45-9P 221686-46-0P
 221686-47-1P 221686-48-2P 221686-49-3P
 221686-50-6P 221686-51-7P 221686-52-8P
 221686-53-9P 221686-54-0P 221686-55-1P
 221686-56-2P 221686-57-3P 221686-58-4P
 221686-59-5P 221686-60-8P 221686-61-9P
 221686-62-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,5-diphenylpyrazoles as COX-2 inhibitors)


RN 221686-11-9 CAPLUS
 CN 1H-Pyrazole, 1-(3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 221686-12-0 CAPLUS
CN 1H-Pyrazole, 1-(4-chloro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-13-1 CAPLUS
CN 1H-Pyrazole, 1-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/764,529


RN 221686-14-2 CAPLUS

CN 1H-Pyrazole, 1-(4-bromo-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-15-3 CAPLUS

CN 1H-Pyrazole, 1-(4-fluoro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-16-4 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-17-5 CAPLUS

CN 1H-Pyrazole, 1-(4-bromo-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-18-6 CAPLUS

CN 1H-Pyrazole, 1-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-19-7 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-20-0 CAPLUS

CN 1H-Pyrazole, 1-(3-bromo-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-21-1 CAPLUS

CN 1H-Pyrazole, 1-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-22-2 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-23-3 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-24-4 CAPLUS

CN 1H-Pyrazole, 1-(4-chloro-3-methylphenyl)-3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-25-5 CAPLUS

CN 1H-Pyrazole, 1-(4-bromo-3-methylphenyl)-3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-26-6 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-27-7 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methylphenyl)-3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-28-8 CAPLUS

CN 1H-Pyrazole, 1-(3-bromo-4-methylphenyl)-3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-29-9 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221686-30-2 CAPLUS


CN 1H-Pyrazole, 1-[4-(1-methylethyl)phenyl]-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 221686-31-3 CAPLUS


10/764,529

CN 1H-Pyrazole, 1-(3-bromo-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221686-32-4 CAPLUS

CN 1H-Pyrazole, 1-(3-chloro-4-methoxyphenyl)-3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-33-5 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-34-6 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-chloro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-35-7 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 1-(4-bromo-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-36-8 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-fluoro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-37-9 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-chloro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221686-38-0 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-bromo-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-39-1 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-40-4 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(3-chloro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-41-5 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(3-bromo-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-42-6 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-43-7 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(3-chloro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-44-8 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(3-bromo-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-45-9 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 221686-46-0 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-47-1 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(4-chloro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-48-2 CAPLUS
CN 1H-Pyrazole, 1-(4-bromo-3-methylphenyl)-3-chloro-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221686-49-3 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(4-chloro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-50-6 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-51-7 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(3-chloro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-52-8 CAPLUS


CN 1H-Pyrazole, 1-(3-bromo-4-methylphenyl)-3-chloro-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221686-53-9 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(3-chloro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-54-0 CAPLUS
CN 1H-Pyrazole, 3-chloro-1-(4-ethylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221686-55-1 CAPLUS


10/764,529

CN 1H-Pyrazole, 3-chloro-1-(3-chloro-4-ethylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-56-2 CAPLUS

CN 1H-Pyrazole, 3-chloro-5-[4-(methylsulfonyl)phenyl]-1-(4-propylphenyl)- (9CI) (CA INDEX NAME)




RN 221686-57-3 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(3-chloro-4-propylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-58-4 CAPLUS

CN 1H-Pyrazole, 1-[3-chloro-4-(1-methylethyl)phenyl]-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 221686-59-5 CAPLUS


CN 1H-Pyrazole, 3-chloro-1-[4-(1-methylethyl)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221686-60-8 CAPLUS


10/764,529

CN 1H-Pyrazole, 3-chloro-1-(4-fluoro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-61-9 CAPLUS

CN Benzonitrile, 5-[3-chloro-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 221686-62-0 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(4-methoxy-3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




IT 151506-66-0 221687-09-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1,5-diphenylpyrazoles as COX-2 inhibitors)


RN 151506-66-0 CAPLUS

CN 1H-Pyrazole, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 221687-09-8 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




IT 221686-65-3P 221686-66-4P 221686-68-6P
 221686-69-7P 221686-70-0P 221686-71-1P
 221686-72-2P 221686-73-3P 221686-74-4P
 221686-76-6P 221686-77-7P 221686-78-8P
 221686-79-9P 221686-80-2P 221686-81-3P
 221686-94-8P 221686-95-9P 221687-00-9P
 221687-01-0P 221687-02-1P 221687-03-2P
 221687-04-3P 221687-05-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1,5-diphenylpyrazoles as COX-2 inhibitors)


RN 221686-65-3 CAPLUS

CN 1H-Pyrazole, 1-(4-methoxy-3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 221686-66-4 CAPLUS

CN Benzenamine, 2-methoxy-5-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 221686-68-6 CAPLUS


10/764,529

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-69-7 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-chloro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-70-0 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-bromo-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-71-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-fluoro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-72-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-chloro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-73-3 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-bromo-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-74-4 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-76-6 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(3-chloro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-77-7 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(3-bromo-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-78-8 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-79-9 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(3-chloro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221686-80-2 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-methoxy-3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 221686-81-3 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 1-(3-amino-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221686-94-8 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(3-methoxy-4-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221686-95-9 CAPLUS

CN Benzenamine, 4-[3-chloro-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 221687-00-9 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(4-ethyl-3-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 221687-01-0 CAPLUS

CN 1H-Pyrazole, 3-chloro-5-[4-(methylsulfonyl)phenyl]-1-(3-nitro-4-propylphenyl)- (9CI) (CA INDEX NAME)




RN 221687-02-1 CAPLUS

CN 1H-Pyrazole, 1-[4-(1-methylethyl)-3-nitrophenyl]-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 221687-03-2 CAPLUS

CN Benzenamine, 5-[3-chloro-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 221687-04-3 CAPLUS

CN Benzenamine, 5-[3-chloro-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-2-propyl- (9CI) (CA INDEX NAME)





RN 221687-05-4 CAPLUS

CN Benzenamine, 2-(1-methylethyl)-5-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = Cl, F2CH, F3C, CN; R2 = II-IV (wherein X = halo, CN, NO₂, NH₂; Y1, Y2 = alkyl, alkoxy; Y3 = Et, Pr, iPr; Z = H, halo)], COX-II inhibiting agents useful for the treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, various immunity diseases, thrombosis, cancer or neurodegenerative diseases, were prepared. Thus, reaction of Et 1-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]pyrazole-3-carboxylate with NaOMe in H₂NCHO followed by treatment of the resulting residue with POCl₃ afforded I [R1 = CN; R2 = 4-F-3-MeC₆H₃] which showed IC₅₀ of < 1 μM against human COX-II.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/764,529

TITLE: Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
INVENTOR(S): Roniker, Barbara; LaChapelle, Richard J.; Connolly, Daniel T.; Seibert, Karen; Needleman, Philip
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|----------|-------------------|-------------|
| WO 9847509 | A1 | 19981029 | WO 1998-US7318 | 19980416 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ; DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| CA 2286673 | AA | 19981029 | CA 1998-2286673 | 19980416 |
| AU 9874662 | A1 | 19981113 | AU 1998-74662 | 19980416 |
| AU 745797 | B2 | 20020328 | | |
| TR 9902545 | T2 | 20000121 | TR 1999-9902545 | 19980416 |
| EP 979077 | A1 | 20000216 | EP 1998-922028 | 19980416 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| EE 9900517 | A | 20000615 | EE 1999-517 | 19980416 |
| BR 9808932 | A | 20000801 | BR 1998-8932 | 19980416 |
| JP 2001527542 | T2 | 20011225 | JP 1998-546113 | 19980416 |
| EE 200300169 | A | 20030616 | EE 2003-200300169 | 19980416 |
| EP 1498140 | A2 | 20050119 | EP 2004-23890 | 19980416 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| ZA 9803249 | A | 19990419 | ZA 1998-3249 | 19980417 |
| MX 9909495 | A | 20000930 | MX 1999-9495 | 19991015 |
| NO 9905077 | A | 19991217 | NO 1999-5077 | 19991018 |
| US 2002035156 | A1 | 20020321 | US 2001-946623 | 20010906 |
| PRIORITY APPLN. INFO.: | | | US 1997-44626P | P 19970418 |
| | | | EP 1998-922028 | A3 19980416 |
| | | | WO 1998-US7318 | W 19980416 |
| | | | US 2000-402634 | A1 20000327 |

OTHER SOURCE(S): MARPAT 129:339868
IT 165251-89-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase-2 inhibitors for prevention of cardiovascular disorders)
RN 165251-89-8 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB The invention relates to the use of cyclooxygenase-2 inhibitors or derivs. thereof in preventing cardiovascular disorders.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 43 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1998:392148 CAPLUS
 DOCUMENT NUMBER: 129:54367
 TITLE: Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
 INVENTOR(S): Talley, John J.; Penning, Thomas D.; Collins, Paul W.; Rogier, Donald J., Jr.; Malecha, James W.; Miyashiro, Julie M.; Bertenshaw, Stephen R.; Khanna, Ish K.; Graneto, Matthew J.; Rogers, Roland S.; Carter, Jeffery S.; Docter, Stephen H.; Yu, Stella S.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: U.S., 55 pp., Cont.-in-part of U. S. 5,521,207.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|------------------------|---|----------|-----------------|-------------|
| US 5760068 | A | 19980602 | US 1996-648113 | 19960906 |
| US 5466823 | A | 19951114 | US 1993-160594 | 19931130 |
| US 5521207 | A | 19960528 | US 1994-223629 | 19940406 |
| WO 9515316 | A1 | 19950608 | WO 1994-US12720 | 19941114 |
| W: | AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,
MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA,
US, US | | | |
| RW: | KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
TD, TG | | | |
| US 6156781 | A | 20001205 | US 1999-449076 | 19991124 |
| US 6413960 | B1 | 20020702 | US 2000-609011 | 20000530 |
| US 6492411 | B1 | 20021210 | US 2002-125325 | 20020417 |
| US 6586603 | B1 | 20030701 | US 2002-274679 | 20021021 |
| US 6716991 | B1 | 20040406 | US 2003-378781 | 20030304 |
| US 2004192930 | A1 | 20040930 | US 2003-700019 | 20031103 |
| US 2005131050 | A1 | 20050616 | US 2005-48037 | 20050131 |
| PRIORITY APPLN. INFO.: | | | US 1993-160594 | A2 19931130 |
| | | | US 1994-223629 | A2 19940406 |
| | | | WO 1994-US12720 | W 19941114 |
| | | | US 1996-648113 | A1 19960906 |
| | | | US 1997-957345 | B1 19971024 |
| | | | US 1999-449076 | A1 19991124 |
| | | | US 2000-609011 | A2 20000530 |
| | | | US 2002-125325 | A1 20020417 |
| | | | US 2002-274679 | A1 20021021 |
| | | | US 2003-378781 | A1 20030304 |
| | | | US 2003-700019 | A3 20031103 |


OTHER SOURCE(S): MARPAT 129:54367

IT 170570-43-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolylbenzenesulfonamides as antiinflammatories)

RN 170570-43-1 CAPLUS

CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)



GI



AB A class of pyrazolyl benzenesulfonamide compds. is described for use in treating inflammation and inflammation-related disorders. Several methods of such treatment are claimed, using various subsets of the title compds., e.g., I [R1 = Ph substituted by \geq 1 halo, C1-10 alkyl, or sulfamyl; R2 = H, haloalkyl, alkoxy carbonyl, cyano, carboxy, aminocarbonyl, alkylaminocarbonyl, carboxyalkyl, aminocarbonylalkyl, hydroxyalkyl, etc.; R3 = H, alkyl, cyano, alkoxy, hydroxyalkyl, alkylthio, alkylsulfonyl, halo; R4 = (un)substituted aralkenyl, aryl, cycloalkyl, cycloalkenyl, heterocyclyl; with numerous provisos]. Claims also cover use of the compds. in treatment of arthritis, pain, and fever, as well as prevention of colorectal cancer. Over 260 synthetic examples are described. For instance, condensation of 4'-methylacetophenone with Et trifluoroacetate gave 94% yield of crude $\text{CF}_3\text{COCH}_2\text{COC}_6\text{H}_4\text{Me}-4$. This underwent cyclocondensation with 4-H₂NSO₂C₆H₄NHNH₂.HCl in refluxing EtOH to give 46% yield of title compound II. The compds. typically showed high selectivity for inhibition of human cyclooxygenase (COX) II over COX I. Selected compds. gave 2-49% inhibition in the carrageenin-induced rat paw edema test at 10-30 mg/kg orally.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:251054 CAPLUS

DOCUMENT NUMBER: 128:304042

TITLE: Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia .

INVENTOR(S): Seibert, Karen; Masferrer, Jaime; Gordon, Gary B.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Seibert, Karen; Masferrer, Jaime; Gordon, Gary B.

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE : English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9816227 | A1 | 19980423 | WO 1997-US18670 | 19971014 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG
 CA 2372912 AA 19980423 CA 1997-2372912 19971014
 AU 9749048 A1 19980511 AU 1997-49048 19971014
 AU 742645 B2 20020110
 EP 932402 A1 19990804 EP 1997-911746 19971014
 EP 932402 B2 20040721
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
 BR 9712314 A 19990831 BR 1997-12314 19971014
 CN 1244122 A 20000209 CN 1997-198754 19971014
 JP 2001503395 T2 20010313 JP 1998-518591 19971014
 NZ 334921 A 20010330 NZ 1997-334921 19971014
 CA 2267186 C 20020514 CA 1997-2267186 19971014
 CA 2267186 AA 19980423
 NZ 506515 A 20020531 NZ 1997-506515 19971014
 NZ 517374 A 20031031 NZ 1997-517374 19971014
 AT 271385 E 20040815 AT 1997-911746 19971014
 RU 2239429 C2 20041110 RU 1999-110192 19971014
 EP 1479385 A1 20041124 EP 2004-11516 19971014
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
 PT 932402 T 20041130 PT 1997-911746 19971014
 ES 2224222 T3 20050301 ES 1997-911746 19971014
 KR 2000049138 A 20000725 KR 1999-703225 19990414
 NO 9901793 A 19990415 NO 1999-1793 19990415
 NZ 509755 A 20020927 NZ 2001-509755 20010207
 PRIORITY APPLN. INFO.: US 1996-28494P P 19961015
 CA 1997-2267186 A3 19971014
 EP 1997-911746 A3 19971014
 NZ 1997-334921 A 19971014
 WO 1997-US18670 W 19971014

OTHER SOURCE(S) : MARPAT 128:304042

IT 165251-89-8



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cyclooxygenase-2 inhibitors for treatment and prevention of neoplasia)


RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB Cyclooxygenase-2 inhibitors or derivs. thereof are used in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of e.g. p-(R2SO2)PhA(R1)(R3) [A = (partially) unsatd. heterocycl, (partially) unsatd. carbocycl; R1 = (substituted) heterocycl, (substituted) cycloalk(en)yl, (substituted) aryl; R2 = Me, amino; R3 = H, halo, alkyl, etc.].

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 45 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:639940 CAPLUS

DOCUMENT NUMBER: 127:314409

TITLE: Studies on anti-inflammatory agents. V. Synthesis and pharmacological properties of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyrazole and related compounds

AUTHOR(S): Tsuji, Kiyoshi; Konishi, Nobukiyo; Spears, Glen W.; Ogino, Takashi; Nakamura, Katsuya; Tojo, Takashi; Ochi, Takehiro; Shimojo, Fumio; Senoh, Hachiro; Matsuo, Masaaki

CORPORATE SOURCE: New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1997), 45(9),

1475-1481

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 127:314409

IT 134729-92-3P 134730-50-0P 134730-87-3P

151507-20-9P 197705-96-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(intermediate; preparation of diphenylpyrazole derivs. as anti-inflammatory
and analgesic agents and structure-activity relationships)

RN 134729-92-3 CAPLUS

CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)-3-
(trifluoromethyl)- (9CI) (CA INDEX NAME)

RN 134730-50-0 CAPLUS


CN Benzenamine, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 134730-87-3 CAPLUS


CN Formamide, N-[4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 151507-20-9 CAPLUS

CN Phenol, 4-[3-(difluoromethyl)-5-[(4-methanesulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 197705-96-7 CAPLUS

CN Formamide, N-methyl-N-[(4-[(4-methanesulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



IT 151506-45-5P


RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(preparation of diphenylpyrazole derivs. as anti-inflammatory and analgesic agents and structure-activity relationships)

RN 151506-45-5 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



IT 134730-00-0P 151506-66-0P 151506-96-6P


197705-97-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diphenylpyrazole derivs. as anti-inflammatory and analgesic agents and structure-activity relationships)


RN 134730-00-0 CAPLUS

CN Benzenamine, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 151506-66-0 CAPLUS


CN 1H-Pyrazole, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 151506-96-6 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 197705-97-8 CAPLUS
CN Benzenamine, N-methyl-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 134729-57-0 134730-34-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of diphenylpyrazole derivs. as anti-inflammatory and analgesic agents and structure-activity relationships)


RN 134729-57-0 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-34-0 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




AB A series of novel 1,5-diphenylpyrazole derivs. bearing hydrophilic substituents was prepared. The anti-inflammatory and analgesic activities of these compds. were evaluated by using the adjuvant arthritis and Randall-Selitto assays in rats, and the structure-activity relationships were studied. The optimal compound was 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyrazole (I) with oral ED₅₀ values of 0.31 and 2.6 mg/kg on adjuvant-induced arthritis and carrageenin-induced foot edema, resp. I showed analgesic activities not only toward inflamed paw but also toward normal paw (ED₃₀=0.55 and 1.8 mg/kg, resp.) in the Randall-Selitto assay, and moreover, I was effective in the tail-pinch assay (ED₅₀=21 mg/kg) similarly to morphine. The asym. synthesis and pharmacol. properties of the enantiomers of I are also reported.

REFERENCE COUNT:


35

THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 46 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:427309 CAPLUS
 DOCUMENT NUMBER: 127:144746
 TITLE: Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives
 AUTHOR(S): Tsuji, Kiyoshi; Nakamura, Katsuya; Konishi, Nobukyo; Tojo, Takashi; Ochi, Takehiro; Senoh, Hachiro; Matsuo, Masaaki
 CORPORATE SOURCE: New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1997), 45(6), 987-995
 CODEN: CPBTAL; ISSN: 0009-2363
 PUBLISHER: Pharmaceutical Society of Japan
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 134728-98-6P 134729-13-8P 193422-46-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and analgesic and anti-inflammatory activity of 1,5-diarylpyrazoles)
 RN 134728-98-6 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134729-13-8 CAPLUS
 CN 1H-Pyrazole-3-carbonitrile, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 193422-46-7 CAPLUS
 CN 1H-Pyrazol-3-amine, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI)
 (CA INDEX NAME)



IT 134729-00-3P 134729-02-5P 134729-22-9P
 134729-53-6P 134729-54-7P 134729-55-8P
 134729-56-9P 134729-57-0P 134729-58-1P
 134729-78-5P 134729-86-5P 134729-93-4P
 134729-96-7P 134730-01-1P 134730-03-3P
 134730-30-6P 134730-31-7P 134730-33-9P
 134730-34-0P 134730-61-3P 134731-18-3P
 134731-47-8P 151506-81-9P 193422-54-7P
 193422-55-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and analgesic and anti-inflammatory activity of
 1,5-diarylpyrazoles)

RN 134729-00-3 CAPLUS
 CN 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-methyl-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-02-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N,N-dimethyl-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134729-22-9 CAPLUS

CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 134729-53-6 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(2-fluorophenyl)-5-[4-


10/764,529

(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)




RN 134729-54-7 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(2,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-55-8 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-56-9 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI)
(CA INDEX NAME)




RN 134729-57-0 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-58-1 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-78-5 CAPLUS
CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-86-5 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 134729-93-4 CAPLUS
CN 1H-Pyrazole, 3-bromo-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 134729-96-7 CAPLUS
CN 1H-Pyrazole, 3-(fluoromethyl)-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-01-1 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-03-3 CAPLUS
CN Pyrrolidine, 1-[[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



10/764,529


RN 134730-30-6 CAPLUS

CN Acetamide, N-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 134730-31-7 CAPLUS

CN Carbamic acid, [1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-Pyrazol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 134730-33-9 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-[4-(dimethylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 134730-34-0 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-61-3 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-[4-(diethylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134731-18-3 CAPLUS
CN 1H-Tetrazole, 5-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 134731-47-8 CAPLUS
CN 1H-Pyrazole, 1-(4-fluorophenyl)-3-(methylsulfonyl)-5-[4-

10/764,529


(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)



RN 151506-81-9 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-cyanophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 193422-54-7 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 193422-55-8 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-[4-(ethylamino)phenyl]-5-[4-


(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)



- IT 134728-99-7P, 1H-Pyrazole-3-carboxylic acid, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- 134730-29-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and analgesic and anti-inflammatory activity of 1,5-diarylpyrazoles)
- RN 134728-99-7 CAPLUS
- CN 1H-Pyrazole-3-carboxylic acid, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



- RN 134730-29-3 CAPLUS
- CN 1H-Pyrazole-3-carbonitrile, 1-(4-aminophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



AB A series of novel 1,5-diarylpyrazole derivs. was synthesized and tested for anti-inflammatory and analgesic activities to develop anti-inflammatory agents with fewer side effects than existing nonsteroidal anti-inflammatory drugs. The structure-activity relationships in this series were extensively studied. Electron-withdrawing substituents such as CN and CF₃ were optimal at the 3-position of the pyrazole ring. Replacement of these substituents with bulky ones gave less active compds. The 4-(methylsulfonyl)phenyl group seemed to be the optimal group at the 5-position of the pyrazole ring. The most potent compound was 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-pyrazole-3-carbonitrile with oral ED₅₀ values of 0.030 and 0.47 mg/kg on adjuvant-induced arthritis and collagen-induced arthritis, resp., and an ED₃₀ value of 7.4 mg/kg in the yeast-induced hyperalgesia (Randall-Selitto) assay. This compound also showed potent inducible cyclooxygenase (COX-2)-inhibitory activity (IC₅₀ = 0.24 μM) with no COX-1 inhibition even at 100 μM.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 47 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:411072 CAPLUS

DOCUMENT NUMBER: 127:108929

TITLE: Preparation of 1,4,5-triphenylpyrazoles for the treatment of inflammation and inflammation-related disorders

INVENTOR(S): Lee, Len F.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: U.S., 18 pp., Cont.-in-part of U.S. 5,401,765.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|---|----------|-----------------|----------|
| US 5639777 | A | 19970617 | US 1996-648118 | 19960521 |
| US 5401765 | A | 19950328 | US 1993-161004 | 19931130 |
| WO 9515317 | A1 | 19950608 | WO 1994-US12721 | 19941114 |
| | W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,
MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA,
US, UZ
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, | | | |

10/764,529

MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
TD, TG

PRIORITY APPLN. INFO.: US 1993-161004 A2 19931130
WO 1994-US12721 W 19941114

OTHER SOURCE(S): MARPAT 127:108929



IT 165251-89-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,4,5-triphenylpyrazoles for the treatment of inflammation and inflammation-related disorders)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



GI



AB The title compds. [I; R1 = H, halo, C1-20 alkyl, etc.; R2 = H, C1-20 alkyl, CN, C1-20 haloalkyl; R3 = H, halo, C1-20 alkyl, etc.; R4 = NH2], useful for the treatment of inflammation, including treatment of pain and disorders such as arthritis, were prepared. Thus, treatment of 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]ethanone with NaH in DMF followed by passing of gaseous CF₃CN to the above mixture, treatment of the resulting 3-amino-4,4,4-trifluoro-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-2-buten-1-one with 6N HCl, reaction of 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-4,4,4-trifluoro-1,3-butanedione with PhNHNH₂ in AcOH, and treatment of 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole with 30% H₂O₂ in AcOH afforded I [R1 = H; R2 = CF₃; R3 = 4-F; R4 = Me] which showed 20% rat paw edema inhibition at 10 mg/kg body weight.

L4 ANSWER 48 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:361629 CAPLUS
 DOCUMENT NUMBER: 126:330613
 TITLE: Preparation of 1,3,5-trisubstituted pyrazoles for treatment of inflammation
 INVENTOR(S): Matsuo, Masaaki; Okumura, Kazuo; Ogino, Takashi;
 Nakamura, Katsuya; Nishimura, Hiroaki; Harada, Keiko;
 Hotta, Yuka; Tsuji, Kiyoshi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9713755 | A1 | 19970417 | WO 1996-JP2919 | 19961008 |
| W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| ZA 9608286 | A | 19970513 | ZA 1996-8286 | 19961002 |
| CA 2234511 | AA | 19970417 | CA 1996-2234511 | 19961008 |
| AU 9671461 | A1 | 19970430 | AU 1996-71461 | 19961008 |
| EP 856000 | A1 | 19980805 | EP 1996-932841 | 19961008 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| CN 1203589 | A | 19981230 | CN 1996-198649 | 19961008 |
| JP 11513403 | T2 | 19991116 | JP 1996-514909 | 19961008 |
| PRIORITY APPLN. INFO.: | | | GB 1995-20584 | A 19951009 |
| | | | WO 1996-JP2919 | W 19961008 |

OTHER SOURCE(S) : MARPAT 126:330613


IT 189699-63-6P 189699-65-8P 189699-69-2P
 189699-75-0P 189699-76-1P 189699-81-8P
 189699-82-9P 189699-83-0P 189699-84-1P
 189699-88-5P 189699-92-1P 189699-93-2P
 189699-94-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,3,5-trisubstituted pyrazoles for treatment of inflammation)

RN 189699-63-6 CAPLUS


CN Benzenemethanol, α -methyl-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

RN 189699-65-8 CAPLUS

CN Benzenemethanol, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- α -methyl- (9CI) (CA INDEX NAME)


RN 189699-69-2 CAPLUS

CN Benzenemethanol, α,α -dimethyl-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 189699-75-0 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-[4-(1-hydroxyethyl)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 189699-76-1 CAPLUS


CN Benzeneethanol, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 189699-81-8 CAPLUS


10/764,529

CN 1H-Pyrazole, 3-chloro-1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 189699-82-9 CAPLUS

CN 1H-Pyrazole, 3-chloro-5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA
INDEX NAME)




RN 189699-83-0 CAPLUS

CN 1H-Pyrazole, 3-chloro-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 189699-84-1 CAPLUS


CN 1H-Pyrazole, 3-chloro-5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)



RN 189699-88-5 CAPLUS

CN Benzenemethanol, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- α -methyl-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 189699-92-1 CAPLUS

CN Benzenemethanol, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- α -methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 189699-93-2 CAPLUS

CN Benzenemethanol, α -methyl-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, (+)- (9CI) (CA INDEX NAME)


Rotation (+).



RN 189699-94-3 CAPLUS

CN Benzenemethanol, α -methyl-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




IT 151506-61-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1,3,5-trisubstituted pyrazoles for treatment of
inflammation)

RN 151506-61-5 CAPLUS

CN Ethanone, 1-[4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 151506-59-1P 189699-98-7P 189699-99-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1,3,5-trisubstituted pyrazoles for treatment of inflammation)


RN 151506-59-1 CAPLUS

CN Ethanone, 1-[4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 189699-98-7 CAPLUS

CN Benzeneacetic acid, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 189699-99-8 CAPLUS

CN Benzeneacetic acid, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R¹ = hydroxyethyl, 1-hydroxy-1-methylethyl, H, halo, NO₂, CN; R² = Cl, CN, lower alkyl optionally substituted with halogen; R³ = lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl], COX-II

inhibitors and useful in the treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, various immunity diseases, thrombosis, cancer or neurodegenerative diseases, were prepared. Thus, treatment of 3-chloro-1-(4-chlorophenyl)-5-[4-(methylthio)phenyl]pyrazole with m-chloroperbenzoic acid in CH₂Cl₂ afforded I [R₁ = 4-Cl; R₂ = Cl; R₃ = 4-(MeSO₂)₂] which showed at 3.2 mg/kg inhibition of secondary lesion of ≥ 95% in female Sprague-Dawley rats injected with Mycobacterium tuberculosis (strain M37 BA).

L4 ANSWER 49 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:342369 CAPLUS

DOCUMENT NUMBER: 126:317377

TITLE: Preparation of substituted pyrazolylbenzenesulfonamides for use in veterinary therapies as antiinflammatory agents

INVENTOR(S): Isakson, Peter C.; Talley, John J.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Isakson, Peter C.; Talley, John J.

SOURCE: PCT Int. Appl., 214 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 9711704 | A1 | 19970403 | WO 1996-US15538 | 19960927 |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM | | | | |
| US 5756529 | A | 19980526 | US 1995-536318 | 19950929 |
| CA 2233620 | AA | 19970403 | CA 1996-2233620 | 19960927 |
| AU 9673768 | A1 | 19970417 | AU 1996-73768 | 19960927 |
| AU 718300 | B2 | 20000413 | | |
| EP 854723 | A1 | 19980729 | EP 1996-936018 | 19960927 |
| EP 854723 | B1 | 20030423 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| CN 1202828 | A | 19981223 | CN 1996-198561 | 19960927 |
| JP 11514991 | T2 | 19991221 | JP 1996-513685 | 19960927 |
| AT 238058 | E | 20030515 | AT 1996-936018 | 19960927 |
| IL 123635 | A1 | 20030624 | IL 1996-123635 | 19960927 |
| PT 854723 | T | 20030829 | PT 1996-936018 | 19960927 |
| ES 2197954 | T3 | 20040116 | ES 1996-936018 | 19960927 |
| RU 2253456 | C2 | 20050610 | RU 1998-107643 | 19960927 |
| NO 9801392 | A | 19980525 | NO 1998-1392 | 19980327 |
| BR 9610974 | A | 19990713 | BR 1996-10974 | 19980330 |
| PRIORITY APPLN. INFO.: | | | US 1995-536318 | A1 19950929 |
| | | | WO 1996-US15538 | W 19960927 |


OTHER SOURCE(S): MARPAT 126:317377

IT 170570-43-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrazolylbenzenesulfonamides for use in veterinary therapies as antiinflammatory agents)

RN 170570-43-1 CAPLUS

CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = substituted aryl (e.g., 4-(H₂NSO₂)C₆H₄), heteroaryl; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, halo, etc.; R4 = (un)substituted aralkenyl, aryl, cycloalkyl, etc.], useful in treating inflammation and inflammation-related disorders (e.g., arthritis and pain) in animals, were prepared. Thus, reaction of Et trifluoroacetate with 4'-chloroacetophenone in the presence NaOMe in Me tert-Bu ether followed by cyclization of the resulting of 4,4,4-trifluoro-1-(4-chlorophenyl)butane-1,3-dione with 4-sulfonamidophenylhydrazine.HCl in EtOH afforded I [R1 = 4-(H₂NSO₂)C₆H₄; R2 = CF₃; R3 = H; R4 = 4-ClC₆H₄] which showed ID₅₀ of <0.1 μM against human cyclooxygenase II.

L4 ANSWER 50 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:231026 CAPLUS

DOCUMENT NUMBER: 126:264035

TITLE: Synthesis and Biological Evaluation of the
1,5-Diarylpyrazole Class of Cyclooxygenase-2
Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
(SC-58635, Celecoxib)

AUTHOR(S): Penning, Thomas D.; Talley, John J.; Bertenshaw,
Stephen R.; Carter, Jeffery S.; Collins, Paul W.;
Docter, Stephen; Graneto, Matthew J.; Lee, Len F.;
Malecha, James W.; Miyashiro, Julie M.; Rogers, Roland
S.; Rogier, D. J.; Yu, Stella S.; Anderson, Gary D.;
Burton, Earl G.; Cogburn, J. Nita; Gregory, Susan A.;
Koboldt, Carol M.; Perkins, William E.; Seibert,

Karen; Veenhuizen, Amy W.; Zhang, Yan Y.; Isakson,
Peter C.

CORPORATE SOURCE: Departments of Chemistry Inflammatory Diseases
Research and Molecular Pharmacology, Searle Research
and Development, Skokie, IL, 60077, USA

SOURCE: Journal of Medicinal Chemistry (1997), 40(9),
1347-1365

PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623
American Chemical Society


DOCUMENT TYPE: Journal
LANGUAGE: English

IT 170570-43-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(diarylpyrazoles as cyclooxygenase 2 inhibitors)

RN 170570-43-1 CAPLUS

CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl] - (9CI) (CA INDEX NAME)



GI



AB Sulfonamide-containing 1,5-diarylpyrazole derivs. were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic

sites were evaluated further *in vivo* in an effort to identify compds. with acceptable pharmacokinetic profiles. This work led to the identification of SC-58635 (celecoxib, I), which is currently in phase III clin. trials for the treatment of rheumatoid arthritis and osteoarthritis.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 51 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:175052 CAPLUS
 DOCUMENT NUMBER: 126:166481
 TITLE: Combination of a cyclooxygenase-2 inhibitor and a leukotriene B₄ receptor antagonist for the treatment of inflammations
 INVENTOR(S): Isakson, Peter C.; Anderson, Gary D.; Gregory, Susan A.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9641645 | A1 | 19961227 | WO 1996-US9905 | 19960611 |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN | | | | |
| CA 2224563 | AA | 19961227 | CA 1996-2224563 | 19960611 |
| AU 9662694 | A1 | 19970109 | AU 1996-62694 | 19960611 |
| EP 833664 | A1 | 19980408 | EP 1996-921477 | 19960611 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| JP 11507669 | T2 | 19990706 | JP 1996-503237 | 19960611 |
| PRIORITY APPLN. INFO.: | | | US 1995-489415 | A 19950612 |
| | | | WO 1996-US9905 | W 19960611 |

OTHER SOURCE(S): MARPAT 126:166481

IT 165251-89-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (combination of a cyclooxygenase-2 inhibitor and a leukotriene B₄ receptor antagonist for treatment of inflammation)

RN 165251-89-8 CAPLUS
 CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB Combinations of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist are described for treatment of inflammation and inflammation-related disorders. The cyclooxygenase-2 inhibitors were prepared. Also, formulations for the drug combination are described.

L4 ANSWER 52 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:174993 CAPLUS
 DOCUMENT NUMBER: 126:166480
 TITLE: Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
 INVENTOR(S): Isakson, Peter C.; Anderson, Gary D.; Gregory, Susan A.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 9641625 | A1 | 19961227 | WO 1996-US10105 | 19960611 |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, | | | | |

ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
 LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
 SE, SG
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN
 US 5700816 A 19971223 US 1995-489468 19950612
 CA 2224379 AA 19961227 CA 1996-2224379 19960611
 AU 9662744 A1 19970109 AU 1996-62744 19960611
 EP 843549 A1 19980527 EP 1996-921540 19960611
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
 JP 11507925 T2 19990713 JP 1997-503272 19960611
 PRIORITY APPLN. INFO.: US 1995-489468 A 19950612
 WO 1996-US10105 W 19960611

OTHER SOURCE(S): MARPAT 126:166480



IT 165251-89-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase-2 inhibitor and leukotriene A4 hydrolase inhibitor for
 treatment of inflammation and inflammation-related disorders, compound
 preparation, pharmaceutical formulations, and antiarthritic activity)

RN 165251-89-8 CAPLUS

CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-
 (trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB Combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase



inhibitor are described for treatment of inflammation and inflammation-related disorders. Preparation of e.g. 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is described., as are pharmaceutical formulations and activity against collagen-induced arthritis in mice.

L4 ANSWER 53 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:174992 CAPLUS
 DOCUMENT NUMBER: 126:166479
 TITLE: Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders
 INVENTOR(S): Isakson, Peter C.; Anderson, Gary D.; Gregory, Susan A.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9641626 | A1 | 19961227 | WO 1996-US10106 | 19960611 |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN | | | | |
| CA 2224517 | AA | 19961227 | CA 1996-2224517 | 19960611 |
| AU 9661117 | A1 | 19970109 | AU 1996-61117 | 19960611 |
| EP 833622 | A1 | 19980408 | EP 1996-918465 | 19960611 |
| EP 833622 | B1 | 20050810 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| JP 11507670 | T2 | 19990706 | JP 1997-503273 | 19960611 |
| AT 301457 | E | 20050815 | AT 1996-918465 | 19960611 |
| PRIORITY APPLN. INFO.: | | | US 1995-489472 | A 19950612 |
| | | | WO 1996-US10106 | W 19960611 |

OTHER SOURCE(S): MARPAT 126:166479
 IT 165251-89-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase-2 inhibitor combination with 5-lipoxygenase inhibitor for treatment of inflammation and inflammation-related disorders, compound preparation, antiarthritic activity and pharmaceutical compns.)
 RN 165251-89-8 CAPLUS
 CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



AB Combinations of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor are described for treatment of inflammation and inflammation-related disorders. Preparation of e.g. 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide is described., as are pharmaceutical formulations and activity against collagen-induced arthritis in mice.

L4 ANSWER 54 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1996:466918 CAPLUS
 DOCUMENT NUMBER: 125:114611
 TITLE: Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
 INVENTOR(S): Numata, Hirotoshi; Okamoto, Yasushi; Shinoda, Masanobu; Kobayashi, Naoki; Miyazawa, Shuhei; Kawahara, Tetsuya; Shiota, Hiroshi; Nagakura, Naoki; Horizoe, Tatsuo; et al.
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 136 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9614302 | A1 | 19960517 | WO 1995-JP2250 | 19951106 |
| W: AU, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9538154 | A1 | 19960531 | AU 1995-38154 | 19951106 |
| JP 10509140 | T2 | 19980908 | JP 1995-515193 | 19951106 |
| ZA 9509475 | A | 19960515 | ZA 1995-9475 | 19951108 |
| PRIORITY APPLN. INFO.: | | | JP 1994-274067 | A 19941108 |
| | | | JP 1994-280705 | A 19941115 |
| | | | JP 1995-48760 | A 19950308 |
| | | | WO 1995-JP2250 | W 19951106 |


OTHER SOURCE(S): MARPAT 125:114611

IT 179325-58-7P 179325-78-1P 179326-05-7P
179326-17-1P 179326-25-1P 179326-26-2P
179326-40-0P 179326-67-1P 179326-82-0P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 179325-58-7 CAPLUS

CN Benzamide, 2-chloro-5-[[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179325-78-1 CAPLUS
CN Benzamide, 2-chloro-5-[[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]dimethoxymethyl]- (9CI) (CA INDEX NAME)



RN 179326-05-7 CAPLUS


CN Benzamide, 4-[methoxy[1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]methyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 179326-17-1 CAPLUS


CN 1H-Pyrazole, 3-[(4-fluorophenyl)methoxymethyl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 179326-25-1 CAPLUS
CN 1H-Pyrazole, 3-[methoxy(3-methoxyphenyl)methyl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 179326-26-2 CAPLUS
CN 1H-Pyrazole, 3-[[(3-fluorophenyl)methoxymethyl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 179326-40-0 CAPLUS
CN 1H-Pyrazole, 1-(4-fluorophenyl)-3-[(4-fluorophenyl)dimethoxymethyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 179326-67-1 CAPLUS
CN 1H-Pyrazole, 3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 179326-82-0 CAPLUS
CN Benzoic acid, 2-chloro-5-[[1-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




IT 179327-02-7


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of analgesic and antiinflammatory pyrazole derivs.)

RN 179327-02-7 CAPLUS

CN Methanone, (4-fluorophenyl)[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)



GI

AB Pyrazole derivs. I (R = H, OH, OMe, OEt; R1 = H, OMe; RR1 = O, OCH₂CH₂O,

O(CH₂)₃O; R₂ = H, OH, F, Cl, Br, OMe, CF₃, CONH₂, etc.; R₃ = H, F, Cl, OMe, CH₂OMe, CO₂H, CO₂Me, CONH₂, etc.) can suppress the production of both prostaglandins and leukotrienes simultaneously, and, therefore, exhibit anti-inflammatory and analgesic effects. Among the approx. 160 compds. prepared, I (R = R₁ = OMe, R₂ = Cl, Me, R₃ = CONH₂; R = H, R₁ = OMe, R₂ = Cl, R₃ = CONH₂) were claimed.

L4 ANSWER 55 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1996:410945 CAPLUS
 DOCUMENT NUMBER: 125:114612
 TITLE: Substituted pyrazolylbenzenesulfonamide for the treatment of inflammation
 INVENTOR(S): Graneto, Matthew J.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 160,594.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 5521207 | A | 19960528 | US 1994-223629 | 19940406 |
| US 5466823 | A | 19951114 | US 1993-160594 | 19931130 |
| CA 2177576 | AA | 19950608 | CA 1994-2177576 | 19941114 |
| CA 2177576 | C | 19991026 | | |
| CA 2276945 | AA | 19950608 | CA 1994-2276945 | 19941114 |
| CA 2276946 | AA | 19950608 | CA 1994-2276946 | 19941114 |
| CA 2277954 | AA | 19950608 | CA 1994-2277954 | 19941114 |
| WO 9515316 | A1 | 19950608 | WO 1994-US12720 | 19941114 |
| W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US | | | | |
| RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9511714 | A1 | 19950619 | AU 1995-11714 | 19941114 |
| AU 690609 | B2 | 19980430 | | |
| EP 731795 | A1 | 19960918 | EP 1995-902444 | 19941114 |
| EP 731795 | B1 | 19991222 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| HU 74180 | A2 | 19961128 | HU 1996-1455 | 19941114 |
| CN 1141630 | A | 19970129 | CN 1994-194833 | 19941114 |
| CN 1061036 | B | 20010124 | | |
| EP 922697 | A1 | 19990616 | EP 1999-101687 | 19941114 |
| EP 922697 | B1 | 20030226 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | |
| EP 924201 | A1 | 19990623 | EP 1999-101677 | 19941114 |
| EP 924201 | B1 | 20020206 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | |
| EP 923933 | A1 | 19990623 | EP 1999-101697 | 19941114 |
| EP 923933 | B1 | 20020703 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | |
| RU 2139281 | C1 | 19991010 | RU 1996-115039 | 19941114 |
| AT 187965 | E | 20000115 | AT 1995-902444 | 19941114 |
| JP 3025017 | B2 | 20000327 | JP 1995-515611 | 19941114 |
| JP 09506350 | T2 | 19970624 | | |
| ES 2141916 | T3 | 20000401 | ES 1995-902444 | 19941114 |


| | | | | |
|---------------|----|----------|------------------------|-----------------|
| JP 2000109466 | A2 | 20000418 | JP 1999-298879 | 19941114 |
| JP 3445762 | B2 | 20030908 | PT 1995-902444 | 19941114 |
| PT 731795 | T | 20000531 | PL 1994-314695 | 19941114 |
| PL 180717 | B1 | 20010330 | AT 1999-101677 | 19941114 |
| AT 212985 | E | 20020215 | PT 1999-101677 | 19941114 |
| PT 924201 | T | 20020628 | AT 1999-101697 | 19941114 |
| AT 219937 | E | 20020715 | ES 1999-101677 | 19941114 |
| ES 2172959 | T3 | 20021001 | PT 1999-101697 | 19941114 |
| PT 923933 | T | 20021031 | ES 1999-101697 | 19941114 |
| ES 2180233 | T3 | 20030201 | AT 1999-101687 | 19941114 |
| AT 233245 | E | 20030315 | RO 1996-1100 | 19941114 |
| RO 118291 | B1 | 20030430 | JP 2003-32958 | 19941114 |
| JP 2003238536 | A2 | 20030827 | ES 1999-101687 | 19941114 |
| ES 2193609 | T3 | 20031101 | CZ 1996-1503 | 19941114 |
| CZ 294630 | B6 | 20050216 | NZ 1994-336428 | 19941114 |
| NZ 336428 | A | 20050225 | ZA 1994-9418 | 19941128 |
| ZA 9409418 | A | 19951128 | US 1995-458079 | 19950601 |
| US 5504215 | A | 19960402 | US 1995-457185 | 19950601 |
| US 5508426 | A | 19960416 | US 1995-456441 | 19950601 |
| US 5510496 | A | 19960423 | US 1995-457654 | 19950601 |
| US 5516907 | A | 19960514 | US 1995-457059 | 19950601 |
| US 5563165 | A | 19961008 | US 1995-534757 | 19950927 |
| US 5753688 | A | 19980519 | FI 1996-2249 | 19960529 |
| FI 9602249 | A | 19960529 | FI 115053 | 19960529 |
| FI 115053 | B1 | 20050228 | NO 1996-2184 | 19960529 |
| NO 9602184 | A | 19960529 | NO 306460 | 19960906 |
| NO 306460 | B1 | 19991108 | US 5760068 | 19981223 |
| US 5760068 | A | 19980602 | HK 1013649 | 19991124 |
| HK 1013649 | A1 | 20000707 | US 6156781 | 19991215 |
| US 6156781 | A | 20001205 | CN 1280125 | 19991215 |
| CN 1280125 | A | 20010117 | CN 1127484 | 19991215 |
| CN 1127484 | B | 20031112 | CN 1280126 | 19991215 |
| CN 1280126 | A | 20010117 | CN 1134417 | 19991215 |
| CN 1134417 | B | 20040114 | CN 1495170 | 19991215 |
| CN 1495170 | A | 20040512 | HK 1021935 | 19991223 |
| HK 1021935 | A1 | 20030404 | GR 3032696 | 20000218 |
| GR 3032696 | T3 | 20000630 | US 6413960 | 20000530 |
| US 6413960 | B1 | 20020702 | US 6492411 | 20020417 |
| US 6492411 | B1 | 20021210 | US 6586603 | 20021021 |
| US 6586603 | B1 | 20030701 | US 6716991 | 20030304 |
| US 6716991 | B1 | 20040406 | US 2004192930 | 20031103 |
| US 2004192930 | A1 | 20040930 | US 2005131050 | 20050131 |
| US 2005131050 | A1 | 20050616 | PRIORITY APPLN. INFO.: | A2 19931130 |
| | | | | US 1993-160594 |
| | | | | US 1994-223629 |
| | | | | CA 1994-2177576 |
| | | | | EP 1995-902444 |
| | | | | JP 1995-515611 |
| | | | | JP 1999-298879 |
| | | | | WO 1994-US12720 |
| | | | | US 1996-648113 |
| | | | | US 1997-957345 |
| | | | | US 1999-449076 |
| | | | | US 2000-609011 |
| | | | | US 2002-125325 |
| | | | | US 2002-274679 |
| | | | | US 2003-378781 |
| | | | | US 2003-700019 |
| | | | | US 2005-48037 |
| | | | | US 1994-223629 |
| | | | | A 19940406 |
| | | | | CA 1994-2177576 |
| | | | | A3 19941114 |
| | | | | EP 1995-902444 |
| | | | | A3 19941114 |
| | | | | JP 1995-515611 |
| | | | | A3 19941114 |
| | | | | JP 1999-298879 |
| | | | | A3 19941114 |
| | | | | WO 1994-US12720 |
| | | | | US 1996-648113 |
| | | | | A1 19960906 |
| | | | | US 1997-957345 |
| | | | | B1 19971024 |
| | | | | US 1999-449076 |
| | | | | A1 19991124 |
| | | | | US 2000-609011 |
| | | | | A2 20000530 |
| | | | | US 2002-125325 |
| | | | | A1 20020417 |
| | | | | US 2002-274679 |
| | | | | A1 20021021 |
| | | | | US 2003-378781 |
| | | | | A1 20030304 |
| | | | | A3 20031103 |

IT 170570-43-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation for treating inflammation)

RN 170570-43-1 CAPLUS

CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



AB A class of pyrazolylbenzenesulfonamide compds. is described for use in treating inflammation and inflammation-related disorders.

L4 ANSWER 56 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:45267 CAPLUS

DOCUMENT NUMBER: 124:202058

TITLE: Synthesis and biological evaluation of 2,3-diarylthiophenes as selective Cox-2 inhibitors. Part II. Replacing the heterocycle

AUTHOR(S): Gautheir, Jacques Yves; Leblanc, Yves; Black, W. Cameron; Chan, Chi-Chung; Cromlish, Wanda A.; Gordon, Robert; Kennedy, Brian P.; Lau, Cheuk K.; Leger, Serge; et al.

CORPORATE SOURCE: Merck Frosst Centre Therapeutic Res., Quebec, QC, H9R 4P8, Can.

SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(1), 87-92
 CODEN: BMCL8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 134729-22-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and cyclooxygenase isoenzyme inhibitory activity of)

RN 134729-22-9 CAPLUS

CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



GI



I

AB The thiophene ring of DuP 697 (I) was replaced by a variety of heterocycles, and the products were tested for their ability to inhibit human Cox-2 and Cox-1, the isoenzymes of cyclooxygenase.

L4 ANSWER 57 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1995:931246 CAPLUS
 DOCUMENT NUMBER: 123:340112
 TITLE: Preparation of pyrazolylbenzenesulfonamides as antiinflammatories.
 INVENTOR(S): Talley, John J.; Penning, Thomas D.; Collins, Paul W.; Rogier, Donald J., Jr.; Malecha, James W.; Miyashiro, Julie M.; Bertenshaw, Stephen R.; Khanna, Ish K.; Granets, Matthew J.; et al.
 PATENT ASSIGNEE(S): G. D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 254 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9515316 | A1 | 19950608 | WO 1994-US12720 | 19941114 |
| W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US | | | | |
| RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, | | | | |


TD, TG

| | | | | |
|---|----|----------|------------------|-------------|
| US 5466823 | A | 19951114 | US 1993-160594 | 19931130 |
| US 5521207 | A | 19960528 | US 1994-223629 | 19940406 |
| AU 9511714 | A1 | 19950619 | AU 1995-11714 | 19941114 |
| AU 690609 | B2 | 19980430 | | |
| EP 731795 | A1 | 19960918 | EP 1995-902444 | 19941114 |
| EP 731795 | B1 | 19991222 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| RU 2139281 | C1 | 19991010 | RU 1996-115039 | 19941114 |
| AT 187965 | E | 20000115 | AT 1995-902444 | 19941114 |
| JP 3025017 | B2 | 20000327 | JP 1995-515611 | 19941114 |
| JP 09506350 | T2 | 19970624 | | |
| PL 180717 | B1 | 20010330 | PL 1994-314695 | 19941114 |
| RO 118291 | B1 | 20030430 | RO 1996-1100 | 19941114 |
| TW 418193 | B | 20010111 | TW 1995-84104854 | 19950516 |
| TW 467900 | B | 20011211 | TW 2000-89104784 | 19950516 |
| FI 9602249 | A | 19960529 | FI 1996-2249 | 19960529 |
| FI 115053 | B1 | 20050228 | | |
| NO 9602184 | A | 19960529 | NO 1996-2184 | 19960529 |
| NO 306460 | B1 | 19991108 | | |
| US 5760068 | A | 19980602 | US 1996-648113 | 19960906 |
| HK 1013649 | A1 | 20000707 | HK 1998-114923 | 19981223 |
| US 6156781 | A | 20001205 | US 1999-449076 | 19991124 |
| GR 3032696 | T3 | 20000630 | GR 2000-400394 | 20000218 |
| US 6413960 | B1 | 20020702 | US 2000-609011 | 20000530 |
| US 6492411 | B1 | 20021210 | US 2002-125325 | 20020417 |
| US 6586603 | B1 | 20030701 | US 2002-274679 | 20021021 |
| US 6716991 | B1 | 20040406 | US 2003-378781 | 20030304 |
| US 2004192930 | A1 | 20040930 | US 2003-700019 | 20031103 |
| US 2005131050 | A1 | 20050616 | US 2005-48037 | 20050131 |
| PRIORITY APPLN. INFO.: | | | US 1993-160594 | A2 19931130 |
| | | | US 1994-223629 | A2 19940604 |
| | | | WO 1994-US12720 | W 19941114 |
| | | | US 1996-648113 | A1 19960906 |
| | | | US 1997-957345 | B1 19971024 |
| | | | US 1999-449076 | A1 19991124 |
| | | | US 2000-609011 | A2 20000530 |
| | | | US 2002-125325 | A1 20020417 |
| | | | US 2002-274679 | A1 20021021 |
| | | | US 2003-378781 | A1 20030304 |
| | | | US 2003-700019 | A3 20031103 |

OTHER SOURCE(S): MARPAT 123:340112

IT 170570-43-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolylbenzenesulfonamides as antiinflammatories)

RN 170570-43-1 CAPLUS
 CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB Title compds. [I; R₁ = (substituted) (hetero)aryl; R₂ = H, alkyl, haloalkyl, alkoxy carbonyl, cyano, NO₂, cyanoalkyl, carboxyl, aminocarbonyl, alkylaminocarbonyl, carboxyalkylaminocarbonyl, carboxyalkyl, aralkoxycarbonylalkylaminocarbonyl, aminocarbonylalkyl, alkoxy carbonylcyanalkenyl, hydroxyalkyl etc.; R₃ = H, alkyl, cyano, NO₂, formyl, cyanoamidino, hydroxyalkyl, cycloalkyl, alkylsulfonyl, halo, heterocyclyl, heterocyclylalkyl, etc.; R₄ = (substituted) aralkenyl, aryl, cycloalkyl, cycloalkenyl, heterocyclyl; R₃R₄ = Q₁; m = 1-3; A = Ph, 5-6 membered heterocyclyl; R₆ = halo, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, carboxyl, aminocarbonyl, sulfamyl, NO₂, acylamino, etc.; provided R₂ and R₃ do not both = H, carboxy, ethoxycarbonyl; further provided that R₂ ≠ carboxyl, Me when R₃ = H and when R₄ is Ph; further provided that R₄ ≠ triazolyl when R₂ = Me; further provided that R₄ ≠ aralkenyl when R₂ = carboxyl, aminocarbonyl, ethoxycarbonyl; further provided that R₄ ≠ Ph when R₂ = Me and R₃ = carboxyl; and further provided that R₄ ≠ unsubstituted thienyl when R₂ = trifluoromethyl, were prepared. Thus, F₃CCO₂Et in MeOCMe₃ was treated with 25% NaOMe and then 4'-chloroacetophenone followed by stirring overnight to give 85% 4,4,4-trifluoro-1-(4-chlorophenyl)butane-1,3-dione. The latter was refluxed with 4-sulfonamidophenylhydrazine hydrochloride in EtOH to give title compound (II). II inhibited human cyclooxygenase II and I with ID₅₀ = <.1 μM and 18 μM, resp.

L4 ANSWER 58 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:696007 CAPLUS
 DOCUMENT NUMBER: 123:83360
 TITLE: 1,4,5-Triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
 INVENTOR(S): Lee, Len F.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: U.S., 14 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| US 5401765 | A | 19950328 | US 1993-161004 | 19931130 |
| CA 2177573 | AA | 19950608 | CA 1994-2177573 | 19941114 |
| WO 9515317 | A1 | 19950608 | WO 1994-US12721 | 19941114 |

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
 GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG,
 MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA,
 US, UZ

RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
 MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,
 TD, TG

| | | | | |
|---|----|----------|-----------------|------------|
| AU 9510887 | A1 | 19950619 | AU 1995-10887 | 19941114 |
| EP 731794 | A1 | 19960918 | EP 1995-901779 | 19941114 |
| EP 731794 | B1 | 19970806 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| JP 09505829 | T2 | 19970610 | JP 1994-515612 | 19941114 |
| AT 156482 | E | 19970815 | AT 1995-901779 | 19941114 |
| ES 2105874 | T3 | 19971016 | ES 1995-901779 | 19941114 |
| US 5639777 | A | 19970617 | US 1996-648118 | 19960521 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 1993-161004 | A 19931130 |
| | | | WO 1994-US12721 | W 19941114 |



OTHER SOURCE(S): MARPAT 123:83360

IT 165251-89-8P 165251-90-1P 165251-91-2P
 165251-92-3P 165251-93-4P 165251-94-5P
 165251-95-6P 165251-96-7P 165251-97-8P
 165251-98-9P 165251-99-0P 165252-00-6P
 165252-01-7P 165252-02-8P 165252-03-9P
 165252-04-0P 165252-05-1P 165252-06-2P
 165252-07-3P 165252-08-4P 165252-09-5P
 165252-10-8P 165252-11-9P 165252-12-0P
 165252-13-1P 165252-14-2P 165252-15-3P
 165252-16-4P 165252-17-5P 165252-18-6P
 165252-19-7P 165252-20-0P 165252-21-1P
 165252-22-2P 165252-23-3P 165252-24-4P
 165252-25-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (1,4,5-tri-Ph pyrazolyl compds. for the treatment of inflammation and inflammation-related disorders)

RN 165251-89-8 CAPLUS
 CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 165251-90-1 CAPLUS
CN 1H-Pyrazole, 4-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A





PAGE 2-A




RN 165251-91-2 CAPLUS
CN 1H-Pyrazole, 4-(4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A





PAGE 2-A



RN 165251-92-3 CAPLUS
CN 1H-Pyrazole, 4-(4-iodophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 165251-93-4 CAPLUS
 CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1,4-diphenyl-3-(trifluoromethyl)-
 (9CI) (CA INDEX NAME)




RN 165251-94-5 CAPLUS
 CN 1H-Pyrazole, 4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A





PAGE 2-A




RN 165251-95-6 CAPLUS
CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-4-[4-(methylthio)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 165251-96-7 CAPLUS
CN 1H-Pyrazole, 4-[4-(methylsulfinyl)phenyl]-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



10/764,529



PAGE 2-A




RN 165251-97-8 CAPLUS

CN Phenol, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





RN 165251-98-9 CAPLUS

CN 1H-Pyrazole, 4-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A



PAGE 2-A





RN 165251-99-0 CAPLUS


CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-4-(4-nitrophenyl)-1-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A





PAGE 2-A




RN 165252-00-6 CAPLUS
CN Benzenamine, 4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A



PAGE 2-A





RN 165252-01-7 CAPLUS


CN Benzenamine, N-methyl-4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A





PAGE 2-A




RN 165252-02-8 CAPLUS

CN Benzenamine, N,N-dimethyl-4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 165252-03-9 CAPLUS
CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 165252-04-0 CAPLUS
CN Acetamide, N-[4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

10/764,529

PAGE 1-A





PAGE 2-A




RN 165252-05-1 CAPLUS


CN Acetamide, N-[[4-[5-[4-(methylsulfonyl)phenyl]-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 165252-06-2 CAPLUS
CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-07-3 CAPLUS
CN 1H-Pyrazole, 1-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-08-4 CAPLUS
CN 1H-Pyrazole, 1-(4-bromophenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-09-5 CAPLUS
CN 1H-Pyrazole, 1-(4-iodophenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-10-8 CAPLUS
CN 1H-Pyrazole, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-11-9 CAPLUS
CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-[4-(methylthio)phenyl]-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-12-0 CAPLUS
CN Phenol, 4-[5-[4-(methylsulfonyl)phenyl]phenyl]-4-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl- (9CI) (CA INDEX NAME)




RN 165252-13-1 CAPLUS
CN 1H-Pyrazole, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-14-2 CAPLUS
CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)-4-phenyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 165252-15-3 CAPLUS
CN Benzenamine, 4-[5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 165252-16-4 CAPLUS
CN Benzenamine, N-methyl-4-[5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 165252-17-5 CAPLUS

CN Benzenamine, N,N-dimethyl-4-[5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 165252-18-6 CAPLUS

CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 165252-19-7 CAPLUS

CN Acetamide, N-[4-[5-[4-(methylsulfonyl)phenyl]-4-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 165252-20-0 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 165252-21-1 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-
(9CI) (CA INDEX NAME)




RN 165252-22-2 CAPLUS
CN 1H-Pyrazole, 4-(4-fluorophenyl)-3-methyl-5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 165252-23-3 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 165252-24-4 CAPLUS
CN 1H-Pyrazole, 1,4-bis(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 165252-25-5 CAPLUS
 CN 1H-Pyrazole, 3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1,4-diphenyl-
 (9CI) (CA INDEX NAME)



GI



I



II

AB Compds. of formula I wherein R^1 is one or more radicals independently selected from the group hydrido, halo, alkyl, alkylthio, alkylsulfinyl,

alkylsulfonyl, nitro, amino, N-monoalkylamino, N,N-dialkylamino, acylamino, acylaminoalkyl, haloalkyl, hydroxy and alkoxy; wherein R₂ is selected from hydrido, alkyl, cyano and haloalkyl; wherein R₃ is one or more radicals independently selected from the group hydrido, halo, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, nitro, amino, N-monoalkylamino, N,N-dialkylamino, acylamino, acylaminoalkyl, haloalkyl, hydroxy and alkoxy; and wherein R₄ is alkyl; or a pharmaceutically-acceptable salt thereof useful for the treatment of inflammation, including treatment of pain and disorders such as arthritis. Thus, e.g., treatment of 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]ethanone with NaH/DMF followed by gaseous trifluoroacetonitrile afforded 3-amino-4,4,4-trifluoro-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-2-buten-1-one (II); hydrolysis of enamine II to the diketone, followed by cyclocondensation with phenylhydrazine afforded a mixture containing the desired 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-1-phenyl-3-(trifluoromethyl)pyrazole together with its regioisomer 4-(4-fluorophenyl)-3-[4-(methylthio)phenyl]-1-phenyl-5-(trifluoromethyl)pyrazole (HPLC purifn); oxidation of the desired isomer with H₂O₂ afforded I (R₄ = Me, R₃ = 4-F, R₂ = CF₃, R₁ = H) which displayed 20% inhibition of rat carrageenan foot pad edema @ 10 mg/kg body weight

L4 ANSWER 59 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:380439 CAPLUS
 DOCUMENT NUMBER: 122:142603
 TITLE: Encapsulated insoluble drug with improved bioavailability
 INVENTOR(S): Hata, Takehisa; Shimojo, Fumio; Kado, Kazutake; Ishii, Kyoko; Sawai, Seiji
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 9501166 | A1 | 19950112 | WO 1994-JP1043 | 19940628 |
| W: AU, CA, CN, JP, KR, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2165789 | AA | 19950112 | CA 1994-2165789 | 19940628 |
| AU 9469842 | A1 | 19950124 | AU 1994-69842 | 19940628 |
| AU 682192 | B2 | 19970925 | | |
| EP 706380 | A1 | 19960417 | EP 1994-918588 | 19940628 |
| EP 706380 | B1 | 20010816 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| CN 1127990 | A | 19960731 | CN 1994-192941 | 19940628 |
| CN 1087933 | B | 20020724 | | |
| JP 09501150 | T2 | 19970204 | JP 1994-503396 | 19940628 |
| AT 204163 | E | 20010915 | AT 1994-918588 | 19940628 |
| ES 2161768 | T3 | 20011216 | ES 1994-918588 | 19940628 |
| PT 706380 | T | 20020228 | PT 1994-918588 | 19940628 |
| US 5683716 | A | 19971104 | US 1996-569122 | 19960102 |
| GR 3036407 | T3 | 20011130 | GR 2001-401130 | 20010817 |
| PRIORITY APPLN. INFO.: | | | JP 1993-160983 | A 19930630 |
| | | | WO 1994-JP1043 | W 19940628 |

IT 151506-45-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (encapsulated insol. drug with improved bioavailability)

RN 151506-45-5 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




AB An encapsulated pharmaceutical dosage form comprises a practically insol. compound or salt thereof, an intracapsular fluid (e.g. a polyol), and/or a surfactant and/or cellulose derivative. Oral absorption of the compound is increased as compared with conventional systems because, on release of the capsule contents from the capsule shell, the practically insol. compound or salt undergoes diminution in crystal size. Thus, a solution of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfonylphenyl)pyrazole (I) 14 in PEG-400 176 was mixed with hydroxypropylmethylcellulose 10 mg and filled into hard gelatin capsules. On stirring in water at 37° for 3 h, the capsules released I as particles with mean diameter 6.5 μm.

L4 ANSWER 60 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1994:533888 CAPLUS
 DOCUMENT NUMBER: 121:133888
 TITLE: Synthesis of triaryl-4-trifluoromethylpyrazoles via
 1,3-dipolar cycloaddition
 AUTHOR(S): Meazza, G.; Zanardi, G.
 CORPORATE SOURCE: Isagro, S.r.l., Via G. Fauser 4, Novara, I-28100,
 Italy
 SOURCE: Journal of Fluorine Chemistry (1994), 67(2), 183-8
 CODEN: JFLCAR; ISSN: 0022-1139
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT 157222-63-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 157222-63-4 CAPLUS
 CN 1H-Pyrazole, 3-(4-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]-1-phenyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



GI



AB Triaryl-substituted (trifluoromethyl)pyrazoles I (R1-R3 = Ph, substituted phenyl) and II (same R1-R3) were prepared from nitrile imines, formed in situ from the corresponding α -halo hydrazones, and various substituted 1-aryl-3,3,3-trifluoro-1-propynes. The spectroscopic characteristics of the products and the regioselectivity of the reaction are discussed.

L4 ANSWER 61 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:8589 CAPLUS
 DOCUMENT NUMBER: 120:8589
 TITLE: Preparation of pyrazole derivatives with antiinflammatory, analgesic, and antithrombotic activity
 INVENTOR(S): Matsuo, Masaaki; Tsuji, Kiyoshi; Ogino, Takashi;
 Konishi, Nobukiyo
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 40 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| EP 554829 | A2 | 19930811 | EP 1993-101569 | 19930202 |
| EP 554829 | A3 | 19940608 | | |
| EP 554829 | B1 | 20020515 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| IL 104311 | A1 | 19970713 | IL 1993-104311 | 19930105 |
| ZA 9300077 | A | 19930804 | ZA 1993-77 | 19930106 |


| | | | | |
|------------------------|----|----------|-----------------|-------------|
| JP 05246997 | A2 | 19930924 | JP 1993-10379 | 19930126 |
| AU 9332174 | A1 | 19930812 | AU 1993-32174 | 19930202 |
| AU 663149 | B2 | 19950928 | | |
| AT 217613 | E | 20020615 | AT 1993-101569 | 19930202 |
| ES 2173875 | T3 | 20021101 | ES 1993-101569 | 19930202 |
| CA 2088835 | AA | 19930806 | CA 1993-2088835 | 19930204 |
| CN 1075959 | A | 19930908 | CN 1993-101069 | 19930204 |
| CN 1045767 | B | 19991020 | | |
| RU 2128172 | C1 | 19990327 | RU 1993-4484 | 19930204 |
| HU 63392 | A2 | 19930830 | HU 1993-309 | 19930205 |
| US 5550147 | A | 19960827 | US 1995-413939 | 19950330 |
| US 5670533 | A | 19970923 | US 1995-579974 | 19951228 |
| PRIORITY APPLN. INFO.: | | | GB 1992-2442 | A 19920205 |
| | | | GB 1992-20427 | A 19920928 |
| | | | US 1993-297 | B1 19930104 |
| | | | US 1995-413939 | A1 19950330 |

OTHER SOURCE(S): MARPAT 120:8589


IT 151506-45-5P 151506-55-7P 151506-57-9P
 151506-58-0P 151506-59-1P 151506-60-4P
 151506-61-5P 151506-63-7P 151506-64-8P
 151506-66-0P 151506-67-1P 151506-68-2P
 151506-75-1P 151506-77-3P 151506-80-8P
 151506-81-9P 151506-82-0P 151506-87-5P
 151506-88-6P 151506-89-7P 151506-90-0P
 151506-91-1P 151506-92-2P 151506-93-3P
 151506-94-4P 151506-95-5P 151506-96-6P
 151506-97-7P 151506-98-8P 151506-99-9P
 151507-01-6P 151507-02-7P 151507-16-3P
 151507-19-6P 151507-20-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antiinflammatory, analgesic, and antithrombotic)


RN 151506-45-5 CAPLUS
 CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 151506-55-7 CAPLUS
 CN Benzonitrile, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 151506-57-9 CAPLUS
CN Benzonitrile, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)




RN 151506-58-0 CAPLUS
CN Benzonitrile, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-(9CI) (CA INDEX NAME)



RN 151506-59-1 CAPLUS
CN Ethanone, 1-[4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-


10/764,529

1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 151506-60-4 CAPLUS

CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-(4-phenoxyphenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 151506-61-5 CAPLUS

CN Ethanone, 1-[4-[5-[4-(methylsulfonyl)phenyl]phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 151506-63-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-(4-cyanophenyl)-N-methyl-5-[4-


10/764,529

(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)




RN 151506-64-8 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-acetylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 151506-66-0 CAPLUS

CN 1H-Pyrazole, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




10/764,529


RN 151506-67-1 CAPLUS
CN 1H-Pyrazole, 3-(chloromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 151506-68-2 CAPLUS
CN 1H-Pyrazole, 3-(difluoromethyl)-1-(2-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 151506-75-1 CAPLUS
CN Benzamide, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 151506-77-3 CAPLUS

CN Benzamide, 4-[3-cyano-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI)
(CA INDEX NAME)



RN 151506-80-8 CAPLUS


CN Benzoic acid, 4-[3-cyano-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-
(9CI) (CA INDEX NAME)



10/764,529


RN 151506-81-9 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-cyanophenyl)-5-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 151506-82-0 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-acetylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 151506-87-5 CAPLUS


CN Benzoic acid, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



10/764,529


RN 151506-88-6 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-carboxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, 3-ethyl ester (9CI) (CA INDEX NAME)




RN 151506-89-7 CAPLUS

CN Benzoic acid, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 151506-90-0 CAPLUS


CN Benzenemethanol, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



10/764,529


RN 151506-91-1 CAPLUS

CN 1H-Pyrazole, 1-[4-(methoxymethoxy)phenyl]-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 151506-92-2 CAPLUS

CN Acetic acid, [4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 151506-93-3 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-[4-(methoxymethoxy)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 151506-94-4 CAPLUS

CN 1H-Pyrazole, 1-(4-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 151506-95-5 CAPLUS

CN 1H-Pyrazole, 1-[4-(1-methylethoxy)phenyl]-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 151506-96-6 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-ethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 151506-97-7 CAPLUS


CN 1H-Pyrazole, 3-(difluoromethyl)-1-[4-(1-methylethoxy)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 151506-98-8 CAPLUS
CN Phenol, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 151506-99-9 CAPLUS
CN Acetic acid, [4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 151507-01-6 CAPLUS
CN Benzoic acid, 4-[3-(aminocarbonyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 151507-02-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4-acetylphenyl)-5-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 151507-16-3 CAPLUS
CN 1H-Pyrazole, 3-bromo-1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 151507-19-6 CAPLUS
CN Phenol, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-


10/764,529

yl]- (9CI) (CA INDEX NAME)




RN 151507-20-9 CAPLUS

CN Phenol, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



GI



AB Title compds. (I; R1 = substituted aryl; R2 = halo, haloalkyl, cyano, acyl; R3 = substituted aryl) were prepared Thus, 4-(MeS)C₆H₄COCH₂COCHF₂ was cyclocondensed with 4-(MeO)C₆H₄NHNH₂·HCl to give title compound II

10/764,529

which gave 93.6% inhibition of mycobacterial adjuvant-induced secondary lesion in rats receiving 3.2 mg/kg/day orally for 23 days.

L4 ANSWER 62 OF 62 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:471593 CAPLUS
DOCUMENT NUMBER: 115:71593
TITLE: Preparation of pyrazole derivatives having antiinflammatory, analgesic, and antithrombotic activities
INVENTOR(S): Matsuo, Masaaki; Tsuji, Kiyoshi; Konishi, Nobukiyo; Nakamura, Katsuya
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 71 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| EP 418845 | A1 | 19910327 | EP 1990-117983 | 19900919 |
| EP 418845 | B1 | 19950809 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| ZA 9007282 | A | 19910731 | ZA 1990-7282 | 19900912 |
| IL 95675 | A1 | 19960331 | IL 1990-95675 | 19900913 |
| US 5134142 | A | 19920728 | US 1990-582358 | 19900914 |
| CA 2025599 | AA | 19910323 | CA 1990-2025599 | 19900918 |
| CA 2025599 | C | 20011120 | | |
| HU 57733 | A2 | 19911230 | HU 1990-5970 | 19900919 |
| HU 208122 | B | 19930830 | | |
| ES 2088933 | T3 | 19961001 | ES 1990-117983 | 19900919 |
| FI 102535 | B1 | 19981231 | FI 1990-4602 | 19900919 |
| JP 03141261 | A2 | 19910617 | JP 1990-252319 | 19900920 |
| JP 2586713 | B2 | 19970305 | | |
| NO 9004134 | A | 19910325 | NO 1990-4134 | 19900921 |
| NO 301006 | B1 | 19970901 | | |
| CN 1050382 | A | 19910403 | CN 1990-107130 | 19900921 |
| CN 1046506 | B | 19991117 | | |
| AU 9063072 | A1 | 19910418 | AU 1990-63072 | 19900921 |
| AU 637142 | B2 | 19930520 | | |
| RU 2021990 | C1 | 19941030 | RU 1990-4831230 | 19900921 |
| KR 182798 | B1 | 19990501 | KR 1990-15110 | 19900921 |
| RU 2059622 | C1 | 19960510 | RU 1991-5010250 | 19911202 |
| PRIORITY APPLN. INFO.: | | | GB 1989-21466 | A 19890922 |
| | | | GB 1990-8399 | A 19900412 |


OTHER SOURCE(S): MARPAT 115:71593
IT 134728-98-6P 134728-99-7P 134729-00-3P
134729-01-4P 134729-02-5P 134729-08-1P
134729-09-2P 134729-10-5P 134729-11-6P
134729-12-7P 134729-13-8P 134729-17-2P
134729-20-7P 134729-22-9P 134729-23-0P
134729-24-1P 134729-53-6P 134729-54-7P
134729-55-8P 134729-56-9P 134729-57-0P
134729-58-1P 134729-78-5P 134729-80-9P
134729-81-0P 134729-82-1P 134729-83-2P
134729-84-3P 134729-85-4P 134729-86-5P
134729-89-8P 134729-90-1P 134729-91-2P
134729-92-3P 134729-93-4P 134729-94-5P
134729-95-6P 134729-96-7P 134729-97-8P

134729-98-9P 134729-99-0P 134730-00-0P
 134730-01-1P 134730-02-2P 134730-03-3P
 134730-04-4P 134730-07-7P 134730-08-8P
 134730-09-9P 134730-10-2P 134730-11-3P
 134730-13-5P 134730-16-8P 134730-17-9P
 134730-18-0P 134730-19-1P 134730-20-4P
 134730-21-5P 134730-26-0P 134730-29-3P
 134730-30-6P 134730-31-7P 134730-32-8P
 134730-33-9P 134730-34-0P 134730-47-5P
 134730-48-6P 134730-50-0P 134730-52-2P
 134730-53-3P 134730-55-5P 134730-57-7P
 134730-58-8P 134730-61-3P 134730-62-4P
 134730-78-2P 134730-84-0P 134730-85-1P
 134730-87-3P 134730-89-5P 134730-91-9P
 134730-97-5P 134730-99-7P 134731-01-4P
 134731-03-6P 134731-05-8P 134731-08-1P
 134731-10-5P 134731-12-7P 134731-14-9P
 134731-15-0P 134731-16-1P 134731-17-2P
 134731-18-3P 134731-26-3P 134731-27-4P
 134731-30-9P 134731-47-8P 134753-99-4P
 134754-02-2P 134754-06-6P 135327-58-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antiinflammatory, analgesic, and antithrombotic)


RN 134728-98-6 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134728-99-7 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134729-00-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-methyl-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-01-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134729-02-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N,N-dimethyl-5-[4-


10/764,529

(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)




RN 134729-08-1 CAPLUS

CN Piperazine, 1-[[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 134729-09-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-hydroxy-N-methyl-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 134729-10-5 CAPLUS
CN Glycine, N-[[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 134729-11-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[4-(methylsulfonyl)phenyl]-1-[4-[(2-oxoethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 134729-12-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N,N-dimethyl-5-[4-(methylsulfonyl)phenyl]-1-[4-[(2-oxoethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 134729-13-8 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134729-17-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-[4-[(2-oxoethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 134729-20-7 CAPLUS
CN 1H-Pyrazole-3-methanamine, 1-(4-fluorophenyl)-N,N-dimethyl-5-[4-(methylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 134729-22-9 CAPLUS
CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 134729-23-0 CAPLUS
CN Ethanone, 1-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl] - (9CI) (CA INDEX NAME)




RN 134729-24-1 CAPLUS

CN Ethanone, 1-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 134729-53-6 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(2-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-54-7 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(2,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 134729-55-8 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-56-9 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI)
(CA INDEX NAME)




RN 134729-57-0 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-58-1 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-78-5 CAPLUS
CN 1H-Pyrazole, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134729-80-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(2-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134729-81-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(2,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134729-82-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134729-83-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 134729-84-3 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134729-85-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134729-86-5 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 134729-89-8 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(2,5-difluorophenyl)-5-[4-


10/764,529

(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)




RN 134729-90-1 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-[4-[(2-oxoethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 134729-91-2 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-fluoro-2-nitrophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 134729-92-3 CAPLUS
CN 1H-Pyrazole, 5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 134729-93-4 CAPLUS
CN 1H-Pyrazole, 3-bromo-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-94-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-95-6 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 134729-96-7 CAPLUS

CN 1H-Pyrazole, 3-(fluoromethyl)-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-97-8 CAPLUS

CN 1H-Pyrazole-3-methanol, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 134729-98-9 CAPLUS

CN 1H-Pyrazole, 3-(chloromethyl)-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134729-99-0 CAPLUS

CN 1H-Pyrazole, 3-(fluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 134730-00-0 CAPLUS

CN Benzenamine, 4-[3-(difluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 134730-01-1 CAPLUS

CN 1H-Pyrazole, 3-(difluoromethyl)-1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-02-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 134730-03-3 CAPLUS

CN Pyrrolidine, 1-[(1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 134730-04-4 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 1-(2-chlorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-07-7 CAPLUS


10/764, 529

CN 1H-Pyrazole-3-carboxylic acid, 1-(2-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-08-8 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(2,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-09-9 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 134730-10-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-11-3 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-13-5 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 1-(4-hydroxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-16-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 1-(2,4-difluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

10/764,529




RN 134730-17-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 1-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 134730-18-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[4-(methylsulfonyl)phenyl]-1-phenyl- (9CI)
(CA INDEX NAME)




RN 134730-19-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 1-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-20-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4-hydroxyphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-21-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-26-0 CAPLUS


10/764,529

CN 1H-Pyrazole-3-carbonitrile, 1-[4-[(methylsulfonyl)oxy]phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-29-3 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-(4-aminophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-30-6 CAPLUS

CN Acetamide, N-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 134730-31-7 CAPLUS

CN Carbamic acid, [1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-Pyrazol-


10/764,529

3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 134730-32-8 CAPLUS

CN Methanesulfonamide, N-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 134730-33-9 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 1-[4-(dimethylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-34-0 CAPLUS

10/764,529


CN 1H-Pyrazole-3-carbonitrile, 1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-47-5 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(2-aminophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134730-48-6 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-(2-amino-4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134730-50-0 CAPLUS
CN Benzenamine, 4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-


10/764,529

pyrazol-1-yl] - (9CI) (CA INDEX NAME)




RN 134730-52-2 CAPLUS

CN Benzenamine, 4-[3-(methylsulfonyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl] - (9CI) (CA INDEX NAME)



RN 134730-53-3 CAPLUS


CN Benzenamine, 4-[3-(fluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl] - (9CI) (CA INDEX NAME)



RN 134730-55-5 CAPLUS


10/764,529

CN 1H-Pyrazole-3-carboxylic acid, 1-(4-aminophenyl)-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134730-57-7 CAPLUS

CN Acetamide, N-[4-[3-cyano-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 134730-58-8 CAPLUS

CN Methanesulfonamide, N-[4-[3-cyano-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 134730-61-3 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 1-[4-(diethylamino)phenyl]-5-[4-


10/764,529

(methylsulfonyl)phenyl] - (9CI) (CA INDEX NAME)




RN 134730-62-4 CAPLUS

CN Benzenamine, 4-[3-(fluoromethyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 134730-78-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[4-(methylsulfonyl)phenyl]-1-[4-[(2-oxoethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 134730-84-0 CAPLUS

CN Formamide, N-[4-[3-cyano-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-


10/764,529

yl]phenyl]- (9CI) (CA INDEX NAME)




RN 134730-85-1 CAPLUS

CN Formamide, N-[2-[3-cyano-5-[4-(methylsulfonyl)phenyl]phenyl]-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 134730-87-3 CAPLUS

CN Formamide, N-[4-[5-[4-(methylsulfonyl)phenyl]phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 134730-89-5 CAPLUS


CN Formamide, N-[4-[3-(methylsulfonyl)-5-[4-(methylsulfonyl)phenyl]phenyl]-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 134730-91-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(formylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134730-97-5 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-[2-[(2-oxoethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 134730-99-7 CAPLUS
CN Acetaldehyde, [{4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}amino]- (9CI) (CA INDEX NAME)




RN 134731-01-4 CAPLUS
CN Acetaldehyde, [{4-[3-(methylsulfonyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]phenyl}amino]- (9CI) (CA INDEX NAME)



RN 134731-03-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-[4-(methylsulfonyl)phenyl]-1-[4-[(2-oxoethyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 134731-05-8 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 134731-08-1 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-[2-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134731-10-5 CAPLUS
CN Benzenamine, N-methyl-4-[5-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 134731-12-7 CAPLUS


CN Benzenamine, N-methyl-4-[3-(methylsulfonyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-1-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 134731-14-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134731-15-0 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-dimethyl-1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134731-16-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134731-17-2 CAPLUS


10/764,529

CN 1H-Pyrazole-3-carboxylic acid, 1-[4-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134731-18-3 CAPLUS

CN 1H-Tetrazole, 5-[1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 134731-26-3 CAPLUS


CN 1H-Pyrazole-3-carbonitrile, 1-[2-(dimethylamino)-4-fluorophenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134731-27-4 CAPLUS


10/764,529

CN 1H-Pyrazole, 3-(methylsulfonyl)-5-[4-(methylsulfonyl)phenyl]-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 134731-30-9 CAPLUS

CN 1H-Pyrazole-3-methanamine, 1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134731-47-8 CAPLUS

CN 1H-Pyrazole, 1-(4-fluorophenyl)-3-(methylsulfonyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




10/764,529


RN 134753-99-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-(3-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134754-02-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-(2-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 134754-06-6 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 1-[4-fluoro-2-(methylamino)phenyl]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 135327-58-1 CAPLUS
CN 1H-Pyrazole-3-carbonitrile, 5-[4-(methylsulfonyl)phenyl]-1-(2-nitrophenyl)-
(9CI) (CA INDEX NAME)






RN 134731-44-5 CAPLUS

CN Propanedioic acid, [(1-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-1H-pyrazol-3-yl]carbonyl]-, diethyl ester (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = heterocyclyl, (un)substituted aryl; R2 = H, CH₂NH₂, alkylaminomethyl, halomethyl, acyloxymethyl, acyl, acylamino, cyano, halo, alkylthio, alkylsulfinyl; R3 = (un)substituted aryl or heterocyclyl; provided that, e.g. when R2 = (esterified) CO₂H, trihalomethyl, R3 = substituted aryl or heterocyclyl] are prepared, e.g. by reaction of R₃COCH₂COR₂, OHCHR₃COR₂, or OHCCHR₂COR₃ with R₁NHNH₂. Thus, a mixture of Et 4-(4-methylthiophenyl)-2,4-dioxobutanoate and 4-FC₆H₄NHNH₂.HCl in EtOH-dioxane was refluxed 5 h to give Et 1-(4-fluorophenyl)-3-(4-methylthiophenyl)pyrazole-5-carboxylate. A total of approx. 250 I were prepared and 9 I at 3.2 or 10 mg/kg/day p.o. for 23

10/764,529

days inhibited 80.6-100% of mycobacterial adjuvant-induced secondary lesion in rat hind paws.

=> log y
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

FULL ESTIMATED COST

307.63 469.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

CA SUBSCRIBER PRICE

-45.26 -45.26

STN INTERNATIONAL LOGOFF AT 15:22:28 ON 27 SEP 2005